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Down's syndrome (trisomy 21) is the single most common recognised cause of mental
handicap in the United Kingdom. Not surprisingly therefore, a number of approaches
have been developed to screen and diagnose Down's syndrome pregnancies
prenatally, affording individuals the opportunity to terminate the pregnancy if desired.
The most effective and widely used of these approaches currently involves
amniocentesis targeted by second trimester screening based upon maternal age in
combination with the measurement of various factors in maternal serum. Such an
approach will detect approximately 60-70% of Down's affected pregnancies with an
overall amniocentesis rate of 5%. However, this of course means that a third of
affected pregnancies remain undetected and that many women expose their pregnancy
to the risks of amniocentesis-related miscarriage. Screening with improved sensitivity
and specificity is therefore desirable.
This thesis describes a series of clinical and laboratory studies examining the value of
inhibins as novel prenatal markers of Down's syndrome. Inhibins are a family of
glycoprotein proteins initially identified in gonadal tissue but known to be secreted by
the placenta in pregnancy. The ontogeny of inhibin secretion in early pregnancy is
described in detail comparing various pregnancy compartments in both normal and
Down's syndrome pregnancies. It is shown that maternal serum levels of inhibin-A,
one of two possible fully processed inhibin dimers, are significantly elevated in
Down's syndrome in both the first and second trimesters of pregnancy. Furthermore,
mathematical modelling studies with other established prenatal markers (maternal age,
human chorionic gonadotrophin and alpha fetoprotein) suggests that inhibin-A could
increase second trimester detection rates by as much as 20%.
Studies on amniotic fluid revealed that, unlike maternal serum in which only inhibin-A
is detectable, both dimers, inhibin-A and inhibin-B, were present raising the
possibility that the fetal membranes secrete significant amounts of inhibin. The lack of
a relationship between inhibin-A levels in paired serum and amniotic fluid samples
supported this hypothesis, representing a significant re-appraisal of the previous
understanding of inhibin biology in pregnancy.
Studies of amniotic fluid inhibin levels in Down's syndrome showed that inhibin-A
levels are significantly lower than normal, the opposite of serum. This suggests that
the fetal membranes not only secrete different inhibins from the placenta but that the
secretion is differentially controlled.
These studies have therefore described, in detail, the biology of specific inhibin forms
in normal and aneuploid pregnancy demonstrating inhibin-A to be the second most
valuable serum marker of Down's syndrome. Novel insights into normal placental
endocrinology have also been afforded by the studies with the promise of new
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Inhibins and Aneuploidy: an Introduction
1.1 Objectives
The studies detailed in this thesis were undertaken to explore the biology of inhibins in
normal and abnormal pregnancy. As will become apparent, until very recently, the
understanding of inhibin biology in man was based largely upon assay technology that
was unable to differentiate between the various inhibin forms that are known to exist in
biological fluids. Thus, as discussed in this and subsequent chapters, data from in
vitro and animal studies were not always consistent with in vivo, clinical human data.
The advent of novel sensitive and specific assays however, has afforded fresh clarity
to the areas of controversy and allowed new insights into the understanding of inhibin
biology.
The focus of this thesis has been to describe the ontogeny of the inhibins in early
normal pregnancy thereby allowing a comparison with abnormal pregnancy, in
particular with pregnancies complicated by Down's syndrome (trisomy 21). The
chapters have been ordered to clarify such comparisons although, as will be apparent,
the studies underlying the chapters were not necessarily performed in the order they
are presented.
It is hoped that the data contained in this thesis, and resultant peer-reviewed
publications, have not only afforded some clarification of the basic biology of inhibins
in pregnancy but have also afforded novel observations that are of direct and
immediate relevance to modern clinical obstetric practice. The following sections in
this chapter will act as way of an introduction to inhibins in general, inhibins in
pregnancy and maternal serum screening for Down's syndrome, as preparation for the
studies and discussions that follow in subsequent chapters.
1.2 Inhibins and related proteins: a brief history
It is now over seventy-five years since it was first observed that impaired testicular
function was associated with changes in the anterior pituitary gland (Mottram and
Cramer 1923) and that those changes probably related to release of the pituitary from
the suppressive influences of a non-steroidal regulator (McCullagh 1932). Indeed, it
was McCullagh who coined the name "inhibin" for the as yet unidentified hormone.
Subsequent to these early in vivo observations there was little further progress until the
1970s when numerous studies showing that follicle-stimulating hormone (FSH)
secretion from the pituitary could be selectively suppressed by various testicular fluids
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and extracts were reported (Franchimont et al 1972, Setchell et al 1974, Keogh et al
1976). However, more rapid progress became possible when it was recognised that,
in addition to the testis and testicular extracts, follicular fluid contained large amounts
of inhibin-like activity (de Jong and Sharpe 1972), because, compared to testes,
bovine and porcine follicular fluid was readily available in very large volumes (Burger
1992).
In 1985 the successful isolation and partial characterisation of inhibin was reported
simultaneously and independently by different groups (Robertson etal 1985, Ling etal
1985). During the numerous extraction and purification steps developed to isolate
inhibin, it became clear that another protein, similar to inhibin, existed but that this
protein stimulated FSH secretion rather than suppress it (Vale et al 1986). Maintaining
McCullagh's terminology this protein was called "activin". Despite the extremely slow
progress made between the 1930s and the 1980s, within three years of the first
isolation of inhibin, the complete family of proteins had been described and named
(Burger and Igarashi 1988), functions attributed (Ying 1988), immunoassays
developed (McLachlan et al 1986, Bicsak etal 1986,Hasegawa etal 1988, McNeilly et
al 1988), specific binding proteins identified (Ying 1988) and messenger ribonucleic
acids (mRNAs) for the three subunits discovered in many and diverse tissues (Meunier
et al 1988). By the close of the 1980s it was clear that the "inhibins" represented a
significant new family of proteins with diverse functions throughout mammalian
reproduction.
1.3 Inhibins: structure and detection
Inhibins and activins are members of the transforming growth factor-ft (TGF-p)
superfamily, a group of structurally similar but functionally diverse growth factors
(Massague 1990, Kingsley 1994). Mature inhibin is a 31-32kDa heterodimeric
glycoprotein composed of an a-subunit and one of two possible p-subunits, [3a or Pr,
joined by disulphide bridges (Burger and Igarashi 1988). Thus, two 32kDa inhibins
exist: inhibin-A (cx-Pa) and inhibin-B (a-Ps). Activin is a homodimer of the p-subunits
and therefore three possible species exist: activin-A (Pa-Pa), activin-B (Pr-Pb), and
activin-AB (Pa-Pb) (Ying 1988). (Figure 1.1, page 5)
The initial purification of inhibin from bovine follicular fluid however, revealed a
58kDa protein and it was only subsequently that a smaller 31kDa species was isolated
(Robertson et al 1985), the difference arising from cleavage of a 43kDa a-subunit
precursor. A number of different molecular weight inhibin species was also reported in
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bovine follicular fluid (Miyamoto et al 1986) and more recently Robertson and his
colleagues have described in detail the numerous and various forms of inhibin in
human serum (male and female) and human follicular fluid (Robertson et al 1995,
Robertson etal 1996). These different molecular weight species relate to unprocessed
and partially processed inhibin cx-subunits, either free or dimerised to a p-subunit. The
mature a-subunit is termed aC but this is processed from a translated
pre-pro-a protein, giving rise to various a-subunit precursors: proaNaC, prouC and a
cleavage product «N. p-subunits are also produced as pre-pro-proteins, processed to
the mature p-subunit.
Figure 1.1














Proa - C aC
Activins
Activin-A Activin-B Activin-AB
It is currently understood that the inhibin subunit monomers (Ying 1988) and probably
the higher molecular weight dimers (Mason et al 1996) are biologically inactive. Only
two studies have reported the inhibin forms present in pregnancy sera. One suggested
that only the fully processed 32kDa inhibin was present in maternal serum
(Muttukrishna et al 1995) while the other described very little 32kDa inhibin but a
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predominance of a 55-60kDa form (Khalil et al 1995). While no studies were
performed as part of this thesis to address this issue directly, for example with affinity
chromatography, data related in Chapters Three, Four and Seven will suggest that
multiple inhibin forms exist in pregnancy sera, as in non-pregnancy and as reported by
Khalil and colleagues (1995), and in other pregnancy compartments, contrary to the
conclusions of Muttukrishna and her colleagues (1995).
While the presence of multiple forms of inhibin, and the existence of specific and
non-specific binding proteins, has clearly complicated the understanding of inhibin
biology, the lack of suitable methods of detection has also hampered progress. Chapter
Two discusses these problems and describes in detail the new sensitive and specific
assays developed by Professor Nigel Groome, generously made available by him for
the studies related here. As described in that chapter, the development of the latest
generation of inhibin, and activin, assays has made possible the basis for the studies
described hereafter in Chapters Three to Nine.
1.4 Inhibins and reproduction
Since the focus of this thesis is inhibins in human pregnancy, only a brief summary of
inhibins in general human reproduction is offered here with an obvious emphasis on
inhibins, rather than activins, in pregnancy. Nonetheless, it is hoped that this limited
introduction will afford a suitable appreciation of the importance of inhibins and
activins in general and further details are available from more extensive and excellent
recent reviews (de Jong 1988, Ying 1988, Baird and Smith 1993, Woodruff and
Mather 1995, Halvorson and DeCherney 1996, Wallace and Healy 1996 ).
While it was from the testis that inhibin-like activity was first demonstrated
(McCullagh 1932), and the testis is indeed the main source of inhibin in men (Ishida
1990), the understanding of the roles of inhibin and activin within the male gonad are
much less well defined than they are within the female. Both the Sertoli and Leydig
cells in the testis secrete inhibin (Steinberger and Steinberger 1976, Le Gac et al 1982,
Risbridger etal 1989), as evidenced by protein immunolocalisation and mRNA in situ
studies (Cuevas etal 1987, Roberts 1989), but it is likely that the Sertoli cells are the
principal source (Maddocks and Sharpe 1989) secreting inhibin under gonadotrophin
control, primarily through regulation of the inhibin u-subunit (Roberts et al 1989,
Krummen etal 1989) rather than either of the inhibin p-subunits (Roberts et al 1989).
Indeed, both gonadotrophins are required for normal levels of circulating inhibin in
men (McLachlan et al 1989b) and a large number of clinical studies have confirmed
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that FSH and LH have important physiological roles in the control of testicular inhibin
secretion (Burger and Scott 1981, McLachlan et al 1988a, 1988b, Burger et al 1988,
Burger et al 1990, Yamaguchi et al 1991, Wallace et al 1993). However, despite
elegant and convincing animal studies (Abeyawardene and Plant 1989, Medhamurthy
1991), until very recently there was no direct evidence to confirm that inhibin had a
physiological role in the suppression of FSH secretion, the basis of the McCullagh's
prediction (1932).
In clinical situations where it might have been expected that inhibin levels would be
altered, such as seminiferous tubular damage associated with elevated circulating FSH,
serum immunoreactive inhibin levels were observed to remain within the normal range
(de Kretser 1989), contrary to the expectation that inhibin levels would be decreased,
thereby releasing FSH from its suppression. However, recent studies using inhibin
specific assays have shown that inhibin-B is the physiologically important form of
inhibin in men (Illingworth et al 1996, Anawalt et al 1996, Nachtigall et al 1996,
Anderson et al 1997, Wallace et al 1997) and that levels of inhibin-B fall progressively
as FSH levels increase following testicular damage (Wallace^ al 1997). Interestingly,
the latter study also showed that pro-aC inhibin levels increased with increasing FSH,
consistent with FSH stimulation of inhibin a-subunit (Toebosch et al 1988, Roberts et
al 1989, Hancock etal 1992) and the observation that immunostaining for the inhibin
a-subunit is increased in infertile men (Bergh and Cajander 1990). It was therefore
suggested that the unchanged immunoreactive inhibin levels observed in the presence
of increased FSH levels reported in previous studies composite changes in both
inhibin-B (decreasing) and free a-subunit (increasing) (Wallace et al 1997). In
summary, inhibins have both important intratesticular functions, helping to orchestrate
spermatogenesis, and probably in consort with testosterone, and possibly oestrogens,
an important endocrine function controlling FSH secretion from the pituitary.
There are many similarities between the inhibin secretion in women and that in men.
Like the testis, the ovary is the main, if not sole, source of circulating inhibin
(Illingworth etal 1991), with secretion from the granulosa cells, or lutein cells in the
corpus luteum, controlled by both gonadotrophins and various other factors (Tsonis et
al 1988, Hillier et al 1991a, Findlay 1993, Hee et al 1993). Circulating
immunoreactive inhibin levels change throughout the menstrual cycle (McLachlan et al
1987a), with inverse changes in FSH levels, and recent studies using specific inhibin
assays have related a similar pattern for inhibin-A (Muttakrishna et al 1994, Groome et
al 1994) with transient changes in inhibin-B during the follicular phase when FSH
levels are falling (Groome et al 1996). A large number of animal and human in vitro
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and in vivo studies have explored the roles of inhibins within the ovary (Ying et a!
1986, Hsueh 1986, LaPolt etal 1989, Woodruff et al 1990, Hillier etal 1991b, Hillier
1991, Xiao and Findlay 1991, Xiao etal 1992, Hillier and Miro 1993, Findlay 1993)
and together they suggest that inhibin and activin, probably in consort with follistatin,
ensure that there is both a mechanism of selecting the dominant follicle, ready for
ovulation, and of preventing premature luteinisation (Findlay 1993, Baird and Smith
1993). As in the male therefore, in the female inhibins appear to have important
intra-gonadal paracrine/autocrine functions and a traditional endocrine role in the
suppression of FSH secretion.
1.5 Inhibins and pregnancy
In addition to controlling gonadal function, inhibins would appear to have important
roles in pregnancy and it is this arena that is explored in this thesis, through various
simple observational studies.
After ovulation the corpus luteum secretes inhibin-A and it would appear to continue to
do so into early pregnancy (Illingworth et al 1996). However, women without
functional ovaries have similar immunoreactive inhibin levels in early pregnancy to
normal women (McLachlan et al 1987, Lenton et al 1991, Santoro et al 1992)
suggesting that the ovary is not a major source of inhibin beyond six weeks of
pregnancy. Indeed, a number of studies, reviewed by Qu and Thomas (1995), have
suggested that the placenta is the main source of inhibins in pregnancy, as predicted by
the first studies of placental extracts (Healy et al 1988) and primary trophoblast cell
cultures (Petraglia eta/1987).
The control of inhibin secretion from the human placenta has not been fully elucidated,
and indeed is the subject of further on-going studies (Chapter Ten), but in vitro,
human chorionic gonadotrophin (hCG) and gonadotrophin releasing hormone (GnRH)
stimulate trophoblastic inhibin secretion (Petraglia et al 1987, Li et al 1994) and
reciprocally, inhibin suppresses hCG secretion. This latter effect is gestation
dependant since there is no inhibin-induced hCG suppression in cell cultures derived
from first trimester trophoblast (Mersol-Barg et al 1990). Opposing inhibin, activin
stimulates hCG secretion from trophoblast cultures (Steele et al 1993) and inhibin and
activin may both regulate progesterone and prostaglandin production (Petraglia et al
1993). Messenger RNAs for the three inhibin subunits, and the proteins themselves,
have been localised to the syncytio- and cytotrophoblast (Petraglia et al 1987, Petraglia
etal 1991, Minamie/a/1992, Rabinovici et al 1992), the same cells secreting GnRH
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and hCG (Petraglia et al 1992), with interesting changes in expression across
gestations. In early pregnancy mRNA for the a-subunit is expressed in larger amounts
than PA-subunit mRNA, with very little Pe subunit mRNA apparent (Petraglia et al
1991). With increasing gestation progressively more PB-subunit mRNA is expressed
suggesting that there is a gestation dependent switch from a predominance of inhibin-A
and activin-A secretion to the presence of many forms (see below).
Circulating inhibin levels are significantly higher during pregnancy than in non-
pregnancy (McLachlan et al 1987, Abe etal 1990, Tovanabutra el al 1993, Kettel et al
1991). Plasma immunoreactive inhibin levels peak at 9-10 weeks, coinciding with the
first trimester peak of hCG (Tovanabutra et al 1993), and then fall to a plateau between
15 and 30 weeks, rising thereafter so that the highest levels are achieved by term (Abe
et al 1990, Tabei et al 1991, Qu et al 1991, Tovanabutra et al 1993). After delivery
inhibin levels become undetectable within 4-5 days (Abe et al 1990, Kettel etal 1991,
Qu and Thomas 1992, Tovanabutra et al 1993). Interestingly, bioactive inhibin levels
have been reported to rise steadily throughout pregnancy without the biphasic profile
described for immunoreactive inhibin (Qu etal 1991), consistent with a relative excess
of inactive forms, either large molecular weight dimers or, more likely, free
a-subunits, in early pregnancy, mirroring the relative excess of a-subunit message at
this gestation (Petraglia et al 1991). However, using a specific assay, it was reported
recently that maternal serum inhibin-A levels display a biphasic profile (Muttukrishna
etal 1995) indicating that the bioassay data were probably confounded by inadequate
stripping of the very high levels of circulating sex steroids in the test samples or by
activins or other proteins that alter FSH secretion from the cells in culture. These
issues are explored further in Chapter Three. In support of the placental in situ and
immunolocalisation studies describing the ontogeny of subunit expression, inhibin-B
is undetectable in peripheral serum during pregnancy (Illingworth et al 1996), a
finding that is also re-examined and discussed in Chapter Three.
Activins have also been detected in the human placenta (de Kretser et al 1994, Knight
etal 1996) and in maternal serum (Knight etal 1995, Petraglia etal 1995, Woodruff et
al 1997), with a number of pieces of evidence to suggest that activins may have an
important role to play in the onset of parturition (Petraglia et al 1993, Petraglia et al
1994a,b, Petraglia et al 1995, Woodruff et al 1997). Given the focus of this thesis
however, no further consideration of these members of the inhibin family is given
here.
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In addition to examining the ontogeny of inhibins in normal pregnancy, a number of
studies have recently assessed circulating levels of inhibin in a variety of pregnancy
abnormalities. In pregnancies where it might be expected that placental mass would be
reduced compared to normal, such as anembryonic pregnancies, ectopic pregnancies
and threatened abortions, maternal serum inhibin levels, particularly prou-C
immunoreactivity, are lower than in normal pregnancy (Yohkaichiya et al 1993,
Illingworth et al 1996). It is therefore possible that inhibin may be useful in monitoring
high risk first trimester pregnancies, although no studies have yet usefully assessed
this possibility. Immunoreactive inhibin levels are higher in multiple pregnancies than
in singletons (Yohkaichiya et al 1993, Khalil et al 1995) and data exploring this
observation for inhibin-A are related in Chapter Three. Inhibin levels are also
significantly higher than normal in association with various pregnancies complications
such as pre-eclampsia, fetal growth restriction, or placental abruption (Khalil et al
1995). These complications are all associated with disruption of the trophoblast
basement membrane and the higher serum inhibin levels may simply reflect leakage.
However, inhibins apart, there is other evidence of placental endocrine dysfunction in
such pregnancies, even in very early pregnancy (Gonen et al 1992) and there is a real
prospect that maternal serum inhibin, with or without other markers,, may provide a
basis for pregnancy complication screening. To date however, there has been no
prospective assessment of any such predictive value of inhibin.
Inhibin is also markedly elevated in molar pregnancy (Yohkaichiya et al 1989) with an
immunohistochemical study localising the inhibin subunits in molar trophoblast
(Minami et al 1993) and suggesting that activin and inhibin may have roles in molar
pathogenesis. However, it would appear that in a clinical setting, inhibin has nothing
useful to add to hCG as a surveillance marker (Baddonel et al 1994)
Despite the focus of the aforementioned studies on the placenta as the source of
inhibins in pregnancy, the studies and results detailed in Chapter Three explore other
possible sources, reappraising current understanding and developing a basis from
which to explore the control of inhibin secretion from different pregnancy tissues. In
particular, the studies provide the basis from which inhibin secretion in Down's
syndrome pregnancies can be better understood (see Chapters Four, Five, Six and
Eight ).
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1.6 Down's syndrome: screening and diagnosis
It is not the intention to give an historical review of Down's syndrome but rather to
focus on prenatal screening and diagnosis of the condition. However, detailed, and
most interesting, accounts of the history of Down's syndrome as a clinical condition
are given elsewhere (Smith and Berg 1976, Zellwerger 1977). Although the first
medical illustration of an individual with Down's syndrome was in 1876 (Fraser and
Mitchell 1876), much earlier representations may exist, including a fifteenth century
painting of Madonna and child by Andrea Mantegna (Ruhrah 1935) and a seventeenth
century painting by Jacob Jordaens (Zellwerger 1968). Further, while John Langdon
Down is generally credited (Smith and Berg 1976) with the "discovery" in 1866 of a
discrete clinical entity (Down 1866), which now carries his name, prior examples may
have been reported (Esquirol 1838, Seguin 1846, Seguin 1866). In any event, the
physical description of Down's syndrome was essentially complete by the beginning
of this century (Smith and Berg 1976, Zellwerger 1977) and it was in 1959 that
LeJeuneand colleagues first identified that an extra chromosome 21 was the cause and
Niebhur (1974) who suggested that gene replication was implied by this additional
chromosomal material.
With an approximate incidence of 1.3 per 1000 live births, Down's syndrome is the
single most important known cause of severe mental handicap in the developed world
(Hook 1994). It is not surprising therefore that screening for Down's syndrome has
become an important component of modern obstetric care (RCOG 1993), both for the
expectant family who do not wish a Down's syndrome child and for society at large
which finds screening and targeted termination highly cost effective (Gill et al 1987). It
has long been recognised that an individual's risk of having an affected child increased
with her age (Fraser and Mitchell 1876), with detailed risk estimates first calculated in
five year intervals (Penrose and Smith 1966), forming the first basis of a screening
test. The application of this screening test was only possible however with the
availability of a diagnostic test for those women who were screen positive (ie older
than 35 at the time of delivery). Such a diagnostic test became available with the
successful karyotyping of fetal cells from amniotic fluid in 1966 (Steele and Breg
1967, Thiede et al 1967) and in particular with the description of second trimester
amniocentesis the following year (Jacobson and Barter 1967) and the first diagnosis of
Down's syndrome (Valentief al 1968). Thus, using a mother's age as a screening test
and an arbitrary cut-off age of 35, approximately 30% of Down's syndrome
pregnancies will be detected (RCOG 1993).
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However, almost all unexpected newborn babies with Down's syndrome are
diagnosed morphologically and it has been long recognised that a number of congenital
abnormalities, including cardiac anomalies (Garrod 1899) are common in the Down's
syndrome fetus. Indeed, approximately 50% of individuals with Down's syndrome
will have a congenital cardiac abnormality (Fabia and Drolette 1970) and the use of
obstetric ultrasound affords the opportunity to detect many of these abnormalities
prenatally. It is now recognised that a number of different abnormalities evident on
ultrasound are associated with Down's syndrome and that the identification of any of
these in a given pregnancy merits the offer of a diagnostic procedure. Such defects
include duodenal atresia, cystic hygroma, nuchal oedema, pyelectasis, echogenic
bowel, macroglossia, fifth digit middle phalanx hyoplasia and multiple combinations
(Benacerraf 1985a,b, 1988, 1990, Nyberg et al 1990, Nicolaides 1993). However,
many (63% in one series) of the abnormalities evident on ultrasound are transient
(Bronshtein and Blumenfeld 1994) and are not apparent beyond 18 weeks, the
traditional timing for a detailed fetal anomaly scan. Thus, ultrasound at 18-20 weeks
will detect only 40% of Down's syndrome fetuses, approximately comparable with
maternal age screening, while earlier examination may detect over 80% of affected
fetuses (Nicolaides et al 1992, Nicolaides et al 1994, Bronshtein and Blumenfeld
1994).
In 1984 the observation that, on average, maternal serum levels of alpha-fetoprotein
(AFP) were lower than normal in association with Down's syndrome (Merkatz et al
1984) represented the first significant progress in prenatal screening for Down's
syndrome since the introduction of maternal age as a "screening test". Maternal serum
AFP had long been used as a screening test for neural tube defects (Brock and
Sutcliffe 1972), conditions where AFP levels are higher in than normal pregnancy.
However, the finding of Merkatz and his colleagues (1984) offered the exciting
possibility that other fetoplacental products may be useful markers of Down's
syndrome or other aneuploidies (Chard et al 1984). This suggestion was realised with
the subsequent report that human chorionic gonadotrophin (hCG) levels in maternal
blood are elevated in association with Down's syndrome (Bogart et al 1987). A very
large number of studies have confirmed this observation (for example Wald etal 1988,
Osathanondh et al 1989, Suchy and Yeager 1990, Bogart et al 1991, Crossley et al
1991, Ryall et al 1992, Spencer et al 1992) and hCG, or more recently the free (Y
subunitof hCG (Macri et al 1990, 1993,1994, Spencer et al 1992, Ryall et al 1992),
has become the single most powerful prenatal serum marker for Down's syndrome.
Many prospective studies have now confirmed that screening programmes based upon
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maternal age and the measurement of AFP and hCG (or free |ThCG), with or without
other markers such as oestriol (Canick et al 1988, Wald et al 1988) or free a-hCG
(Ryall et al 1992), affords an overall detection rate of 60-70% for an amniocentesis
rate, or approximate false positive rate (FPR) of 5% (RCOG 1993). Such programmes
are now widely available throughout the United Kingdom (RCOG 1993, Seth and
Ellis 1994) and elsewhere (Ryall et al 1992, Golbus et al 1994, Mantingh et al 1994,
Mullerand Boue 1994).
However, it remains desirable to improve upon these detection rates, while minimising
the FPR and the studies in Chapter Five relate the application of inhibin as a marker in
the second trimester both alone and in combination with other markers. Furthermore,
with the successful karyotyping from first trimester placental tissue by transcervical
(Old etal 1982, Ward etal 1983, Simoni et al 1983) and then transabdominal (Smidt-
Jensen et al 1984) chorion villus sampling diagnosis earlier than that afforded by
second trimester amniocentesis became possible, thereby creating the desire for earlier
screening. As discussed in more detail in Chapters Four and Six, a number of serum
markers have been assessed in the first trimester (Macintosh and Chard 1993) and
predicted detection rates look very promising indeed (Krantz et al 1996). Similarly, as
discussed above and in Chapter Six, the use of ultrasound markers in the late first
trimester looks extremely exciting. The studies in Chapters Four and Six describe the
application of inhibin as a prenatal marker of Down's syndrome in the first trimester of
pregnancy and relate this application to other biochemical and ultrasound markers at
these early gestations, discussing the benefits and disadvantages of screening at this
early gestation.
1.7 Conclusions
It is hoped that this chapter has afforded a useful background to both the biology of
inhibins in reproduction and to the prenatal screening and diagnosis of Down's
syndrome. The chapters that follow will expand upon this introduction, detailing a
number of different studies reporting some novel observations in both inhibin biology
and Down's syndrome screening. The last chapter will briefly review these data and
more importantly, offer up for consideration the exciting future prospects that research
in inhibins in human pregnancy may offer.
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2.1 Introduction
Prior to the development of radioimmunoassay, it was only possible to assess
inhibin-like activity by observing changes in gonadal weight, reflecting FSH
stimulation, under test conditions (Steelman and Pohley 1953). Subsequently, the
recognition of the existence of a specific regulator of FSH secretion from the anterior
pituitary gland (Franchimont et al 1972, Setchell etal 1974, Keogh et al 1974) and the
development of a radioimmunoassay for FSH (Midgley 1967) afforded the
development of other in vivo bioassays utilising the in vivo suppression of FSH in
castrated animals (de Jong and Sharpe 1974, Marder et al 1977). However, the first
sensitive and reliable assays for inhibin were in vitro bioassays using dispersed
anterior pituitary cells (Vale etal 1972). Inhibin was measured by assessing either the
suppression of FSH secretion by pituitary cells into culture media (Eddie et al 1979) or
the decrease in pituitary cell content of FSH (Scott et al 1980). Unfortunately, the
interpretation of results from such bioassays was complicated by the presence in the
test sample of activins, binding proteins and other FSH-modulating substances which
could oppose the in vitro actions of inhibin. Therefore, in reality the resulting "inhibin"
levels were a crude balance between inhibin and activin bioactivity. Other bioassays
utilising the differential actions of inhibin and activin on human erythroid stem cell
lines was also developed (Yu etal 1987, Schwall and Lai 1991) but they also reflected
composite levels of the two proteins and other interfering substances.
The purification of inhibin in 1985 (Robertson etal 1985, Ling et al 1985) and activin
in 1986 (Valeetal 1986) however, allowed the generation of antibodies raised against
either native protein or synthetic peptides. A variety of assays were thereafter
developed (McLachlane/ al 1986b, McLachlan et al 1987, Ying etal 1986, Hasegawa
et al 1988, McNeilly et al 1988, Saito et al 1989, Vaughan et al 1989, Baly et al 1993),
the most useful of which was a radioimmunoassay developed by McLachlan and
co-workers, which became known as the "Monash assay", denoting its institution of
origin, but the reagents for which were provided to the National Institutes of Health
(NIH) for distribution worldwide.
This assay utilises a polyclonal antibody (AS 1989) raised against 31 kD bovine inhibin
with epitopes for the antibody on the inhibin <x-subunit. Following its development, it
became apparent that in addition to bioactive dimeric inhibin free inhibin cx-subunits
exist in serum (Knight etal 1989, Sugino etal 1989, Schneyer etal 1990) and that the
Monash assay, and others using anti-inhibin u-subunit antibodies, detected these
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(Schneyer et al 1990). As discussed in Chapter One, the free cx-subunits are not
thought to be biologically active and are of uncertain physiological relevance. Further,
circulating binding proteins, such as follistatin and a2-macroglobulin, were reported to
alter antibody-antigen binding in clinical samples such as plasma (Vaughan and Vale
1993, Krummen et al 1993) and apparent inhibin levels were altered by in vitro
protease activity (Bramley et al 1992). It is clear therefore that the interpretation of
"inhibin" results obtained with a-subunit assays had to be necessarily cautious and
limited (Burger 1993).
Recently, a new generation of two-site assays has been developed for both inhibins
and activins, including assays specific for inhibin-A, inhibin-B, activin-A, activin-B
and a-subunit precursors (Groome 1991, Knight et al 1991, Baly et al 1993,
Woodruff et al 1993, Knight and Muttukrishna 1994, Woodruff et al 1994, Groome
and O'Brien 1994, Poncelet and Franchimont 1994, Groome et al 1995, Knight et al
1996). These assays promise to clarify what were a number of apparent
inconsistencies in data obtained with a-subunit based assays, exploring for the first
time the control and relative ontogeny of the two mature forms of inhibin (inhibin-A
and inhibin-B) and, by using a panel of assays, assessing levels of non-bioactive
subunits of different molecular weights, exploring the biological processing of these
proteins.
This thesis is concerned with the application of three sensitive inhibin enzyme-linked
immunosorbent assays (ELISAs) specific for inhibin-A (Groome and O'Brien 1993),
inhibin-B (Groome etal 1996) and pro-aC containing inhibins (Groome et al 1995) to
explore the biology of inhibin in normal human and Down's syndrome pregnancy. In
addition, a small study of immunoreactive inhibins, using two different
immunoassays, in Down's syndrome pregnancies will be reported.
2.2 Immunoreactive inhibin assays
In Chapter Four a small preliminary study is reported using two different inhibin
immunoassays. The methodology of these are described here.
2.2.1 "Monash " inhibin assay.
This assay is a heterologous radioimmunoassay using an antibody (AS 1989) raised
against 31kDa bovine inhibin and a tracer of iodinated 31kDa bovine inhibin
(McLachlan et al 1986, McLachlan et al 1987). Recombinant human inhibin A
(rhINH-R-90/1) was used for standards with the results expressed as pg/ml. The
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sensitivity of the assay was 780pg/ml and the coefficients of variation of intra-assay
and inter-assay were 6.6% and 11.5% respectively. This assay is now distributed by
the National Institute of Child Health and Human Development (NICHD), a section of
NIH.
2.2.1.1 Materials required
1. Assay buffer: 0.01M PBS, 0.5% BSA (ph7.4)
2. Tracer buffer: Assay buffer +0.1 % Triton X
3. 1st antibody: lin 3000 antisera(AS#1989) (NICHD) and
lin 400 normal rabbit serum (#5162L) (SAPU, Scotland, UK)
4. 2nd antibody: lin 64 donkey anti-rabbit serum (#5257M) (SAPU, Scotland, UK)
5. Tracer: 125I bovine 3IK Inhibin (iodinated in house) (NICHD)
6. Standards: purified human follicular fluid, calibrated against ovine rete testis
fluid in a sheep pituitary bioassay (in-house).
2.2.1.2 Methodology
1. Prepare buffer, lsl antibody and standards (from storage).
2. Add sample (200//I or 300//1), or standard (100//1) and 100jA 1st antibody (± buffer
depending on standards used) to each LP3 tube and vortex. See method grids
below for volumes.
3. Incubate at room temperature for 24 hours.
4. Prepare tracer buffer. To make tracer solution add approximately 100//I of stock
tracer to 1 Omls of tracer buffer. Adjust to allow for ~ 10,000 cpm in 100//1 of tracer.
5. Add 100//1 tracer to all tubes and cap Tc tubes. Vortex. Incubate at room
temperature for 24 hours.
6. Prepare 2nd antibody and add 100//1 to all tubes except Tcs. Vortex. Incubate at 4°C
overnight (16 hours).
7. Prepare normal saline and add 2mls to each tube except Tc's.
8. Centrifuge at 2500rpm for 45mins at 4°C.
9. Aspirate the supernatant carefully and keep the tubes upright prior to counting. In
large assays keep tubes at 4°C while waiting to aspirate. Counting can be performed
immediately.
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Method grid for 200^1 sample and standards in buffer.
sample/ ,r ' volume Buffer Antibody Tracer STD/Sample Serum
Tc - - 100 -
NSB 200 - 100 - 200
Bo 100 100 100 - 200
STDS - 100 100 100 200
Sample 100 100 100 200 -
Method srid for 300«1 samole and standards in serum
sample/ .^ 'volume Buffer Antibody Tracer STD/Sample Serum
Tc - - 100 - -
NSB 100 - 100 - 300
Bo - 100 100 - 300
STDS - 100 100 100 200
Sample - 100 100 300 -
Method grid for 300^1 sample and standards in buffer
sample/ .r 'volume Buffer Antibody Tracer STD/Sample Serum
Tc - - 100 - -
NSB 200 - 100 - 300
Bo 100 100 100 - 300
STDS - 100 100 100 300
Sample 100 100 100 300 -
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2.2.1.3 Assay buffers
Three buffer solutions are required for the Monash based RIA for human Inhibin:
1. Assay buffer: 0.01M PBS, 0.5% BSA, pH7.4
1. Make stock solution (0.5M PBS) by:
Add7.8g NaH2P04.2H20(MWt= 156.01 g) to lOOmls distilled water (0.5M soP)
Add 7.1g of Na2HPC>4 andydrous (MWt = 141,96g) to lOOmls distilled water
(0.5M soP). Mix 23.5mls of the first solution with lOOmls of the second and adjust
pH to 7.4. Store at -20°C in 10ml aliquots.
ii. Dilute stock (0.5MPBS) 1 in 50 by adding 490mls distilled water to a 10ml aliquot
iii.Add4.5g NaCl, 500mg Na Azide, 2.5g BSA
2. Tracer buffer:
i. Add 0.1 % (v/v) Triton X to Assay buffer.
3. Separation stage buffer: normal saline (0.9% NaCl)
2.2.2 Medgenix assay
The second immunoassay used was a commercial solid-phase two site
immunoenzymatic assay (Medgenix, High Wycombe UK), used according to the
manufacturers instructions. The two antibodies employed in this assay were directed
against distinct epitopes of the a-subunit of human inhibin. Human inhibin was used
as standards and the results were expressed as U/ml. The sensitivity of the assay was
0.1 U/ml and the coefficients of variation of intra-assay and inter-assay were 1.9% and
8.9% respectively.
There are reports of the use of both of the inhibin immunoassays in human sera in
pregnancy (McLachlan et al 1987, Yohkaichiya et al 1991, Tabei et al 1991, Kettel et
al 1991, van Lith et al 1992, Yohkaichiya et al 1993) and no further validation of these
assays was performed.
2.3 Inhibin enzyme linked immunosorbent assays (ELISAs)
2.3.1 Inhibin-A ELISA
The preparation of monoclonal antibodies to the inhibin <x-subunit (Groome etal 1990)
and subsequently the inhibin p-subunit (Groome and Lawrence 1991) allowed the
development of a two-site immunoassay for inhibin-A (Groome 1991). Assay
sensitivity sufficient for the application of the assay to human sera was achieved with
modifications to the assay format (Groome and O'Brien 1993), including a pre-assay
sample treatment step that oxidises the methionine residues in the p-subunit epitope
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(Knight and Muttukrishna 1994). The assay has been previously validated for human
sera, firstly in non-pregnant menstrual cycle sera (Groome et al 1994, Muttukrishna et
al 1994) and then in pregnancy sera (Muttukrishna et al 1995).
During the course of the studies undertaken for this thesis a number of further
modifications were made to this ELISA. These modifications were suggested by Nigel
Groome and led to significant cost savings and improved assay performance. The
original method (format I) and the various modifications are described succinctly
below and simply referred to by format number elsewhere in the thesis. The current,
preferred format is format III (see also Chapter Seven) and the full methodology of
this format is given in detail.
Format I: Prior to adding to the microtitre plate, each sample or standard is mixed with
1 % hydrogen peroxide (final w/v) and incubated at room temperature for 30 minutes.
This is the peroxide step that modifies the G-subunit epitopes to improve reactivity with
the respective antibody (Knight and Muttukrishna 1994) and thereby increases the
assay sensitivity. Each sample or standard is then diluted 1:1 in assay diluent (0.1M
Tris HC1, 0.15M NaCl with 5% triton X100, 10% bovine serum albumin, 5% normal
mouse serum, pH7.5) and then added to the plate. The assay utilises an immobilised
anti (Sa-in hi bin subunit monoclonal antibody (E4) as a capture antibody, covalently
coupled to hydrazide microplates (Avidplate-HZ, UniSyn Technologies, CA, USA).
The Fab fraction of a mouse anti a-inhibin subunit monoclonal antibody (Rl) is used
as a second antibody diluted in assay diluent. This is conjugated to alkaline
phosphatase, allowing detection by the addition of an amplified enzyme assay (Life
Technologies, Paisley, UK) which affords colour change. Absorbency is measured
after 20-30 minutes at 490nm in a microplate reader (Thermomax, Molecular Devices
Corp., CA, USA) using dedicated software (Softmax, Molecular Devices Corp.).
Results are expressed as pg/ml. The sensitivity of the assay is 8 pg/ml and the intra-
and inter-plate coefficients of variation are 4.7% and 10%, respectively.
Format II - This method is identical to method I except for the method of signal
detection. The high degree of sensitivity developed in the original method, while
required for the detection of inhibin-A throughout the human menstrual cycle (Groome
et al 1994), was not required for the very high levels of inhibin-A in pregnancy sera
(ChaptersFour, Five and Six). A simplified and cheaper method of detection using a
non-amplified alkaline phosphatase substrate, p-nitrophenylphosphate (pNPP),
(Kirkegaard and Perry Laboratories, Maryland, USA) was therefore validated by
Groome. Using this method plates are read after 2-4hrs at 405 nm in a microplate
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reader as before. Results are expressed as pg/ml with an assay sensitivity of 23 pg/ml.
The intraplate and interplate coefficients of variation are 5.6% and 6.3%, respectively.
Format III - This method involves an additional sample preparation step, performed
prior to oxidation. During the early application of the assay to clinical serum samples it
was observed that signals could not be obtained from some samples, particularly,
though not exclusively, those with evidence of haemolysis (E Wallace, personal
observation). This was believed to be due to a reaction between catalase, an enzyme
released by red blood cells on lysing, and the peroxide, quenching the oxidative effect
on the inhibin. Recently, Groome and his colleagues developed and described ELISAs
similar to the inhibin-A assay but specific for inhibin-B and activin-A (Groome et al
1996, Knight et al 1996). These latter assays incorporated a pretreatment step,
involving heating the sample or standard in a waterbath at 100°C for 3 minutes after
mixing with 2% (final w/v) sodium dodecylsulphate (SDS). This was found to be
effective in removing interfering substances from the samples and was subsequently
applied to the inhibin-A assay. While parallelism, recovery and sensitivity of the
modified assay are comparable to the original method (Groome, in-house data) it was
observed that with the modification signals could be generated from all samples,
including those in which no inhibin had been previously detectable. Detection is
afforded by the addition of pNPP as detailed in method II. Results are expressed as
pg/ml with an assay sensitivity of 23 pg/ml. The intra- and inter-plate co-efficient of
variation are 4.9% and 8.7%, respectively.
Standard preparations: in addition to the modifications to the assay format described
above, Nigel Groome prepared an in-house calibrator, allowing the commercial
distribution of his reagents. Some of the studies reported in this thesis utilised the
original standard (a 32kD recombinant human (rh) inhibin supplied by Genentech
Inc.,CA, USA), denoted in this thesis by "RH", while others utilised the new
preparation. This is partially purified from human follicular fluid and was calibrated
against the rh inhibin using assay format I. It is denoted by "IP" hereafter.
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The full methodology of the inhibin-A ELISA (format III) is:
2.3.1.1 Oxidation ofprimary antibody, E4 (and- inhibin f-subunit Ab)
1. Take 2 mis of E4 Ab (1 mg/mL), out of the refrigerator.
2. Take the benzoylated dialysis tubing out of the refrigerator, cut an appropriate
piece off and wash with distilled water.
3. Put the 2 mis E4 Ab in the dialysis tubing and close the tubing securely with clips.
4. Dialyse E4 Ab against 3 changes of 5 litres 50mM acetate buffer (soP 1) at 4°C.
5. Add 0.1 volume sodium periodate solution (soP 2) to the E4 Ab and incubate in
the dark at room temperature.
6. Add 0.01 volume of ethylene glycol.
7. Dialyse the antibody solution against 5 litres of acetate buffer at 4°C, overnight.
8. Read the final absorbance in a 1 cm cell, to calculate amount of antibody. Ab
concentration (mb/mL) = absorbance/1.4.
2.3.1.2 Coating plates
1. Remove dry plates (Avidplate-HZ, UniSyn Technologies, CA, USA) from
refrigerator. Bring to room temperature.
2. Make up Ab/coating solution (soP 3), using stock coating solution (soP 2) and
oxidised E4 Ab.
3. Add 50p\ solution to each well. Incubate at room temperature in a covered box,
keeping moist, overnight.
4. One plate at a time, bang dry and add 150//1 of blocking solution (soP 4).
5. Plates can be stored refrigerated for 3-6 months. Evaporation must be prevented.
2.3.1.3 Assay method
1. Defrost samples and standards. Mix on vortex when thawed.
2. Defrost assay diluent (soP 5).
3. If the expected inhibin level is in excess of top standard (1500pg/ml) then dilute
appropriately with fetal calf serum.
4. Put 100/d of each standard and bloodsample, or 50p\ of amniotic fluid sample
into a 2mL Sarstedt tube.
5. Add 50p\ of 6% SDS (soP 6) to each standard and sample. Mix.
6. Using polystyrene "floats" place all standards and samples in boiling water for 3
minutes. Allow to cool.
7. Add 10/d of 15% hydrogen peroxide (soP 7) to each sample or standard. Mix.
Allow to stand for 30 minutes.
8. Remove plates from refrigerator.
9. Add 100^1 of assay diluent to each tube. Mix.
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10. Take an E4 coated hydrazide plate and wash it 10 times in wash buffer (soP 8).
Bang dry on tissue. Without allowing the plate to dry, add 100/d of the sample to
duplicate wells on the microtitre plate. Cover the plate with a seal and place in the
refrigerator.
11. Incubate the plate overnight. Shaking is not required.
12. The following day, wash the plate 4 times with wash buffer and bang dry.
13. Immediately add 50/d Fab R1 alkaline phosphatase conjugate to each well (soP
9). Reseal plate and shake at room temperature for 1 to 2 hours.
14. Wash the plate 10 times in wash buffer and bang dry.
15. Immediately add 100/d of alkaline phosphatase substrate (pNPP)(soP 10). Reseal
the plate and shake for 3 to 4 hours.
16. Stop the colour change with 100/d of 5% EDTA (soP 11). Read the plate with
plate reader at 405nm and 650nm.
2.3.1.4 Assay solutions
1. Acetate buffer / Coating solution: Add 20.5g Na acetate-anhydrous and 42.5g
NaCI to 5000mls of distilled H20. pH was adjusted to 5.0.
2. Sodium periodate solution (lOOmM): Add 21mg Na periodate to 1ml distilled
HA
3. Antibody coating solution (5fig Ab /ml): To coat 20 plates lOOmls (500 fig Ab)
are required. Add Ab to SoP 1.
4. Blocking solution: Add lOOmls stock 0.4M HC1 to 300mls distilled H20 (0.1M
HC1) Discard 50mls and add 4.24g Tris (1.22g/100mls), 3.5g of bovine serum
albumine and 0.35g sodium azide. Adjust pH to 7.5
5. Assay diluent: Add 12.10g Tris and 8.8g of NaCI to lOOOmls 0.1M HC1. Adjust
pH to 7.5 with NaOH. Remove lOOmls and add 50mls of triton X100 (5% w/v),
lOOg protease free bovine serum albumin (10% w/v), 50mls of normal mouse
serum (pre-fdtered 0.4/d fdter) and lg of NA sodium azide. Freeze in 100ml
aliquots.
6. Sodium dodecyl sulfate solution: Add 6g of SDS to 100 mis distilled HzO.
7. Hydrogen peroxide solution (15%): Add 3mL stock hydrogen peroxide (30%) to
3mL distilled HzO.
8. Wash buffer solution: Add 52.62g NaCI, 36.36g Tris, and 3mls of Tween 20 to
5.5L distilled HzO. Using HC1 adjust to pH 7.5 and make up to 6L with distilled
H20. Store at room temperature.
9. Fab R1 alkaline phosphatase conjugate (1:200 dil.): Add 120/d of R1 to 24mls
soP 5
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10. P-nitrophenylphosphate substrate: Add 9mls of diethanolamine concentrate, 9
substrate tablets and 45]A of 1M magnesium chloride to 36mls distilled H20.
11. 5% ethylenediaminetetra-acetic-acid solution: Add 5g EDTA disodium salt to
lOOmls distilled H2O.
2.3.2 Inhibin-B ELISA
Inhibin-B was measured using a similar two-site ELISA as previously described
(Groome et al 1996). The detailed protocol and assay buffers and wash solution are
essentially identical. A monoclonal antibody (C5) raised against the human inhibin fig
subunit was used as a capture antibody, biotinylated and immobilised on streptavidin-
coated microplates (Life Sciences International, Basingstoke, UK). The same second
antibody (Rl) as used in the inhibin-A assay was employed. Samples and standards
were also pretreated as detailed above, but in this assay the signal was detected using
the alkaline phosphatase amplification kit detailed in format I of the inhibin-A assay
(Life Technologies, Paisley, UK). Standard preparation IP was used as a standard but
was calibrated against recombinant human inhibin-B with results expressed in pg/ml.
Plates were read at 490nm using the same apparatus and software as detailed for the
inhibin-A assay. The assay detection limit was less than 5pg/ml. Activin-A, activin-B,
follistatin and purified human pro-«C had less than 0.1% cross reaction while
recombinant inhibin-A had a 0.5% cross reaction. The intra- and inter-plate
co-efficients of variation are 7.6% and 8.1%, respectively.
The full methodology of the inhibin-B ELISA is:
2.3.2.1 Coating Plates
1. Remove streptavidin coated dry plates (Combiplate 8) from refrigerator. Bring to
room temperature.
2. Makeup Ab/coatingsolution. (5//g/ml biotinylated C5 in 1% BSA Tris-HCl, pH
7.5)
3. One plate at a time, wash several times in distilled HzO and add 50/d Ab solution
to each well.
4. Incubate at room temperature in a covered box, keeping moist, overnight.
5. One plate at a time, bang dry and add 100^1 of blocking solution (Sol- 4 above).
Plates can be stored refrigerated for 3-6 months. Evaporation must be prevented.
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2.3.2.2 Assay method
1. Defrost samples and standards. Mix on vortex when thawed.
2. Defrost assay diluent (sola 5).
3. If the expected inhibin level is in excess of top standard (1625pg/ml) then dilute
appropriately with fetal calf serum.
4. Put 100/d of each standard and sample into a 2mL Sarstedt tube.
5. Add 50/d of 6% SDS (sola 6) to each standard and sample. Mix.
6. Using polystyrene "floats" place all standards and samples in boiling water for 3
minutes. Allow to cool.
7. Add 10/d of 15% hydrogen peroxide (sol" 7) to each sample or standard. Mix.
Allow to stand for 30 minutes.
8. Remove plates from refrigerator.
9. Add 100/d of assay diluent to each tube. Mix.
10. Take an C5 coated streptavidin plate and wash it 10 times in wash buffer (sop 8).
Bang dry on tissue. Without allowing the plate to dry, add 100/d of the sample to
duplicate wells on the micro plate. Cover the plate with a seal and place in the
refrigerator.
11. Incubate the plate overnight. Shaking is not required.
12. The following day, wash the plate 10 times with wash buffer and bang dry.
13. Immediately add 50/d of the Fab Rl alkaline phosphatase conjugate (soln 9) to
each well. Reseal plate and shake at room temperature for 1 to 2 hours.
14. Reconstitute alkaline phosphatase substrate (2 bottles for 4 plates). Mix, stand for
10 minutes prior to use. (Remember to add 12/d MgCl to substrate)
15. Wash the plate 10 times in wash buffer and bang dry.
16. Immediately add 50/d of alkaline phosphatase substrate. Reseal the plate and
incubate at 37°C for 2 hours.
17. Reconstitute alkaline phosphatase amplifier (2 bottles for 4 plates). Mix, stand for
10 minutes prior to use.
18. Add 50/d of amplifier to each well. Watch as colour develops and stop with 50/d
of 0.4M HC1. Read plate at 490nm and 650nm.
2.3.3 Pro-aC containing inhibins ELISA
Inhibin forms containing pro-aC were detected using the specific ELISA as recently
described (Groome et al., 1995) with some modifications. This assay uses a capture
monoclonal antibody (INPRO) raised against a sequence of the pro-aC (x-subunit, and
an immunopurified standard calibrated against rh 32kDa inhibin, as described in detail
(Groome et al 1995). Unlike the inhibin-A and inhibin-B assays, after diluting samples
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with assay buffer, standards and samples samples were added directly to the plate
without pre-assay oxidation or boiling. The same detection antibody (Rl) was used as
in the dimeric inhibin assays, and the alkaline phosphatase activity was detected using
pNPP substrate, as in the inhibin-A assay formats II and III. Recombinant forms of
inhibin-A, inhibin-B and follistatin all cross-react less than 0.02%, although this
antibody may cross-react with the larger dimeric inhibin isoforms containing the
(x-subunit pro sequences as demonstrated by immunoblotting studies (Groome et al
1995). The intra- and inter-plate coefficients of variation are 5.2% and 8.1%,
respectively. The detection limit was 3 pg/ml.
The full methodology of the inhibin pro «C ELISA is:
2.3.3.1 Assay method
1. Defrost samples and standards. Mix on vortex when thawed.
2. Remove plates from refrigerator.
3. If the expected inhibin level is in excess of top standard (lOOpg/ml) then dilute
appropriately with fetal calf serum.
4. Take a Pro-aC coated plate and wash it 10 times in wash buffer. Bang dry on
tissue. Without allowing the plate to dry, add 50/d of the sample / standard to
duplicate wells on the microplate. Cover the plate with a seal and place in the
refrigerator.
5. Incubate the plate overnight. Shaking is not required.
6. The following day, wash the plate 10 times with wash buffer and bang dry.
7. Immediately add 50/d of the Fab Rl alkaline phosphatase conjugate (check
dilution - this may vary) to each well. Reseal plate and shake at room temperature
for 1-2 hours.
8. Switch on incubator, set for 37°C, ready for step 11.
9. Reconstitute alkaline phosphatase substrate (2 bottles for 4 plates). Mix, stand for
10 minutes prior to use. (Remember to add 12/d MgCl to substrate)
10. Wash the plate 10 times in wash buffer and bang dry.
11. Immediately add 50/d of alkaline phosphatase substrate. Reseal the plate and
incubate at 37°C for 2 hours.
12. Remove plates from incubator and allow to cool for 5 minutes.
13. Reconstitute alkaline phosphatase amplifier (2 bottles for 4 plates). Mix, stand for
10 minutes prior to use.
14. Add 50/d of amplifier to each well. Watch as colour develops and stop with 50/d
of 0.4M HC1. Read plate at 490nm and 650nm.
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2.4 Validation of the inhibin-A ELISA
The use of the inhibin-A, inhibin-B and pro-aC inhibins ELISAs in pregnancy sera has
been previously reported and validated (Muttukrishna et al 1995, Illingworth et al
1996a). However, there are no previous studies reporting their application to human
amniotic fluid or extra-embryonic coelomic fluid, nor are there studies describing the
performance of the different inhibin-A ELISA formats. Validation of the inhibin-A
ELISA in extra-embryonic coelomic fluid and the inhibin-B and pro-aC inhibin
ELISAs in amniotic fluid and extra-embryonic coelomic fluid was performed by Dr
Simon Riley, University of Edinburgh specifically for these studies. Details of these
procedures are therefore not reported here, as is appropriate, but are reported
elsewhere (Riley etal 1996, Wallace etal 1997). However, validation of the inhibin-A
assay in amniotic fluid and formal assessment of the performance of this assay in
clinical samples is reported here, representing original and novel work.
2.4.1 Serum stability study
The potential usefulness of any marker of Down's syndrome will depend in part upon
the stability of the marker in vitro. For example, levels of free p-hCG increase
significantly over 72 hours under conditions similar to those that would be expected
during sample transport between doctor and laboratory (Sancken and Bahner 1995),
an effect that may alter risk estimates and so require correction prior to interpretation.
To explore the possibility that storage might alter the level of inhibin-A detected a small
stability study was undertaken.
2.4.1.1 Methods
Blood was collected, with consent, by routine venepuncture from ten normal women
in midpregnancy. Each sample was divided into two aliquots. One aliquot was
centrifuged and the other kept unseparated at room temperature. The serum from the
former aliquot was further divided into three sub-aliquots, one of which was frozen at
-20°C immediately. The remaining two serum sub-aliquots were kept at room
temperature with subsequent frozen storage (-20°C) of one after 24 hours and the other
after 48 hours. The whole blood aliquot was similarly divided into 2 sub-aliquots.
These were centrifuged at 24 and 48 hours, allowing frozen storage (-20°C) of the
serum at those times. Inhibin-A levels were measured using assay formats II and III
with the IP standard. Ethical approval was obtained from the Lothian Research Ethics
Committee.
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2.4.1.2 Statistical analyses
Statistical analyses were performed using the software package Statview 4.1 (Abacus
Inc., Berkeley, CA, USA). Inhibin-A levelswere subjected to two-way analysis of
variance (ANOVA)for repeated measures. Significance was recognised when p<0.05.
2.4.1.3 Results
Figure 2.1 shows the mean ± SEM inhibin-A level in the ten samples as measured by
assay formats II and III and by method of storage. Using format II the mean inhibin-A
level in samples stored as whole blood declined significantly (p<0.01), with a fall of
42% at 48 hours, whereas levels were stable for the samples stored as serum. When
format III was employed however, no significant changes in the mean inhibin-A level
were observed, regardless of how the samples had been stored.
Figure 2.1.
Changes in inhibin-A levels with storage (mean ±SEM) in samples from 10 pregnant
women. Baseline sample = E3, whole blood=H, serum=D .
350
280 -
fresh 24 hours 48 hours fresh 24 hours 48 hours
Assay format II Assay format III
27
Assay Methodology and Validation
2.4.2 Freeze-thaw stability study
Similarly, considering that many of the studies related in this thesis were performed
using archival sera, some of which had been freeze-thawed on more than one
occasion, it was considered important to examine whether these processes exerted a
significant effect on inhibin-A levels.
2.4.2.1 Methods
Blood samples were collected, with written informed consent, from eleven women in
midpregnancy. In each case, the serum was separated in to six aliquots. On the day of
collection, the fresh sample was assayed, without freezing, for inhibin-A. Each of the
other aliquots was exposed to from one to five freeze-thaw cycles and then assayed for
inhibin-A.
2.4.2.2 Statistical analyses
Statistical analyses were performed using the software package Statview 4.1 (Abacus
Inc., Berkeley, CA, USA). The levels of inhibin-A, expressed as a percentage of
baseline, were subjected to two-way analysis of variance (ANOVA) for repeated
measures. Significance was recognised when p<0.05.
2.4.2.3 Results
There was no significant change in inhibin-A levels with repetitive freeze-thawing of
up to five cycles (figure 2.2, page 29).
2.4.3 Assessment of the effect of incubation time on inhibin-A levels using format II
In addition to affording significant cost benefits, the use of a simple alkaline
phosphatase substrate in the inhibin-A ELISA format II, in place of the amplification
kit in format I, allowed plate reading to be performed over a very broad time window.
In comparison, using format I colour changes was often maximum at only 10-15
minutes after adding the amplifier. However, no data were available to assess the
effects of prolonging the incubation time following the addition of the substrate pNPP
nor to allow a comparison between this format and format I.
2.4.3.1 Methods
Two assays with identical samples were run simultaneously, one using format I and
one using format II. No stop solution was added to the format II plate allowing
multiple readings over several hours. Levels of inhibin-A were then compared between
methods and over time.
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2.4.3.2 Statisticalanalyses
Statistical analyses were performed using the software package Statview 4.1 (Abacus
Inc., Berkeley, CA, USA). Simple regression analysis was performed between the
results obtained by the two methods or between readings.
Figure 2.2
Inhibin-A levels (mean ±SD), expressed as a percentage of baseline (fresh) in 11























There was a strong and highly significant correlation of inhibin-A levels obtained by
format I with format II, irrespective of when the format II plate was read (figure 2.3,
page 30) . Similarly, delayed reading, up to 20 hours, did not affect the relative levels
of inhibin-A obtained with format II, except that with increasing time the samples with
high levels, and the top standards, became un-readable.
2.4.4 Validation of inhibin-A assay in amnioticfluid.
2.4.4.1 Methods
Recombinant human inhibin-A was added to ten amniotic fluid samples, each of
known inhibin-A content. Serial dilution of amniotic fluid samples was also performed
and the dilutions assayed for inhibin-A.
29
Assay Methodology and Validation
2.4.4.2 Results
Recovery of recombinant human inhibin-A spiked into AF was quantitative (mean
±SEM 108 ± 13%, n=10). Serial dilution of AF samples gave dose responses parallel
to that of the immunopurified standard (figure 2.4, page 31).
Figure 2.3
Regression plots of inhibin-A levels obtained using ELISA formats I and II and of
inhibin-A levels over time of plate incubation in format II.
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Figure 2.4
Dose-response relationships for immunopurified inhibin standards with serially diluted
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2.5 Discussion and conclusions
This chapter has described in detail the different inhibin immunoassays used in the
studies reported in this thesis. In particular, the recently developed sensitive and
specific ELISAs for inhibin-A, inhibin-B and pro-aC inhibins are described in detail.
Further, since the inhibin-A ELISA evolved considerably over the course of the
studies, this process of evolution is described and evaluated. Chapter Seven re-visits
this issue in the context of Down's syndrome screening and affords insights into, not
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The simple stability studies showed that inhibin-A is stable under repetitive
freeze-thaw cycles to at least five cycles. Further, the studies showed that inhibin-A
levels fell when samples were stored, at room temperature, as whole blood but not as
serum, and that when the samples were boiled prior to assay the decline was
prevented. The changes observed with format II (no boiling) could not have been due
to dissociation of the inhibin dimer, because levels were stable with format III (SDS
boiling), but rather to an effect related to storage as whole blood, but not serum. This
is quite different to hCG which dissociates during storage (Sancken and Bahner
1995), an effect recently shown to be secondary to microbial action (Kardana and Cole
1997). It is therefore suggested, and discussed again in more detail in Chapter Seven,
that this effect is due to the release of catalase from the red blood cells, which will
quench the oxidising effect of the hydrogen peroxide pretreatment step. Importantly, a
quenched inhibin-A signal was evident in the stability study samples even without
obvious haemolysis. These data therefore suggest that while the apparent inhibin-A
levels is stable in clinical samples, this is only so when using format III. In the context
of possible prenatal screening programmes, when samples might travel for some
distance and time prior to assay, this is clearly an important observation.
The introduction of a simple alkaline phosphatase substrate (formats II and III)
afforded significant cost savings. However, the colour change reaction was much
slower than that observed with the amplified substrate method used in format I and it
was not known what the stability of this process was. The simple experiment detailed
in 2.4.3 showed that not only were the results obtained with formats I and II very
similar (r<0.9), a finding expanded upon in Chapter Seven, but that this was so,
irrespective of when the format II plate was read, up to 20 hours. Similarly, levels of
inhibin-A obtained with format II did not change with time of plate reading, again up
to 20 hours. This was an important finding because it allowed many plates to be run
consecutively and then read the following day.
The spiking and serial dilution experiments represent simple methods of assay
validation for amniotic fluid. As in serum (Groome et al 1994), it would appear that
the ELISA is detecting inhibin-A.
In conclusion, the series of small, but necessary, experiments related in this chapter
have set the foundations on which the studies detailed in the following chapters are
based.
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3.1 Introduction
As discussed in detail in Chapter One while inhibins were originally identified and
isolated from gonadal tissue it was soon apparent that a number of other tissues might
produce and secrete inhibins, including the placenta. The presence of inhibin-like
bioactivity in the placenta was first demonstrated using aqueous extracts of rabbit
placentae to suppress FSH secretion from dispersed rat anterior pituitary cells in vitro
(Hochberg et al 1981). Subsequently, the development of an inhibin
radioimmunoassay (McLachlan ct al 1986b) afforded the observation that a substance
with inhibin bioactivity and inhibin immunoactivity that diluted in parallel to human
follicular fluid was present in the human placenta (McLachlan et al 1986a). Messenger
mRNA for the inhibin a-subunit was also identified in a human placental cDNA library
(Mayo et al 1986) and inhibin-like activity immunolocalised within the placenta
(Petraglia et al 1987). Studies of placental extracts (Healy et al 1988) and primary
trophoblastcell cultures (Petraglia et al 1987) also confirmed that the placenta yielded
large concentrations of inhibin immunoactivity.
Considering these data, that circulating serum levels of immunoreactive inhibin in
pregnancy are much higher than observed in non-pregnancy (McLachlan et al 1987,
Abe et al 1990, Kettel et al 1991, Tabei et al 1991, Tovanabutra et al 1993) and that
after delivery of the placenta inhibin levels become undetectable within 4 - 5 days (Abe
et al 1990, Kettel et al 1991, Qu and Thomas 1992, Tovanabutra et al 1993) the
placenta is currently considered the major, if not sole, source of inhibin in human
pregnancy (Qu and Thomas 1995).
However, all of the aforementioned studies that reported circulating levels of inhibin
were performed using non-specific immunoassays and were unable to discern levels of
bioactive, and so presumably physiologically important, inhibin forms from inactive
free inhibin subunits. Indeed, while the immunoassays revealed a biphasic pattern of
inhibin secretion in pregnancy, with an initial peak of inhibin levels at 9 -10 weeks
(Abe et al 1990, Tabei et al 1992, Tovanabutra et al 1993) then a fall to a plateau
between 15 and 30 weeks, rising thereafter so that the highest levels are achieved by
term (Abe et al 1990, Tabei et al 1992, Qu and Thomas 1992, Tovanabutra et al 1993),
bioactive inhibin levels appeared to rise steadily throughout pregnancy without the
biphasic profile (Qu and Thomas 1991). This apparent difference between the
ontogeny of inhibin bioactivity and immunoactivity would be consistent with a relative
excess of inactive forms in early pregnancy, mirroring the relative excess of inhibin
(x-subunit mRNA at this gestation (Petraglia et al 1991). However, more recently,
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using an ELISA specific for inhibin-A, it was reported that maternal serum inhibin A
levels in pregnancy display a biphasic profile (Muttakrishna et al 1995, Illingworth et
al 1996) consistent with the inhibin immunoreactivedata rather than the bioactive data.
Furthermore, there has been some debate about the relative contributions of the
placenta and the ovary to maternal serum levels of inhibin in very early pregnancy
(McLachlan etal 1987, Lenton et al 1991, Santoro et al 1992, Illingworth et al 1996,
Rombauts et al 1996).
This series of studies were undertaken to explore more fully the biology of inhibins in
early human pregnancy by describing the levels of inhibins in different pregnancy
compartments at different gestations in chromosomally normal singleton and twin
pregnancies.
3.2 Materials and Methods
3.2.1 Matched first trimester maternal serum, amniotic and extra-embryonic fluid
samples
Matched samples of maternal serum (MS), extra-embryonic coelomic fluid (EECF)
and amniotic fluid (AF) from 20 pregnancies were generously supplied by Professor
Tim Chard, St Bartholomew's Hospital, London. The EECF and AF had been
obtained by transvaginal ultrasound guided needle aspiration prior to the termination of
pregnancy under general anaesthesia, as described previously (Wathen et al, 1991).
All pregnancies were between 8 and 11 weeks of gestation at the time of surgery,
calculated by measurement of the crown-rump length (Drumm et al 1976), and were
confirmed viable by ultrasound. Women with vaginal bleeding were not included in
the study. The MS samples were obtained prior to the induction of anaesthesia. This
study had local hospital ethical approval.
3.2.2 Maternalserum samples.
Sera were provided through collaboration with Dr David Aitken and Dr Jenny
Crossley, both of the Duncan Guthrie Institute of Human Genetics, Glasgow. The
sera had been collected prospectively, as part of the routine West of Scotland Down's
syndrome and neural tube defects prenatal screening programme and from an ongoing
first trimester study of maternal serum markers, and retrieved from storage in Glasgow
for this study. Specifically, sera from chromosomally normal singleton and twin
pregnancies were identified, through the exclusion of chromosomally abnormal
pregnancies, and retrieved from storage. All chromosomally abnormal pregnancies are
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identified by the screening programme, either through early pregnancy karyotyping or
birth records where karyotyping is not been performed. At the time of collection each
sample had been centrifuged and the serum separated within three days of collection
and stored at -20°C. For this study, the retrieved sera were transported in dry ice to
Edinburgh for assay.
The case-records of a random cohort of the samples were also retrieved affording
details of the sex of the babies from the pregnancies studied
3.2.3 Amniotic fluid samples.
Aliquots of amniotic fluid (AF) were obtained through collaboration with Dr Pat Ellis
and Mrs Mary Shade, both of the regional cytogenetics laboratory in Edinburgh,
Scotland. These had been collected prospectively as part of the clinical amniocentesis
service in South East Scotland. In each case AF has separated from fetal epithelial
squamous cells by centrifugation at 250 x g either on the day of collection or on the
day after. An aliquot of each AF sample was then taken specifically for this study and
stored at -20°C prior to assay. The karyotype from each sample was reported
subsequently.
3.2.3 Matched maternalserum and amnioticfluid samples.
In 47 women venepuncture was performed immediately prior to amniocentesis. In
each case amniocentesis was performed for maternal age and all samples were
collected at between 14 and 16 weeks of pregnancy. The blood was centrifuged and
the serum separated on the day of collection and stored at -20°C until assay. The AF
was processed by the cytogenetics laboratory as detailed above. In each case the
karyotype was subsequently reported as normal.
3.2.5 Umbilical cord serum samples.
Umbilical blood, both arterial and venous, was collected from 45 normal singleton
pregnancies. In each case, labour onset had been spontaneous and at term (37-41
weeks of pregnancy). After delivery of the baby the cord was double clamped and
blood taken after completion of the third stage of labour (delivery of the placenta). The
blood, both arterial and venous, was centrifuged on the day of collection, the serum
separated and stored at -20°C until assay.
For each of the sample sets (EECF, AF, MS or umbilical cord serum) the gestation at
the time of sampling was calculated from certain menstrual dates or from an early
pregnancy ultrasound scan and is reported in completed weeks of pregnancy.
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3.2.6 Inhibin assays.
In all of the sample sets inhibin-A was measured using the fully modified two-site
ELISA as described in Chapter Two (page 19). Similarly, inhibin-B and pro-aC
containing inhibins were measured using the ELISAs described and validated in
Chapter Two (page 22 and 24, respectively).
3.2.7 Statistical analyses.
All statistical analyses were performed using Statview 4.1 (Abacus, USA) and SPSS
for Windows (SPSS Inc, USA). Where appropriate, regressed medians were
calculated to compare the ontogeny of the inhibins in each compartment and multiples
of the median (MoM) were used to correct for gestational changes, allowing group
comparisons across gestations. The regression equations were kindly calculated by Dr
Jenny Crossley (see Acknowledgments, page viii).
The regression equations calculated were:
AF inhibin-A: median= e(l 1.3209 - 84.616/gestation)
AF inhibin-B: median= e(9-3254 ~ 41.656/gestation)
MS inhibin-A: median = -0.0129006x5 + 0.988003x4 - 29.6031 x3 + 434.528x2-
3136.00x + 9078.01, (where x = gestation).
3.3 Results
3.3.1 Inhibins in First Trimester Pregnancy Compartments.
There were insufficient cases (n=20) to be able to discern any changes in protein levels
with gestation and therefore the results for all 20 pregnancies have been grouped
together and analysed by protein and by pregnancy compartment, with no assessment
of the effect of gestation. Figure 3.1 and table 3.1 display the individual sample results
and the median (±SEM) concentration of each protein in MS, AF and EECF,
respectively.
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Figure 3.1
Levels of inhibin-A (•), inhibin-B (a) and pro-aC containing inhibins (♦) in MS,


































Inhibin-A was present in MS and EECF with concentrations significantly higher in MS
(p=0.04, Wilcoxon rank sum), but was undetectable in AF, except for one sample.
Inhibin-B was present in EECF but was undetectable in both AF and MS. In EECF,
there was significantly more inhibin-A than inhibin-B (p<0.0001, Wilcoxon rank
sum). Pro-uC containing inhibin was detectable in all three compartments, with no
significant differences between levels in the compartment (Wilcoxon rank sums; all
p>0.05). Concentrations of the immunoreactive pro-aC form were significantly higher
than the other two proteins in extra-embryonic coelomic and amniotic fluid and in
maternal serum (p< 0.0001, MS inhibin-A v MS pro-«C; p<0.0001 EECF inhibin-A v
pro-aC; pcO.0001 EECF inhibin-B v pro-aC; all Wilcoxon rank sums).
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Table 3.1
Levels of inhibin-A, inhibin-B and pro-aC containing inhibin (pg/mL, median ±SEM)
in 20 matched samples of EECF, AF and MS at 8-11 weeks of pregnancy
Inhibin-A Inhibin-B pro-aC
Extra-embryonic coelomicfluid 236.0 +24.8 62.0 ±8.6 591.7±60.5
amniotic fluid - - 452.4±76.8
maternal serum 360.2±32.9 - 539.4+39.5
The levels of immunoreactive pro-«C in all three compartments were not significantly
associated with each other nor with levels of inhibin-A in MS. In EECF, and
inhibin-A were significantly associated (r=0.62, p=0.003), but not pro-«C inhibins
and inhibin-B (r=0.12, p=0.61). Inhibin-A and inhibin-B in EECF were weakly but
not significantly associated (r=0.42, p=0.06).
3.3.2 Dimeric inhibins in maternalserumfrom 10 to 20 weeks ofpregnancy.
Inhibin-A and inhibin-B were measured in maternal sera from 807 chromosomally
normal singleton pregnancies from 10 to 20 completed weeks of pregnancy. Table 3.2
(page 40) details the distribution of these sera by gestation and the median (10^ - 90^
percentiles) inhibin-A levels. Figure 3.2 (page 41) displays the regressed data,
showing that inhibin-A levels fell from 10 weeks to a nadir at 17 weeks, rising again
to 20 weeks.
Sexing information was available from the case-records of 165 (20%) of the 807
pregnancies. 91 (55%) of these 165 pregnancies were males and 74 (45%) were
females. These were distributed across the gestational ages as detailed in table 3.3
(page 40). When expressed as multiples of the median (MoM), to correct for gestation,
there were no differences between the males and females (1.02 MoM v 1.04 MoM for
male and females respectively, p=0.88, Mann-Whitney U test).
Inhibin-A was measured in MS from 268 chromosomally normal twin pregnancies
between 10 and 20 weeks of gestation. Table 3.4 shows the lO^1, 50^ and 90^
percentiles for inhibin -A in these pregnancies. No significant differences with
gestation were apparent (p>0.05). However, when compared to the MS inhibin-A
levels observed in the 807 singleton pregnancies, levels in twin pregnancies were
significantly higher (Mann-Whitney U test, p<0.001), being approximately doubled.
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Table 3.2
Median, 10th and 90th percentile inhibin-A levels (pg/mL) in maternal serum from 807
chromosomally normal singleton pregnancies
Gestation
(completed weeks)
No. of samples 10th 50th 90th
10 75 101.4 177.5 290.7
11 75 88.8 164.3 277.8
12 75 86.8 159.1 253.5
13 75 62.3 133.9 212.2
14 75 73.8 157.4 295.0
15 75 73.2 142.5 261.2
16 75 54.2 119.2 189.4
17 75 59.5 111.9 200.3
18 75 67.3 156.0 291.2
19 75 61.2 146.2 180.3
20 57 74.1 277.4 327.2
Table 3.3
Fetal sex and gestation of 165 chromosomally normal singleton pregnancies
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Figure 3.2 Regressed median maternal serum levels of inhibin-A (#) and amniotic
fluid levels of inhibin-A (4) and inhibin-B (0).
1500 -i
Gestation (completed weeks)
3.3.3 Dimeric inhibins in early second trimester amnioticfluid.
Amniotic fluid samples from 603 amniocenteses were available for measurement of
inhibin-A content. These represent consecutive chromosomally normal pregnancies.
Table 3.5 details the indications for the amniocenteses, showing that 388 (64.3%)
were unselected with regard to placental function (group A). The remaining 215
(35.7%) amniocenteses (group B) had been performed following an abnormal result
from a screening test.
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Table 3.4
Median, 10th and 90th percentile inhibin-A levels (pg/mL) in maternal serum from 268
chromosomally normal twin pregnancies
Gestation
(completed weeks)
No. of samples 10th 50th 90th
10 11 192.1 253.0 314.1
11 18 193.3 360.8 630.3
12 9 160.0 286.8 380.5
13 6 46.9 203.6 330.6
14 6 98.5 246.4 391.0
15 57 124.4 231.1 457.0
16 85 140.9 256.9 450.2
17 34 144.6 246.2 532.7
18 10 138.0 270.0 620.8
19 7 122.6 176.8 467.0
20 2 - 351.7 -
Expressed as multiples of the normal singleton regressed median (MoM), the median
inhibin-A level in the twin pregnancies was 2.14 MoM (95% CI 1.99 - 2.31).




A: normal indication maternal age 350
anxiety 19
previous abnormal pregnancy 19
total 388
B: abnormal indication maternal serum screening 200
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Inhibin-A levels were analysed for each of these two groups separately, by completed
week of gestation and by fetal sex within each group. There were no significant
differences in inhibin-A levels between the two groups (p> 0.05, Mann-Whitney U
test) nor between sexes in either group A or B (p> 0.05, Mann-Whitney U test). Data
from all AF samples were therefore combined, irrespective of indication for sampling
or fetal sex, and analysed by gestational age.
Table 3.6 details the median, lO^1 and 90^ percentiles for inhibin-A in AF in these
603 pregnancies. Levels increased steadily and significantly (p<0.0001,
Mann-Whitney U test) across the gestational window of 14 to 20 weeks, as evidenced
by the regressed medians (figure 3.2, page 41).
Table 3.6
Median, 10th and 90th percentile inhibin-A levels (pg/mL) in amniotic fluid from 603
chromosomally normal singleton pregnancies.
Gestation (wks) 14 15 16 17 18 19 20
number 73 117 87 133 137 47 9
10th percentile 158.2 183.7 206.9 212.7 322.8 282.0 489.4
50th percentile 615 680.2 728.7 997.8 1195.9 1130.7 1336.0
90th percentile 1124.6 1438.8 1389.4 2156.0 2717.4 2608.2 2084.1
Inhibin-B assays were performed on 189 of the 603 AF samples. Where possible
(weeks 14-18 inclusive) all AF samples were from Group A and 15 samples for each
sex were selected at random for each gestation. At 19 and 20 weeks however there
were insufficient numbers in Group A alone and 7 samples at each of these gestations
(1 female and 6 male at 19 weeks and 3 female and 4 male at 20 weeks) were derived
from group B. There were no significant differences in inhibin-B levels between the
23 AF samples from Group A and the 7 from Group B at 19 weeks gestation nor
between the sexes at any gestation (p>0.05, Mann-Whitney U test). The data were
therefore grouped by gestation, combining both sexes within each group. Table 3.7
(page 44) details the median, 10th and 90th percentiles for inhibin-B in these 189
pregnancies. Levels increased steadily and significantly across the gestational window
as shown in figure 3.2 (page 41).
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Table 3.7
Median, 10th and 90th percentile inhibin-B levels (pg/mL) in amniotic fluid from 189
chromosomally normal singleton pregnancies
Gestation (wks) 14 15 16 17 18 19 20
number 30 30 30 30 30 30 9
10th percentile 67.4 116.0 133.1 114.0 255.6 280.4 439.3
50th percentile 216.6 334.6 261.4 631.8 775.4 1089.2 1078.2
90th percentile 554.6 884.4 1451.8 1738.4 1887.5 2874 2482.5
The rate of increase of inhibin-A and inhibin-B levels in AF differed. At 14 - 16 weeks
gestation there was significantly more inhibin-A than inhibin-B (p<0.001,
Mann-Whitney U test), but this became non-significant at 17 weeks because of the
more rapidly rising levels of inhibin-B (figure 3.2, page 41). There was a significant
but weak association between the levels of inhibin-A and inhibin-B in the 189 amniotic
fluids from which data for both proteins were available (correlation coefficient =0.42,
p=0.0001)
Inhibin-A was measured in matched maternal sera and AF samples collected from 47
women at 14 to 16 weeks gestation. The median (10th - 90th percentiles) inhibin-A
levels in MS and AF were 123.7 (79.0 - 196.1) pg/mL and 802.5 (250.6 - 1731.4)
pg/mL, respectively. The AF inhibin-A levels were significantly higher than those in
MS (paired t-test, p<0.001), but there was no significant correlation of the inhibin-A
levels in the AF with those in the matched maternal blood (correlation coefficient =
0.19, p>0.05, figure 3.3, page 45)
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Figure 3.3
Inhibin-A levels (pg/mL) in 47 matched pairs of maternal serum and amniotic fluid at
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3.3.4 Dimeric inhibins in fetal serum at term.
Cord blood was examined from 45 consecutive term (37-41 weeks) pregnancies. Of
these, 24 (53%) were from a female baby and 21 (47%) from a male, as evident on
examination immediately after delivery. Karyotyping was not performed on these
babies but clinical examination was normal in each case and all were discharged home
with their mother after an uneventful immediate post-natal period.
Inhibin-A was undetectable in the cord serum samples, both arterial and venous, from
all 45 pregnancies. Inhibin-B was undetectable in the cord serum from all 24 female
babies but was present in serum from all 21 male babies, with no differences between
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arterial or venous blood levels. The median (10th - 90th percentile) inhibin-B level in
the umbilical vein was 167.4 (111.2 - 224.8) pg/mL. As expected, gestation and
birthweight were significantly associated (r=0.56, p<0.01) but there was no
association between cord inhibin-B level with either gestation (r=0.005, p=0.98) or
birthweight (r=0.11, p=0.6).
3.4 Discussion and conclusions
These are the first data describing the distribution of specific inhibins in first and
second trimester pregnancy compartments. In summary, prior to 12 weeks of
pregnancy, the approximate timing of the fusion of the amnion and chorion, inhibin-A,
inhibin-B and pro-«C containing inhibin are present in EECF, inhibin-A and pro-«C
inhibin are present in maternal serum and only pro «C containing inhibin is present in
AF. After 12 weeks however, both inhibin-A and inhibin-B become detectable in AF
while inhibin-A remains the only dimer in MS with AF levels of inhibin-A
approximately five fold those in MS. In contrast, in serum from the term fetus
inhibin-A is undetectable, in both males and females, whereas inhibin-B is present in
males. It is proposed that these data, derived from studies using high resolution
ultrasound to selectively sample the different early pregnancy compartments, as
previously described (Jauniaux etal 1991, Wathen etal 1991) and illustrated in figures
3.4 and 3.5 (pages 47 and 48), at different gestations, have afforded some
clarification of the biology of inhibin in pregnancy.
While the current understanding of inhibin secretion in pregnancy is that the placenta is
the major source, as reviewed earlier in this chapter and also in Chapter One, and by
Qu and Thomas (1995), the suggestion that the placenta may not be the single most
significant source of hCG (Chard et al 1995) and the observation that the ontogenies of
hCG and inhibin are similar (Tovanabutra et al 1993) raises obvious similar questions
over the source(s) of inhibin in pregnancy. Considering the tissue distribution of the
mRNAs for the inhibin subunits (Meuniercta/1988, Petraglia et d. 1990, Tuuri et al
1994) there are a number of possible sources of inhibins in early pregnancy including
the maternal ovary (specifically the corpus luteum), the decidua, the placenta, the fetal
membranes and the fetus. While the corpus luteum is probably the predominant source
of inhibin in MS for the first six weeks of pregnancy (Illingworth etal 1996), and will
increase inhibin-A secretion under pharmacological manipulation (Rombauts et d
1996, Illingworth et d 1996), MS inhibin-A levels are actually quite low and stable
until the luteo-placental shift when levels increase rapidly (Illingworth et al 1996).
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Thus, in the normal pregnancies studied here, which are all of a gestation beyond the
luteo-placental shift, it is likely that the corpus luteum is not a significant source of
inhibin-A.
Similarly, although the decidua expresses mRNAs for inhibin-cx and both inhibin-B
subunits (Petraglia et cd. 1990) a number of observations argue against the decidua as a
significant source of inhibins. The decidua preferentially expresses Pb subunit mRNA
(Petraglia et al. 1990), suggesting that it would secrete more inhibin-B than inhibin-A,
the converse of what we have observed. Further, other decidual products such as
prolactin
Fig 3.4
A schematic representation of a human pregnancy at approximately six weeks gestation






(Golander et a! 1978) and placental protein 14 (ppl4), which is actually an endometrial
product (Julkunen et al 1985), are found in both the maternal serum and in the
intra-uterine cavities (EECF and AF) with the highest levels in the latter (Wathen et al
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1992, 1993, Kletsky et al 1985). In contrast, the levels of inhibin-A are highest in
maternal serum. This does not entirely exclude a decidual contribution of inhibin-A to
MS and EECF and indeed may simply reflect either a placental, or, less likely, an
ovarian contribution to MS inhibin content in early pregnancy (Santoro et al 1992,
Illingworth et al 1996, Rombauts et al 1996). However, the significant association
between the levels of the two inhibin dimers in EECF suggests a common source for
the inhibins in this compartment and since inhibin-B is not detectable at all in maternal
serum, indicating that the deciduals not the source of inhibin-B in EECF, the decidua
appears a most unlikely source for inhibin-A. The secondary yolk sac, which is
enclosed within the extra-embryonic coelom (figures 3.4, page 47, and 3.5) is also an
unlikely source of EECF inhibin-A because it degenerates at the end of the first
trimester when dimeric inhibin concentrations are increasing.
Figure 3.5
Schematic representation of the progressive changes in the in utero pregnancy
compartments with increasing gestation. (Arrows represent direction of change).
chorion
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The fetal membranes and the placenta are therefore the likely sources of inhibins in the
compartments studied. Of the two fetal membrane layers, the amnion selectively
expresses Pe-subunit mRNA (Petragliaet al 1993) which is more indicative of activin
production. The chorion however, expresses mRNA for both the Pa- and a-subunits
(Petraglia et al 1993), consistent with inhibin secretion, and is therefore the likely
source of inhibins in EECF and AF. Indeed, the presence of inhibin-A and inhibin-B
in EECF, but not AF, at gestations prior to amnion-chorion fusion and the increasing
levels of both dimers in AF thereafter is similar in ontogenetic pattern to sex steroids
and hCG (lies et al 1992, Atkinson et al 1996) which are known products of the
chorion. That the chorion may be the principal source of inhibins in these in utero
compartments would also be in keeping with the extremely high inhibin-A levels
observed in utero compared to levels in maternal serum in the second trimester, an
observation made previously for immunoreactive inhibin (van Fith 1994, Yokhaichiya
et al 1991). The presence of inhibin-A but total absence of inhibin-B in MS however,
suggests that either the chorion selectively secretes inhibin-A into maternal serum or
that there are different sources of inhibins for AF and MS. A number of observations
would support the latter.
Firstly, the ontogenies of inhibin secretion in the two compartments differ. In MS
inhibin-A displays a biphasic profde with levels reasonably stable between 14 and 20
weeks of gestation when AF levels of both inhibin-A and inhibin-B are increasing
rapidly. Secondly, in the study of matched MS and AF there was no significant
correlation between AF inhibin-A and MS inhibin-A, suggesting separate and
differentially regulated sources. The other source is almost certainly the placenta. In
the pregnancies studied at 8-11 weeks of gestation the distribution of inhibin-A is
identical to that of pregnancy-associated plasma protein A (PAPP-A), a placental
product, with higher levels in maternal serum than in extra-embryonic coelom and an
absence in amniotic fluid (lies etal., 1994). Taken together, these data therefore imply
that, in early pregnancy, the placenta is the major contributor to MS inhibin levels
while the chorion secretes inhibins into AF. The data would also imply that the amnion
is not permeable to inhibins until chorion-amnion fusion occurs at approximately 12
weeks. Given the molecular size of inhibins (Robertson et al 1995) and that the
amnion is impermeable to much smaller molecules (Jauniaux et al., 1991, Gulbis et
al., 1992) this would also appear plausible.
Immunoreactive pro-aC inhibin is present in maternal serum in early pregnancy and as
for inhibin-A, the corpus luteum is likely the predominant source during early
pregnancy (Illingworth etal. 1996, Rombauts etal 1996). The pro-uC inhibin content
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of extra-embryonic coelom is similar to that of maternal serum and may arise from
maternal serum or directly from the chorion, as suggested for the two inhibin dimers.
The lack of association of immunoreactive pro-aC levels between compartments
would be in favour of the latter, as would the association of pro-aC with inhibin-A in
extra-embryonic coelom. The presence of pro-aC inhibin in amniotic fluid prior to
chorion-amnion fusion is perhaps surprising however. As detailed above, it is unlikely
that pro-aC inhibins could traverse the amnion (Jauniaux et al., 1991, Gulbis et al.,
1992) suggesting that the amnion itself or the fetus may be the source of these
inhibins. While the mRNA for the inhibin a-subunit is expressed in both the amnion
(Petraglia etal 1993) and in human fetal steroidogenic tissues (Tuuri et al., 1994) it is
unclear how the cx-inhibins would be secreted by the fetus into the amniotic cavity at
this very early gestation, except perhaps by simple leakage. It is therefore suggested
that the principal source of immunoreactive pro-aC inhibin in the amniotic fluid prior
to 12 weeks is probably the amnion.
Of course, the fetus as a significant source of inhibins cannot be completely excluded.
There are certainly similarities between the distributions of inhibin-A and AFP, which
is of fetal origin (Wathen et al 1991) and immunoreactive inhibin is present in fetal
blood (Tabei etal 1991, Massa et al 1992, Billiar etal., 1995, Rombauts el al., 1996).
However, previous studies of immunoreactive inhibin in cord serum concluded that
the fetus was not a significant source of inhibin (Abe et al 1990, Tabei et al 1991,
Kettel et al 1991), largely because fetal serum levels were lower than maternal levels
(Tabei etal 1991, Kettel etal 1991). While fetal blood at 10-20 weeks of gestation was
not available for study, at term there is no inhibin-A in the fetal circulation suggesting
that the high levels of inhibin-A in MS, AF and EECF are unlikely to be fetally
derived. However, inhibin-B was detectable in cord serum from male, though not
female, babies. Indeed, the levels observed are comparable to those reported in adult
men (Illingworth et al 1996). This finding is in direct contradiction to a previous report
that no dimeric inhibin is present in the fetal circulation (Billiar et al 1996). That Billiar
and colleagues found no inhibin-B can be explained by the capture antibody (E4) used
in their "ELISA-B" assay which is an anti inhibin PA-subunit antibody, displaying no
significant affinity for the inhibin Pe-subunit. Interestingly, there are no sex
differences in immunoreactive inhibin levels in cord serum at term (Abe et al 1990,
Kettel et al 1991, Khalil et al 1995), suggesting that the majority of the inhibin detected
in cord serum by the inhibin a-subunit assays used in previous studies (Abe et al
1990, Kettel etal 1991, Tabei etal 1991) was free a-subunit (Billiar et al 1995) rather
than dimeric inhibin. Importantly, given that no differences in AF inhibin-B levels at
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14-20 weeks of gestation were observed between males and females it would appear
unlikely that the inhibin-B detected in AF was derived from the fetus. Rather, it
remains likely that the chorion is the sole, if not major source, although, as for
inhibin-A, no fetal sera at this gestation were available for study.
In keeping with inhibin-B in male but not female sera, the fetal testis expresses mRNA
for the inhibin subunits, while the ovary does not (Tuuri et al 1994) suggesting that the
inhibin-B may be of testicular origin, rather than from another endocrine organ
common to both sexes such as the adrenal. If confirmed, these data present the first
evidence that the human fetal testis actively secretes dimeric inhibin at term and
suggests that the inhibin-B ELISA will afford opportunities for new insights into the
control and development of the male fetal hypothalamo-pituitary-gonadal axis. Indeed,
at 26-28 weeks immunoreactive inhibin levels are higher in males than females (Massa
et al 1992), whereas there are no differences at term (Abe et al 1990, Kettel et al 1991,
Khalil etal 1995). In light of the inhibin-B data, the immunoreactive inhibin findings
at earlier gestations may represent relative changes in inhibin-B, particularly when at
these gestations FSH levels in males are significantly lower than in females (Reyes et
al 1974, Winter 1982, Massa et al 1992). This sex difference in circulating FSH has
been previously explained by the higher circulating levels of testosterone in males
(Reyes et al 1974, Winter 1982) but it is possible that it may, at least in part, be due to
inhibin-B, being evidence of negative feedback by inhibin-B on fetal pituitary FSH
secretion at these gestations. It would certainly now be intriguing to re-visit previous
studies of the pituitary-gonadal axis in term and preterm neonates, exploring the
possible role(s) of inhibins in the functional development of the axis. In particular, it
would be interesting to investigate whether the enhanced gonadotrophin secretion
observed in preterm female neonates compared to term neonates (Tapanainen et al
1981) corresponds to a transient role for inhibins in the female axis, a role not evident
in the simple term observations reported here.
In addition to exploring the source(s) of inhibins in pregnancy the studies reported
here have also clarified other areas of inhibin biology in pregnancy. Levels of
immunoreactive inhibin in maternal serum throughout pregnancy have been
extensively reported previously using inhibin a-subunit based assays (Abe et al 1990,
Tabei et al 1991, Tovanabutra et al 1993, Kettel et al 1991, Qu and Thomas 1992).
Levels rise from ovulation to a peak at 9-10 weeks gestation, falling to a plateau at
approximately 15 weeks and thereafter rising in the third trimester to a new peak at
term. In contrast, Qu and colleagues (1991) showed that bioactive levels of inhibin, as
determined by the suppression of FSH release from a dispersed sheep anterior
<'{#j -M*<s /
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pituitary cell assay (Tsonis et al 1986), increased steadily, without this biphasic
profile, suggesting that the biphasic immunoreactive profile reflected a preponderance
of non-bioactive inhibin forms, presumably monomelic inhibin a-subunits, in the
early first trimester with increasing circulating levels of dimeric inhibin as pregnancy
progresses. This would certainly be feasible given the ability of the inhibin
immunoassays to detect free inhibin a-subunit (Schneyer et al 1990, also see Chapter
Two ) Furthermore, this interpretation would be in keeping with
immunohistochemistry and in situ hybridisation studies that have suggested a relative
excess of inhibin a-subunit in early pregnancy trophoblast with increasing production
of the inhibin |1A- and pB-subunits as gestation increases. In those studies, there was
"intense" expression of the inhibin a-subunit mRNA, less of the (3A-subunit mRNA
and no (3B-subunit in first and second trimester trophoblast whereas in late pregnancy
trophoblast low levels of |3B-subunit mRNA were detectable for the first time with
maximum levels of mRNAs for the other two subunits (Petraglia et al 1991).
Mirroring the changes in mRNAs, immunostaining for the three inhibin subunits in the
placenta reveals a relative excess of a-subunit in early pregnancy with some inhibin
|3A-subunit and very weak staining for the |fB-subunit. With increasing gestation, the
relative staining for inhibin a-subunit declines as |3A-subunit and pB-subunit staining
increases (Petraglia etal 1991, Minamieta/1992).
More recently however, studies using inhibin-specific ELISAs (Muttukrishna et al
1995, 111ingworth etal 1996, Rombautseta/ 1996) have afforded useful new insights
into the biology of inhibins in pregnancy. These studies have suggested that of the two
inhibin dimers, only inhibin-A is detectable in maternal serum. Indeed, using gel
permeation chromatography of pooled pregnancy sera Muttukrishna and her colleagues
(1995) demonstrated that of the various molecular weight forms of inhibin that are
known to exist in follicular fluid and non-pregnant female serum (Robertson et al
1995) only the fully processed 31kDa inhibin-A is present in pregnancy, although data
related later in this thesis dispute this latter suggestion (Chapter Seven ) as do the
recent data of Khalil and colleagues (1995). Furthermore, the recent reports have
shown that the ontogeny of inhibin-A in pregnancy is biphasic, similar to that of
immunoreactive inhibin (Muttukrishna etal 1995, Illingworth etal 1996) but different
from the bioactive data (Qu et al 1991). On this much larger series of maternal serum
samples than previously reported, and with the normal range series reported in Chapter
Five, page 72, it is confirmed that the ontogeny of inhibin-A in maternal serum shows
a biphasic pattern. However, the data presented here suggests that the secondary rise
commences at 18 weeks of gestation, much earlier than previously reported
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(Muttukrishna el al 1995). These data would therefore suggest that the bioactive
inhibin levels previously described may have been confounded by either other
FSH-regulating peptides, such as activin which is produced by the placenta and is
present in MS (Petraglia et al 1995, Yokoyama el al 1995, Harada el al
1996,Muttukrishna etal 19996), or by inadequate stripping of the very high levels of
circulating sex steroids that exist in pregnancy (Qu etal 1991). The presence of inhibin
binding proteins such as follistatin (Robertson etal 1987, Ueno era/1987, Shimonaka
et al 199, Krummen et al 1993) and a2-macroglobulin (Vaughan and Vale 1993) in
serum may also confound in vitro bioassays. This is a particularly plausible
explanation since the levels of binding proteins increase in pregnancy (Studd et al
1970) and chromatography has confirmed that active and significant binding of inhibin
in pregnancy sera appears to occur (Khalil etal 1995).
The mechanisms underlying the biphasic profile of inhibin-A secretion in pregnancy is
unknown. However, this secretory pattern is similar to that of hCG (Tovanabutra et al
1993) and it has been suggested that the hCG peak at 9-10 weeks of pregnancy may be
related to altered chorionic function, secondary to the fusion with the amnion that
occurs at this gestation (Chard et al 1995). This hypothesis requires the chorionic
trophoblast, rather than simply the placental trophoblast, to be a major contributor to
hCG in the maternal circulation and this prerequisite would similarly apply to inhibins.
Unfortunately, the studies reported here do not explore the possibility that inhibin
secretion by the chorion into maternal serum is altered by amnion-chorion fusion
although they do suggest that the chorion is a significant source of inhibins, as
discussed above.
The higher maternal serum levels of inhibin-A in twin pregnancies were not
unexpected. It has been shown previously that immunoreactive inhibin levels are
higher in multiple pregnancies (Norman etal 1993) than in singletons and that maternal
serum levels of hCG in twin pregnancies are approximately double those of singletons
pregnancies (Wald et al 1991). The median MoM of 2.14 for the twin pregnancies is
entirely in keeping with these previous data, suggesting that in twin pregnancies the
secretion of inhibins and hCG are increased two-fold over singletons. Whether this is
simply related to the increased mass of tissue, either placental, chorionic or both,
which seems likely or whether there is a more complex explanation remains
unexplored. Nonetheless, the inhibin-A findings reported here have been recently
confirmed by another study of 200 twin and 600 singleton pregnancies (Watt et al
1996). These authors reported a median MoM of 1.99 for the twin pregnancies, not
significantly different from the data reported here.
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It has been reported previously that the maternal serum immunoreactive inhibin level is
sex dependant with higher levels observed in pregnancies with a female fetus (Khalil et
al 1995), similar to hCG (Obiekwe and Chard 1982, Leporrier et al 1992). Such
gender differences for inhibin-A were not observed here. Furthermore, no sex-related
differences in AF levels of either inhibin-A or inhibin-B at 14 to 20 weeks gestation
were observed. Together these data would suggest that either there are gender
differences for inhibins not detected by the dimeric inhibin assays, perhaps free inhibin
cx-subunit, or that the differences are only apparent at later gestations, as is indeed the
case for hCG (Muller et al 1993), or that the differences observed, using stepwise
multiple regression, may have been secondary to the small number of samples studied
(n=33) (Khalil etal 1995). A study of inhibin-A and pro-«C containing inhibin levels
in maternal serum throughout pregnancy in a larger dataset would be useful in
exploring these possibilities further and presently it remains unclear whether gender
differences in specific inhibin levels exist in later pregnancy or not. However, given
that levels of immunoreactive inhibin in fetal serum are lower in females compared to
males (Massa etal 1992) opposite findings in MS would be most intriguing.
The studies reported here also demonstrate for the first time that inhibin-B is not
detectable in MS at 10-20 weeks gestation, extending a previous report that inhibin-B
was absent in MS up to 11 weeks gestation (Illingworth et al 1996). Interestingly,
recent and unpublished data would suggest that inhibin-B is present in MS at term
(Petraglia, personal communication) which remains in keeping with the existing
molecular and immunostaining data, as previously described, and merits further
exploration.
In summary, the data presented in this chapter offer some clarification of the biology
of inhibins in pregnancy and are illustrated by figure 3.6, page 55. Further, the data
provide evidence to challenge the concept that the placenta is the only significant
source of inhibins in pregnancy. It is suggested that the placenta secretes inhibin-A
primarily into the maternal circulation while the fetal membranes are the likely major
source of both inhibin-A and inhibin-B in EECF and AF. The data also suggest for the
first time that the fetal testis secretes inhibin-B, implicating this hormone in the
development and control of fetal hypothalamo-pituitary-testicular axis.
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Figure 3.6
A schematic representation of a human pregnancy at approximately 12-13 weeks of
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4.1 Introduction
As discussed in Chapter One, prenatal screening for Down's syndrome has become an
important and established part of modern obstetric care. While there are a number of
approaches to screening (Cuckle 1994, Brizot et al 1994, Brambati et al 1994, Borrell
etal 1996), currently most programmes depend upon maternal age in combination with
the measurement of human chorionic gonadotrophin (hCG) and alpha feto-protein
(AFP), with or without unconjugated oestriol (UE3), in maternal serum from 15 weeks
gestation. Extensive prospective study, in many countries, has shown that such an
approach will detect approximately 65-70% of Down's syndrome pregnancies for an
amniocentesis rate of 5% (RCOG 1993). Of course, assessment of new and different
serum markers is ever continuing in the hope of increasing detection rates further.
Recently, it was reported that, as might have been expected from the in vitro
relationship between hCG and inhibin, that second trimester maternal serum levels of
immunoreactive inhibin are increased in Down's syndrome pregnancies and that
inhibin may be useful as a serum marker for Down's syndrome (van Lith et al 1992).
On average, the median (95% CI) inhibin level in Down's syndrome pregnancies was
1.9 (1.3-2.8) MoMs, very similar to hCG, though lower than free p hCG (Macri et al
1994). Subsequently, Spencer and his colleagues (1993) reported an even higher
median MoM of 3.65, confirming that immunoreactive inhibin levels are indeed
elevated in Down's syndrome pregnancies in the second trimester. However, the latter
authors suggested that inhibin was unlikely to be a useful prenatal marker because
there was a strong correlation with free p-hCG (r=0.74), suggesting that inhibin
would add little to the performance of screening combinations using free [1-hCG, and
because the width of distribution of inhibin levels was too broad, implying that there
would be unacceptable overlap between normal and affected pregnancies. The only
other report of immunoreactive inhibin as a second trimester prenatal marker of
Down's syndrome was equally gloomy about the potential value of this protein in a
screening context (Cuckle et al 1994). Again, the significant association with hCG was
cited as the main reason and in addition, in this series the degree of increase of inhibin
in the Down's syndrome sera was much less (1.3 MoM, 95% CI 0.9-1.9).
Nonetheless, it remained conceivable that inhibin may be a useful first trimester
marker, even if it was not useful in the second trimester. Pregnancy associated plasma
protein-A (PAPP-A) is an extremely useful marker of Down's syndrome in the first
trimester of pregnancy, with levels of approximately only 0.3 MoM (Brambati et al
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1991, Brambati etal 1993, Muller et at 1993, Hurley et al 1993) and yet is unable to
differentiate between cases and controls in the second trimester (Cuckle et al 1992).
Therefore, it was decided to assess first trimester maternal serum inhibin levels in
chromosomally normal and Down's syndrome pregnancies.
4.2 Materials and Methods
4.2.1 Serum samples
In Lothian, serum is routinely, prospectively collected from all women at the first
hospital antenatal visit and stored at -20°C. Eleven women (mean age 31.6 ± 5.1
years) were identified from records of known Down's affected pregnancies (detected
by maternal serum AFP at 16 weeks and subsequent amniocentesis), allowing their
stored serum to be retrieved. The serum from five of these women had been collected
at 11 completed weeks of gestation and the other six at 12 completed weeks, calculated
from an ultrasound scan performed on the day of sampling. For each Down's
syndrome case four women, matched for gestation (ultrasound determined) and
duration of storage, who had had a chromosomally normal pregnancy were identified
(mean age 27.5 ± 4.9 years) and their samples retrieved for analysis.
4.2.2 Inhibin assays
Inhibin was assayed using two different immunoassays, as described in detail in
Chapter Two. The first of the assays (McLachlan etal 1986b, 1987) is now distributed
by the National Institute of Child Health and Human Development (NICHD) while the
second is commercially produced and distributed by Medgenix (High Wycombe,
England). Importantly, both of these assays utilise antibodies directed against epitopes
on the inhibin a-subunit and are thus able to detect both forms of dimeric inhibin,
inhibin-A and inhibin-B, and monomelic a-subunit (Schneyer et al 1990).
Immunoreactive inhibin detected with these assays do not therefore necessarily reflect
bioactive protein.
4.2.3 Statistical analyses
The results obtained from neither assay were distributed normally and data were
transformed, using square root and logarithmic transformation for the NICHD and
Medgenix assays results, respectively to allow statistical comparisons. Analysis of
variance (ANOVA) was performed on the transformed data to assess the effects of
gestation and Down's syndrome. Where significance was detected (p<0.05), a
post-hoc analysis was performed using Duncan's test.
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4.3 Results
4.3.1 NICHD Assay
The mean (± SEM) maternal serum immunoreactive inhibin at 11 and 12 weeks
gestation in the Down's syndrome samples were 3186 ± 195pg/ml and 2517 ±
441pg/ml and in the controls 2020 ± 172pg/ml and 2561 ± 198pg/ml, respectively.
The mean immunoreactive inhibin levels at the two gestations were not significantly
different for either group. Figure 4.1 shows the data from both gestations combined,
revealing no significant difference between Down's syndrome and normal pregnancies
(2821 ± 267pg/ml v 2317+ 138pg/ml respectively, n.s.). However, analysing each
gestation separately, at 11 weeks the mean serum immunoreactive inhibin in Down's
syndrome and control pregnancies was 3186 ± 195 pg/ml and 2020 ± 172 pg/ml,
respectively (figure 4.2, page 60). The mean inhibin level at 11 weeks gestation was
significantly higher in the Down's affected pregnancies when compared to the controls
(Mann-Whitney U test, p<0.01). No significant differences existed at 12 weeks (2517
±441 pg/ml v 2561 ±198 pg/ml) (figure 4.2).
Figure 4.1.
Maternal serum immunoreactive inhibin levels detected by two different immunoassays
in 11 Down's syndrome and 44 chromosomally normal pregnancies.
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Figure 4.2.
Maternal serum immunoreactive inhibin levels in sera from 11 Down's syndrome
pregnancies and 44 control pregnancies at 11 and 12 weeks of pregnancy.
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4.3.2 Medgenix Assay
The mean (± SEM) maternal serum immunoreactive inhibin at 11 and 12 weeks
gestation in the Down's syndrome samples was 2.46 ±0.56 U/ml and 2.35 ±0.62
U/ml and in the controls 1.84 ±0.17 U/ml and 2.20 ±0.33 U/ml, respectively. The
mean immunoreactive inhibin levels at the two gestations were not significantly
different for either group. Figure 4.1 (page 59) shows the data from each gestation
combined, revealing no significant difference between Down's syndrome and normal
pregnancies (2.4 ±0.4 U/ml v 2.04 ± 0.19 U/ml respectively, n.s.). Analysis of each
gestation separately also revealed no significant effect on inhibin levels exerted by
Down's syndrome (data not shown).
4.3.3 Assay comparisons
There was no significant correlation between the inhibin levels derived from the two
assays, r=0.28, p>0.05 (figure 4.3).
Figure 4.3.
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4.4 Discussion and conclusions
Established maternal serum screening programmes for Down's syndrome are currently
timed for 15 to 20 weeks of pregnancy (RCOG 1993), utilising maternal age in
combination with the measurement of maternal serum hCG, either intact or free (3-
hCG, and AFP, with or without unconjugated oestriol (uE3). Recently, it was reported
that immunoreactive inhibin may be a useful second trimester marker for Down's
syndrome (van Lith etal 1992), although this was not a universal interpretation of the
elevated inhibin levels observed (Spencer et al 1993, Cuckle etal 1994). However,
even the data of Spencer and his colleagues (1993), who did not believe that inhibin
would find a useful role as a prenatal marker of Down's syndrome, suggest that
inhibin alone, without maternal age or other serum markers, might offer a detection
rate of 66% for a false positive rate of 5.3% - an impressive rate indeed. Nonetheless,
in the time since those reports immunoreactive inhibin has not found any further
application as a prenatal marker, probably due in part to concerns regarding
reproducibility (Cuckle etal 1994), unsuitable distribution widths (Spencer et al 1993,
Cuckle etal 1994) and significant associations between inhibin and hCG (Spencer et al
1993, Cuckle et al 1994).
As reviewed by Macintosh and Chard (1993), a number of fetal and placental products
have also been investigated as putative first trimester markers. This study was the first
to assess immunoreactive inhibin as a marker for Down's syndrome at this earlier
gestation and remains the only study to have examined inhibin levels in Down's
syndrome pregnancies, at any gestation, using two different immunoassays. The
resultant data show that there is no apparent effect of gestation on maternal serum
immunoreactive inhibin, as detected by either assay, at 11 and 12 weeks of pregnancy
and that when the data for the two gestations are combined, there is no significant
difference between inhibin levels observed in Down's syndrome cases and those in
chromosomally normal controls. Again, this finding applied equally to both assays
studied. However, using the "NICHD assay", but not the Medgenix assay, a
significant difference in maternal serum inhibin levels between Down's syndrome
cases and normal controls was apparent at eleven weeks of gestation but not at twelve
weeks. The extremely small number of cases in this study necessitates cautious
interpretation but the data would not support immunoreactive inhibin, as detected by
these two assays, as a useful marker of Down's syndrome at 11 and 12 weeks of
pregnancy. A subsequent report from the Dutch Working Party on Prenatal Diagnosis
(van Lith et al 1994) confirms this conclusion, using only the Medgenix assay. The
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isolated significant elevation in serum immunoreactive inhibin at 11 weeks, and not at
12 weeks, is surprising when the previously reports of screening in the second
trimester are considered (van Lith et al 1992, Spencer et al 1993, Cuckle et al 1994).
However, the published second trimester data were obtained using the Medgenix assay
and it is possible that the NICHD assay is detecting inhibin species, not detected by the
Medgenix antibodies, that are elevated in Down's syndrome in the first trimester.
Nonetheless, this isolated finding at 11 weeks gestation suggests that inhibin is
unlikely to be a useful marker. In summary therefore, it would appear that
immunoreactive inhibin is not a useful marker of Down's syndrome in either the first
or second trimester. Table 4.1 displays the median levels of immunoreactive inhibin in
the published series to date.
Table 4.1
Maternal serum immunoreactive inhibin levels in Down's syndrome in 5 studies.
Author Assay Trimester Median (95% CI) MoM
van Lith etal 1992 Medgenix Second 1.9 (1.3 - 2.8)
Spenceretal 1993 Medgenix Second 3.65 (1.8- 7.5)
Cuckle etal 1994 Medgenix Second 1.3 (0.9 - 1.9)
Wallace etal 1994 NICHD First 1.3 (1.0- 1.6)
Wallace etal 1994 Medgenix First 0.88 (0.7 - 1.5)
van Lith etal 1994 Medgenix First 1.3 (0.8 - 2.1)
Perhaps more intriguing was the observation that the inhibin levels obtained with the
two assays were poorly correlated, suggesting that different inhibin species were being
detected. This may have significant implications for the future of inhibin as a marker
and in this context a comparison with hCG as a marker of Down's syndrome in the
first and second trimesters is worthwhile.
Although it is nearly ten years since it was first recognised that hCG levels are
increased in association with trisomy 21 (Bogart et al 1987), and that these levels
reflect increased placental mRNA expression for both hCG subunits (Eldar-Geva et al
1995), it remains unclear what the mechanisms underlying these changes are.
However, it is clear that while maternal serum levels of both intact hCG (Bogart et al
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1987) and free p-hCG (Macri et al 1990) are elevated in Down's syndrome in the
second trimester, intact hCG is not elevated in the first trimester (Cuckle et al 1988,
Aitken etal 1993) and yet free (3-hCG is (Spencer etal 1992, Aitken et al 1993, Macri
et al 1993). This may be explained by differentially controlled transcription of hCG
a- and p-subunits (Jameson and Hollenberg 1993) with a relative excess of free |3-
subunit present in the first trimester (Cole et al 1984).
Similarly, it is possible that the forms or molecular sizes of inhibin in maternal sera in
normal and Down's syndrome pregnancies may differ and that these differences are
gestation dependant. Thus, assays for different immunoreactive inhibin species might
have different sensitivities in Down's syndrome detection at different stages of
pregnancy. Indeed, the finding of a lack of correlation of results between the two
assays suggests that the two assays used in this study are detecting different inhibin
species in these pregnancy samples. Interestingly, a similar disassociation of the two
assays in serum samples from non-pregnant women was not observed (unpublished
data) and so the current data may reflect changes in inhibin secretion specific to
pregnancy. In this regard, it was reported recently that a2-macroglobulin binds inhibin
in plasma (Vaughan and Vale 1993), altering immunoreactive detectable levels by
masking different epitopes. Levels of a2-macroglobulin rise by approximately 30% in
pregnancy (Studd et al 1970) and it is conceivable that this could differentially interfere
with antigen-antibody binding in one or other of these two assays. Thus, the
remaining uncertainty about which inhibin proteins are being detected in pregnancy
and whether the placenta of a Down's syndrome pregnancy secretes different inhibins
from a chromosomally normal placenta merits the evaluation of other inhibin assays in
the detection of Down's syndrome in both the first and second trimesters of
pregnancy. In particular, it would be important to assess assays specific for dimeric
inhibin or the inhibin p-subunit.
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5.1 Introduction
Despite the disappointing data from the studies of immunoreactive inhibins as a
prenatal marker of Down's syndrome in the first (Chapter Four , van Lith et al 1994),
and second trimesters (van Lith et al 1992, Spencer et al 1993, Cuckle et al 1994) of
pregnancy, overall the second trimester data remained encouraging. Indeed, the
knowledge that the inhibin immunoassays available at that time were non-specific, able
to detect monomeric inhibin u-subunit in addition to dimeric inhibins (Schneyer et al
1990), and that two different assays appeared to detect different inhibin moieties in
pregnancy sera (Chapter Four) offered the prospect that of the different forms of
inhibins circulating in pregnancy only selected ones were elevated in association with
Down's syndrome. If it was possible to specifically detect these forms, eliminating the
"background noise" of the other forms, then the performance of inhibin as a marker
could be significantly improved. Of course this possibility depended on the
development of novel detection methods for inhibin.
In 1991 Groome and his colleagues first described the development of a new two site
assay that utilised monoclonal antibodies, one each directed against the inhibin
(x-subunit and the inhibin pA-subunit (Knight et al 1991, Groome and O'Brien 1993).
Subsequently, modifications to the assay (Knight and Muttukrishna 1994), as
described in detail in Chapter Two, afforded a sensitivity sufficient to detect inhibin-A
(u-pA) in human sera, for which it was validated (Groome et al 1994). The studies
related in this chapter describe the application of this specific assay to maternal sera
from chromosomally normal and Down's syndrome pregnancies in the second
trimester.
5.2 Materials and Methods
5.2.1 Study one.
5.2.1.1 Serum samples
In south-east Scotland prenatal screening for Down's syndrome and neural tube
defects is offered to all women booking antenatally with a singleton pregnancy. An
aliquot of each serum sample collected for this programme is routinely stored at -20°C.
Of the known Down's affected pregnancies during 1992-1993 there were twenty-one
women from whom stored serum was available and these sera were retrieved. All
these women had been at 15-17 completed weeks of pregnancy at the time of
66
Inhibin-A: a second trimester marker ofDown's syndrome
sampling, as calculated from a first or early second trimester ultrasound scan. Fourteen
of the 21 (67%) had been detected prenatally by the screening programme. Samples
from 150 control women with a chromosomally normal pregnancy matched for
gestation (within one week as determined by ultrasound) and duration of storage, were
identified and retrieved. Forty-five of the control samples were at 15 completed weeks,
55 at 16 completed weeks and 50 at 17 completed weeks of pregnancy.
5.2.1.2 Inhibin-A assay
Format I (Chapter Two) of the assay was used in this study, employing the
recombinant 32kDa human inhibin-A preparation (Genentech Inc, CA, USA) as the
calibrating standard. The sensitivity of the assay was 8 pg/mL and the intraplate and
interplate coefficients of variation were 2.5% and 7.0% respectively. Thus, in the
context of Chapters Two and Nine the assay format used in this study was I-RH.
5.2.1.3 Statistical analyses
Statistical analyses were performed using the software package Statview 4.1 (Abacus
Inc. Berkeley, CA, USA). Inhibin levels in the control samples at each separate week
of gestation were compared using the Mann-Whitney U test. Since a significant
difference across gestation of pregnancy was detected in the controls, the Down's
samples and controls were expressed as multiples of the normal median (MoM) to
allow comparison between the two groups. Each MoM, for both control and Down's
samples, was calculated from the normal median of the respective gestation.
5.2.2 Study two
5.2.2.1 Serum samples
Aliquots of selected maternal serum samples that had been collected as part of the West
of Scotland prenatal screening programme for Down's syndrome and neural tube
defects between 1987 and 1994 were retrieved from storage. In total, 528 serum
samples were available for study from this programme, of which 254 samples had
been collected in the first trimester (7 to 14 weeks of pregnancy) and 274 in the second
trimester (15 to 18 weeks of pregnancy). While the inhibin-A results for all 438
chromosomally normal samples are reported in this chapter for clarity, for the trisomic
pregnancies only the analyses and data relating to the second trimester samples will be
discussed here. Therefore, of the 274 second trimester samples, 202 were from a
chromosomally normal pregnancy, 44 from a trisomy 21 (Down's syndrome)
pregnancy and 28 from a trisomy 18 (Edward's syndrome) pregnancy. Of the Down's
syndrome samples, 35 had been previously reported in a prospective study (Crossley
et al 1994). The control samples had been chosen, from archival records, to match the
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trisomic samples for gestation and duration of storage. Gestation had been calculated,
for all samples, in completed weeks of pregnancy from certain menstrual dates or from
an ultrasound scan. The identification and retrieval of all samples was performed by Dr
Jenny Crossley and Dr David Aitken, Duncan Guthrie Institute, Glasgow as part of a
collaborative project.
5.2.2.2 Assays
Inhibin-A was measured in Edinburgh using format I-RH of the inhibin-A ELISA, as
described in Chapter Two. The sensitivity of the assay was 8 pg/mL and the intraplate
and interplate coefficients of variation were 2.5% and 7.0%, respectively.
Other analyte assays had been previously performed in Glasgow. Intact hCG and AFP
had been measured prospectively, as part of the routine screening programme
(Crossley et al 1994), using a commercial immunoradiometric assay (MAIAClone,
Serono, Rome, Italy) and an in-house immunoradiometric assay (Aitken et al 1993),
respectively. Samples were analysed for free p-hCG retrospectively, using an ELISA
as previously described (Macri et al 1993).
All samples were assayed for all analytes blinded to whether they were from a normal
or a trisomic pregnancy.
5.2.2.3 Statistical analyses
Statistical analysis of the data was performed by Dr Jenny Crossley, Duncan Guthrie
Institute, Glasgow.
To allow comparisons between normal controls and trisomic pregnancies, values of all
analytes were converted to multiples of the median (MoM). The median inhibin-A level
for each completed week of gestation was calculated from the 438 chromosomally
normal controls and levels in both the control and trisomic samples thereafter
converted to MoMs using these median values. MoMs for intact hCG, free p-hCG and
AFP were calculated from median normal values previously calculated from the much
larger dataset from which the samples reported here had been derived.
Goodness of fit to log gaussian distributions for each marker in both the control and
trisomic samples was assessed by probability plot and the Kolmogorov-Smirnov test.
Measures of distribution for each marker, in both normal and trisomic samples, were
calculated by using the log10 of the median as the mean and the difference between the
10lh and 90th percentiles in logs, divided by 2.56 as the standard deviation (Cuckle etal
1987).
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For the Down's syndrome samples, detection and false positive rates were calculated
with gaussian models of the distribution of likelihood ratios and the age distribution of
pregnancies in the population from which the samples had been derived, as described
in detail elsewhere (Reynolds and Penny 1990, Zeitune etal 1991, Aitken et al 1996).
5.3 Results
5.3.1 Study one
Table 5.1 (page 70) shows the median (95% CI) maternal serum levels of dimeric
inhibin A in the chromosomally normal pregnancies. The level at 17 weeks gestation
was significantly lower than that at 16 weeks (p<0.02, Mann-Whitney U test). There
were no other significant differences.
In all of the Down's syndrome samples the dimeric inhibin levels were above the
normal median (Figure 5.1, page 71). The median (95% CI) MoM was 2.6 (2.25-
3.57), significantly higher than controls (p<0.0001, Mann-Whitney U test). For a
given false positive rate (FPR) of 5.3% (8/150), 62% (13/21) of the Down's
syndrome samples would have be detected at a cut off MoM of 2.2. Table 5.2 (page
70) shows the detection rates and corresponding FPRs at different arbitrary MoMs.
The inhibin data fitted a log Gaussian frequency distribution with standard deviation of
log10(inhibin-A) of 0.27 in the controls and 0.20 in the Down's syndrome cases. The
mean log10(inhibin-A) in the Down's syndrome cases was 0.41.
Of the seven Down's samples that had been undetected by the routine screening
programme two had dimeric inhibin A levels above the arbitrary threshold of 2.2 MoM
while three Down's samples with levels below this arbitrary detection limit had been
detected by screening (table 5.3, page 72).
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Table 5.1
Median (95% CI) maternal serum dimeric inhibin A levels in 150 chromosomally
normal singleton pregnancies at 15 - 17 weeks gestation.
Gestation (weeks) Number of samples Inhibin-A (pg/mL)
15 45 220.4 (201.5 - 273.4)
16 55 246.5 (235.4 - 298.5)
17 50 182.0 (178.5 - 235.9)
Table 5.2







0.5 21(100) 135 (90)
1.0 21 (100) 76 (51)
1.5 21(100) 28(19)
2.0 14(67) 11(7)
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Figure 5.1
Median maternal serum inhibin-A MoMs (10th - 90th percentiles) in 150
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Table 5.3
Maternal serum inhibin-A levels (MoM) in 21 Down's affected pregnancies compared





6.0 undetected 2.4 detected
5.7 detected 2.2 detected
5.0 detected 2.1 detected
4.5 detected 1.9 undetected
4.2 detected 1.8 undetected
4.1 detected 1.6 undetected
3.2 detected 1.6 detected
2.9 undetected 1.5 undetected
2.6 detected 1.5 detected
2.6 detected 1.1 undetected
2.6 detected
5.3.2 Study two
Figure 5.2 (page 73) shows the inhibin-A levels in the normal control samples across
the complete control sample set from 7 to 18 weeks of pregnancy. Levels fall from a
peak at 8-9 weeks of pregnancy to a plateau at 15 weeks.
Table 5.4 (page 74) shows the levels of inhibin-A, intact hCG, free p-hCG and AFP
in the control and Down's syndrome samples. In the Down's syndrome samples
inhibin-A, intact hCG and free p-hCG were significantly elevated and AFP was
significantly decreased (Mann-Whitney U test). The extent of the inhibin-A increase
was favourable in comparison to both intact hCG and free p-hCG.
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Figure 5.2
Median (10,h-90th percentiles) inhibin-A levels (pg/mL) in 438 chromosomally normal
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Table 5.4
Levels of serum markers, expressed as MoMs, in control and Down's syndrome
pregnancies at 15-18 weeks of gestation.
Marker Controls Down's Syndrome p-value
No. of samples MoM No. of samples MoM
Inhibin-A 202 1.00 44 2.24 <0.001
Intact hCG 202 1.03 44 2.04 <0.001
Free p hCG 142 1.03 44 2.05 <0.001
AFP 202 0.95 44 0.74 <0.001
The goodness of fit for inhibin-A was optimum to a log-gaussian distribution, as
assessed by the Kolmogorov-Smirnov test, and subsequent analyses were performed
assuming log normality for the inhibin-A results. It was known from previous studies
(Zeituntetal 1991, Crossley etal 1992, Spencer etal 1992) that AFP, intact hCG and
free (ThCG fitted log gaussian distributions. Table 5.5 shows the correlation statistics
between the different markers, including maternal age. Inhibin-A significantly
correlated with intact hCG levels in both the control and Down's syndrome samples
and with AFP in the controls only. Inhibin-A was not correlated with free p-hCG nor
with maternal age, in either the controls or the affected cases.
Table 5.5
Coefficients of correlation (r) between prenatal markers of Down's syndrome in 202
chromosomally normal control and 44 Down's syndrome pregnancies at 15-18
completed weeks of pregnancy.
Controls Down's cases
r p-value r p-value
Log (inhibin MoM) v Log (intact hCG MoM) 0.27 <0.001 0.39 0.008
Log (inhibin MoM) v Log (F(5hCG MoM) 0.15 0.107 0.23 0.134
Log (inhibin MoM) v Log (AFP MoM) 0.24 0.001 0.24 0.110
Log (inhibin MoM) v maternal age -0.03 0.690 0.25 0.098
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The distribution parameters of the analytes are described below in table 5.6.
Table 5.6
Means and standard deviations (SD) of log gaussian distributions for analytes in 202
chromosomally normal control and 44 Down's syndrome pregnancies at 15-18
completed weeks of pregnancy.
Analyte Controls Down's cases
mean SD mean SD
Inhibin-A 0.0000 0.2967 0.3502 0.3521
Intact hCG 0.0128 0.2196 0.3086 0.2064
Free phCG 0.0128 0.2609 0.3188 0.3061
AFP -0.0223 0.1609 -0.1337 0.1805
Using the distribution statistics for each marker in both the normal controls and the
Down's syndrome cases, the detection rates, for a fixed 5% FPR, were calculated for
different marker combinations. In this dataset, the optimum marker combination, in
terms of the detection rate, was maternal age/AFP/free p-hCG/inhibin-A which
afforded a detection rate of 75% for a FPR of 5% (table 5.7).
Table 5.7
Detection rates (95% CI), at a 5% false positive rate, for Down's syndrome for
various marker combinations.
Combination DR (%) 95% CI
AFP / intact hCG / age 54 38-69
AFP / FphCG / age 53 37-68
AFP / inhibin-A / age 57 41 -72
FphCG / inhibin-A / age 68 52-81
AFP / intact hCG / inhibin-A / age 72 57-84
AFP / FphCG / inhibin-A / age 75 60-87
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Expressed as MoMs, the inhibin-A level in the trisomy 18 samples and controls was
0.84 and 1.0, respectively, not significantly different, in contrast, the intact hCG level
in the same samples was 0.3 and 1.03, respectively (p<0.001, Mann-Whitney U test).
5.4 Discussion and conclusions
Maternal serum inhibin levels have previously been shown to be elevated in Down's
affected pregnancies in the second (Van Lith etal 1992, Spencer et al 1993, Cuckle et
al 1994) but not first trimester (Chapter Four, van Lith et al 1995 ). However, in the
three second trimester studies the variation in both the absolute inhibin levels in the
controls and in the degree of elevation in the Down's cases reported and the strong
association between inhibin and hCG levels suggested that immunoreactive inhibin, as
detected, was unlikely to prove a valuable prenatal marker of Down's syndrome
(Cuckle etal 1994).
Nonetheless, there are a number of possible inhibin species circulating in peripheral
blood including the two 31kDa dimeric forms (inhibin-A and inhibin-B), larger
dimeric forms (58-73kDa), large free precursor a-subunits and the free processed
a-subunit (Robertson et al 1995). By the nature of the antibodies employed, the
immunoreactive assays used in the above studies (van Lith et al 1992, Spencer et al
1993, Cuckle etal 1994, Chapter Four, van Lith et al 1995) are unable to specifically
detect intact dimeric inhibin A but probably also detect free inhibin a-subunits and the
related pro-aC and pro-«C-pro-«N fractions (Schneyer et al 1990). It is possible that
this non-specificity may account for the very heterogeneity of the results that has
caused some concern (Cuckle et al 1995). In Chapter Four however, it was reported
that two immunoassays, both utilising anti inhibin a-subunit antibodies, appeared to
recognise different inhibin species in the same pregnancy samples, possibly due to
differing antibody affinities for different species. Further, serum factors that are
known to interfere with immunoreactive inhibin detection (Vaughan and Vale 1993)
increase in pregnancy (Studd et al 1970). It is clear therefore, that the usefulness of
inhibin in prenatal screening for Down's syndrome may crucially depend on which
inhibin species are being detected and thus on the antibodies utilised in the assay(s)
applied. The studies reported here represent the first application of an assay specific
for inhibin-A to the detection of Down's syndrome in the second trimester. Chapter
Six relates similarly novel data for the first trimester.
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Despite the wide distribution of non-specific immunoreactive inhibin noted previously,
using the Medgenix inhibin assay van Lith and colleagues (1992) reported a
preliminary detection rate of 40% with a false positive rate of 5% and a median MoM
(95% CI) of 1.3 (0.9 - 1.9) for inhibin alone across a gestational range of 14-18
weeks. In Study One reported here the corresponding detection rate of 62% for a 5.3%
FPR and median MoM (95% CI) of 2.6 (2.25-3.57) for inhibin A at 15-17 weeks
gestation would appear very favourable to non-specific immunoreactive inhibin. Also,
in the same study the standard deviations of log10(inhibin-A) in both the controls and
the Down's cases show that inhibin-A levels are less widely distributed than the non¬
specific immunoreactive inhibin previously reported. This phenomenon could explain
the improved detection performance of intact dimeric inhibin-A relative to
immunoreactive inhibin. It is also possible that only some of the circulating inhibin
species are discriminatory with regard to Down's syndrome. If the less specific assays
were detecting some of the non-discriminatory inhibin species, undetected by the
dimeric assay, then poorer detection performance would be observed. In support of
this suggestion, Illingworth and his colleagues (1996a) recently showed that pro-aC
containing inhibins circulate in early pregnancy, probably reflecting monomelic
(x-subunit rather than dimers containing this precursor fragment (Robertson el al
1997), and that levels of pro-cxC inhibins in Down's syndrome are not significantly
different from normal (Wallace, unpublished data). Further, in collaboration with
Howard Cuckle, Leeds University, the author has assayed inhibin-A in the sample set
on which immunoreactive inhibin levels were previously reported (Cuckle et al 1994).
Instead of the median MoM of 1.3 observed for immunoreactive inhibin, the median
inhibin-A level in the Down's syndrome cases was 1.6, significantly higher (Cuckle et
al 1995), suggesting preferred detection of discerning inhibin forms by the inhibin-A
assay.
In Study One it was also encouraging to observe that inhibin-A detected Down's
syndrome cases that had previously screened negative with traditional markers. This
suggests that this inhibin species is not associated with hCG and so may have a useful
role as an adjuvant marker in the second trimester, increasing detection rates. This
observation is quite different from the tight correlations previously observed between
hCG and immunoreactive inhibin (Spencer et al 1993, Cuckle et al 1994). Study Two
was therefore undertaken to expand upon these initially exciting observations and to
formally assess the relationships between inhibin-A and existing prenatal serum
markers.
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Confirming the results from Study One, Study Two demonstrated significantly higher
inhibin-A levels in Down's syndrome compared to normal pregnancy. Indeed, while
the extent of this elevation was not as high as observed in Study One, it was still
higher than either intact hCG or free (3-hCG. Importantly, Study Two showed that
there was no significant association between inhibin-A and free (5-hCG levels. This
would suggest that these two markers would have additional power in the detection of
affected cases. Interestingly, a more recent report did not confirm this lack of
association (Spencer etal 1996) and the more limited additional detection afforded by
inhibin-A in that series reflects that observation. Nonetheless, in this series inhibin-A
added an additional 20% detection to existing marker combinations, representing a
significant improvement in screening performance. In other, more recent series,
similar improvements in detection rates have been reported (Wald etal 1996, Cuckle et
al 1996) with a meta-analysis of all data, excepting those of Spencer and his colleagues
(1996), suggesting that inhibin-A will improve the detection rate of Down's syndrome
by approximately 10% for a fixed 5% FPR (Cuckle etal 1996).
Intriguingly, while the maternal serum level of inhibin-A in trisomy 18 samples was,
on average, slightly reduced it was not significantly so. This was a surprising finding
considering the hCG level was profoundly low, as has been reported by others
previously (Ozturk et al 1990). Indeed, this observation represents the first
disassociation of inhibin and hCG levels in maternal serum and may provide some
new insights into the differential control of the secretion of these proteins.
The normal range data derived from Study Two and displayed in figure 5.2, page 73,
extends back into the first trimester, further than any previous data reported in this
thesis and usefully confirms the biphasic ontogeny described at length in Chapter
Three and elsewhere (Muttukrishna et al 1995, Illingworth et al 1996). Furthermore,
the plateauing levels at 15-18 weeks is a useful observation. The levels of all serum
markers change with gestation, hence the requirement for expressing levels as MoMs
allowing comparisons across gestations. Therefore, inaccuracies in gestational dating
impact upon the performance of screening and will either decrease the detection rate, if
the FPR is kept constant, or increase the FPR if the detection rate is maintained
(RCOG 1993). This effect is especially critical because in 10-45% of pregnancies
women are uncertain of their menstrual dates (Campbell et al 1985) and even in those
women with certain dates, in a third there will be an error in excess of 7 days
(Geirsson 1991). However, inhibin-A levels change minimally across the window of
15-18 weeks and so gestation-associated errors would be minimal with this marker, a
most useful attribute.
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In conclusion, the studies reported in this chapter have shown that inhibin-A is
significantly elevated in maternal serum in Down's syndrome pregnancies in the
second trimester and that, when combined with existing markers, inhibin-A will
improve prenatal screening detection rates. This represents a significant development
in Down's syndrome screening and the eventual application of inhibin-A now depends
upon cost-benefit analyses of the new marker combinations (Wald et al 1996).
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6.1 Introduction
While second trimester maternal serum screening for Down's syndrome is certainly
highly effective (RCOG 1993), it is generally accepted that it would be desirable to
offer similar screening earlier in pregnancy. This approach would afford women, and
their partners, the opportunity of earlier diagnosis, if indicated, and earlier termination
of pregnancy, if appropriate. It is assumed, although not tested, that in cases of fetal
abnormality, such as aneuploidy, a surgical termination of pregnancy performed under
general anaesthesia as a day-case is less traumatic psychologically than a prostaglandin
termination which requires the women to "deliver" her fetus vaginally while
conscious. In support of this assumption is the recent finding that women undergoing
early pregnancy termination for pyschosocial reasons appear to prefer termination
performed under general anaesthesia to medical termination which essentially induces a
"miscarriage" (Cameron et al 1996). Accepting these arguments, which are very
plausible but remain to be explored objectively, it is clearly important to be able to
offer women early screening if early termination is to be an option. There are however,
other considerations.
Approximately two thirds of Down's syndrome pregnancies will be lost spontaneously
before delivery at term, with as many as 15-30% being lost between 10 and 16 weeks
(Macintosh et al 1996, Halliday et al 1995). This is of critical importance because
some affected pregnancies that are viable at 10-14 weeks and so accessible to first
trimester screening may miscarry before second trimester serum screening is
performed. Indeed, abnormal screening may preferentially identify pregnancies
destined to be lost (Hyett etal 1996, Benn et al 1996). It is thus conceivable that first
trimester screening would expose many women unnecessarily to significant distress
and anguish over choices regarding termination (Wallace 1997), representing a real
disadvantage of earlier testing. Furthermore, current second trimester serum screening
is for aneuploidy (trisomies 21 and 18) and neural tube defects, whereas first trimester
serum screening would not be a sensitive method of screening for neural tube defects
(Shalev et al 1992, Wald et al 1993) and later screening would still have to be
performed.
Nonetheless, the feasibility of first trimester serum screening for Down's syndrome
has received much attention, as reviewed recently by Macintosh and Chard (1993). Of
the various serum markers assessed free f?-hCG, AFP and pregnancy associated
plasma protein A (PAPP-A) have been the most fully evaluated to date (Macintosh and
Chard 1993). Maternal serum fflhCG is significantly elevated in Down's syndrome
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pregnancies (Spencer et al 1992, Macri et al 1993) while AFP (Brambati et al 1986,
Sciosca^ra/1987, Crandall et al 1991, Cuckle etal 1988, Brock et al 1990, Aitken et
al 1993) and PAPP-A (Brambati et al 1991, Brambati et al 1993, Muller et al 1993,
Hurley etal 1993) are significantly lowered. In combination with maternal age, a first
trimester serum screening programme based upon these markers might offer a
detection rate of approximately 60% for a 5% false positive rate (Aitken et al 1993,
Krantz et al 1996), almost as good as is achieved by the optimum marker combination
in the second trimester.
As discussed in Chapters Four and Five, the finding that, within the same samples,
there was no correlation between maternal serum immunoreactive inhibin levels
detected by two different assays, an observation previously not made for menstrual
cycle sera, and that immunoreactive inhibin levels were elevated in the second
trimester, merited further assessment of specific inhibins as markers of Down's
syndrome. With respect to first trimester screening, the small study examining
i mm unoreactive inhibin levels described earlier (Chapter Four) did suggest that one of
the assays used (NICHD) may have detected differences in inhibin levels between
controls and Down's syndrome pregnancies at eleven weeks gestation. Thus, when an
assay specific for inhibin-A and sensitive enough to detect levels in sera became
available (Groome et al 1994) the potential of this inhibin dimer as a first trimester
marker of Down's syndrome was examined. Importantly, the studies detailed in this
chapter were performed contemporaneously with those in Chapter Five, as is evident
from the similar evolution of assay methodology used in the different studies, as
explained in ChapterTwo and examined again in ChapterSeven.
6.2 Materials and Methods
6.2.1 Study one.
6.2.1.1 Serum samples
As described in Chapter Four (4.2.1, page 58) in Lothian sera are routinely stored
from first trimester booking blood serology. From these records, of all known
Down's affected pregnancies twenty-three women (mean age 32.1 years, range 22-44
years) were identified retrospectively allowing their stored serum to be retrieved. The
sera from eight of these women had been collected at 11 completed weeks of gestation,
eight at 12 completed weeks and seven at 13 completed weeks, calculated from
ultrasound scans performed on the day of sampling. In 11 of these women
immunoreactive inhibin had been previously measured (Chapter Four). For each
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Down's affected sample four control women, matched for gestation (ultrasound
determined) and duration of storage, were identified and their samples retrieved (mean
age 27.7 years, range 19-38 years). Three control samples, one each matched for three
different 11 week Down's samples, were unable to be used due to insufficient sample
volume, making 89 control samples available for assay.
6.2.1.2 Assays
Inhibin-A assay format I-RH was utilised in this study. The sensitivity of the assay
was
8 pg/ml and the intraplate and interplate coefficients of variation were 2.5% and 7.0%,
respectively.
Pregnancy associated plasma protein A (PAPP-A) and free (fhCG were measured by a
commercial assay in development by the laboratory of the relevant company (Johnson
and Johnson, Cardiff, UK). This facility was generously made available by Dr Chris
Davies of Johnson and Johnson (see Acknowledgments, page viii).
All assays were performed blinded to whether the sample was from a normal or
Down's syndrome pregnancy.
6.2.1.3 Statistical analyses
Statistical analyses were performed using the software package Statview 4.1 (Abacus
Inc. Berkeley, CA, USA). Inhibin levels in the control samples at each separate week
of gestation were compared using the Mann-Whitney U test. Since a significant
difference across gestation of pregnancy was detected in the controls, the Down's
samples and controls were expressed as multiples of the normal median (MoM) to
allow comparison between the two groups. Each MoM, for both control and Down's
samples, was calculated from the normal median of the respective gestation.
Similar analyses were performed for both PAPP-A and free fi-hCG. Relationships
between levels of the three proteins were also explored using simple correlation
analysis of log transformed data.
6.2.2 Study two.
6.2.2.1 Samples, assays and analyses
This study is the first trimester component of Study Two in Chapter Five, page 67. As
detailed in that chapter, there were 254 first trimester samples from 7-14 completed
weeks of gestation. Four of these samples were from trisomy 18 pregnancies and will
not be discussed further (see page 76). Of the remaining 250 samples, 236 were from
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a chromosomally normal singleton pregnancy and 14 from a trisomy 21 pregnancy.
The assays and statistical analyses are as described previously (page 68).
6.2.3 Study three
6.2.3.1 Serum samples
All the samples for this study were generously supplied by Dr Penny Noble for a
collaborative project with Professor Kypros Nicolaides at the Harris Birthright
Research Centre for Fetal Medicine, London (see Acknowledgments, page viii). In
each case, blood had been collected immediately before an ultrasound examination at
the Harris Birthright Research Centre for Fetal Medicine and stored at 4°C until
assayed for free p-hCG the following day. Thereafter the sera were stored at -20°C,
for up to 12 months, until analysed, in Edinburgh, for inhibin-A content. Seventy-six
samples from Down's syndrome pregnancies and 800 with normal pregnancies were
available for analysis. In each case, the women were self referrals to the Harris
Birthright Research Centre for Fetal Medicine for screening for Down's syndrome.
Gestation (in completed weeks) was calculated from the ultrasound scan performed
prior to sampling.
Ethical approval had been granted for this study by the King's College Hospital ethics
committee.
6.2.3.2 Assays
Inhibin-A was assayed using a hybrid format not detailed elsewhere. Indeed, this
study is the only one to have been performed with this format. Sample preparation was
similar to format I (ie no boiling pre-treatment) but detection of the signal was afforded
with the simple alkaline phosphatase substrate, pNPP (KPL, Maryland, USA). The
standard preparation used was the recombinant product from Genentech. As detailed in
Chapter Seven the method of detection does not affect the results obtained, provided
levels remain within levels of detection. This assay is therefore most like format I-RH
than any other. The sensitivity of the assay was 39 pg/ml and the intraplate and
interplate coefficients of variation were 4.3% and 5.6%, respectively.
Free p-hCG was measured, in London, using a commercial immunoradiometric assay
(CIS, Paris, France). The sensitivity of the assay was 0.15ng/mL and the intra-assay
and inter-assay coefficients of variation were 3.1% and 5.7%, respectively.
6.2.3.3 Statistical analyses
Statistical analyses were performed using the software package Statview 4.1 (Abacus
Inc. Berkeley, CA, USA). Inhibin levels in the control samples at each separate week
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of gestation were compared using the Mann-Whitney U test. Since a significant
difference across gestation of pregnancy was detected in the controls, the Down's
samples and controls were expressed as multiples of the normal median (MoM) to
allow comparison between the two groups. Each MoM, for both control and Down's
samples, was calculated from the normal median of the respective gestation.
Similar analyses were performed for free phCG. Relationships between levels of the




Table 6.1 (below) shows the inhibin-A levels in the control samples. There was no
significant difference between the levels at 11 and 12 weeks (p=0.054, Mann-Whitney
U test) but the mean level at 13 weeks was significantly lower than that at 11 weeks
(p=0.0004, Mann-Whitney U test) though not 12 weeks (p=0.055).
Figure 6.1 (page 86) shows inhibin-A levels, expressed as MoMs, in the 23 Down's
syndrome cases. The median (95% CI) MoM for the Down's syndrome samples was
2.46 (2.11-3.26), significantly higher than the controls (p<0.0001 v controls, Mann
Whitney U test). Table 6.2 (page 87) displays the number of affected and unaffected
pregnancies at different MoMs. In this series, for a given false positive rate of 4%
(4/89), 65% (15/23) of the Down's cases would have been detected.
Maternal serum Inhibin-A was not associated with maternal age (r=l .0, p=0.49).
Table 6.1
Median (10th-90th percentiles) maternal serum inhibin-A in 89 chromosomally normal
singleton pregnancies at 11 -13 weeks of pregnancy.
Gestation (weeks) Number of samples Inhibin-A (pg/mL)
11 29 361.8 (250.8-524.6)
12 32 279.7 (183.5-564.5)13 28 221,0 (120.9-453.8)
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Forty-four control and eleven Down's syndrome samples were available to study
associations between inhibin-A levels and immunoreactive inhibin levels. In the
control samples, there was a significant association between log10(inhibin-A MoM)
and logI0(NICHD inhibin MoM) (r=0.35, p=0.03) but no association between
log10(inhibin-A MoM) and logl0(Medgenix inhibin MoM) (r=0.17, p=0.29). In the
Down's syndrome samples there were no significant associations (r=0.28, p=0.4 and
r=0.45, p=0.17 for Iog10(inhibin-A MoM) v log10(NICHD inhibin MoM) and
log10(inhibin-A MoM) v logI0(Medgenix inhibin MoM), respectively).
Figure 6.1.
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6.3.1.2 PAPP-A and free fi-hCG results
Table 6.3 (page 87) shows the median (95% CI) PAPP-A and free (ThCG levels in
the control sera. Levels of PAPP-A increased across the gestations studies while free
p-hCG levels decreased. Expressed as MoMs (95% CI), in the 23 Down's syndrome
samples the PAPP-A level was 0.89 (0.71-1.27) MoM, not significantly different
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from normal (p>0.05, Mann-Whitney U test) and the free (3-hCG level was 1.89
(1.72-2.67), significantly elevated (p<0.0001, Mann-Whitney U test).
Table 6.2.
Number (percentage) of affected and unaffected pregnancies with a given MoM above
different arbitrary levels.




0.5 23(100) 86 (97)
1.0 22 (96) 42 (47)
1.5 19 (83) 18(20)







Median (10th-90th percentiles) maternal serum inhibin-A in 89 chromosomally normal
singleton pregnancies at 11-13 weeks of pregnancy.
Gestation (weeks) Number of samples PAPP-A (iu/mL) F|3-hCG (iu/L)
11 29 2959(912-4922) 22.9 (10.3-34.9)
12 32 3315 (1306-5274) 19.6 (7.3-29.3)13 28 4606.0 (1753-5539) 15.4 (5.7-21.6)
6.3.1.3 Correlation between inhibin-A, PAPP-A andfree (i-hCG.
In both the control and Down's syndrome samples log10(inhibin-A MoM) was
significantly correlated with log10(free (f-hCG MoM) (r=0.61, p<0.001 for the
controls and r=0.65, p<0.001 for the Down's syndrome cases). There were no other
significant associations between proteins in either the controls or the Down's
syndrome cases.
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6.3.2 Study two
The median inhibin-A level in the normal control pregnancies is shown in figure 5.2,
page 73. In the Down's syndrome pregnancies, at 7-11 weeks gestation the median
inhibin-A level was not significantly different from normal but it was significantly
elevated at 13-14 weeks. Free (3-hCG levels in the Down's syndrome samples were
elevated at all gestations (table 6.4)
Table 6.4
Levels of serum markers, expressed as MoMs, in control and Down's syndrome
pregnancies at 7-14 weeks of gestation.
Marker Gestation Controls Down's p-value
No. MoM No. MoM
Inhibin-A 7-11 148 1.00 8 0.98 0.68
13-14 88 1.00 6 2.60 0.002
Intact hCG 7-11 148 1.08 8 0.95 <0.001
13-14 88 0.93 6 1.19 0.09
Free p hCG 7-11 140 1.00 8 1.79 <0.001
13-14 88 0.94 6 2.15 0.002
AFP 7-11 148 0.99 8 0.7 0.10
13-14 88 0.96 6 0.59 0.02
6.3.3 Study three
6.3.3.1 Inhibin-A results
Table 6.5 (page 89) shows the median levels (10th-90th percentiles) of inhibin-A in
the 800 chromosomally normal control samples across the gestation 10-13 weeks,
inclusive. Levels fell significantly from 207 ng/mL at 10 weeks to 146.6 ng/mL at 13
weeks (p<0.001, Mann-Whitney U test).
In the Down's syndrome samples, the median (95% CI) inhibin-A level, expressed as
MoMs, was 1.46 (1.37 - 1.85), significantly higher than in the controls (p<0.0001,
Mann-Whitney U test). Figure 6.2 (page 90) displays the individual cases. For a given
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5% false positive rate, inhibin-A alone would have detected 12.8% of the Down's
syndrome cases.
Table 6.5
Median (10th-90th percentiles) maternal serum inhibin-A and free phCG levels in 800
chromosomally normal singleton pregnancies at 10-13 weeks of pregnancy.
Gestation (weeks) Number of samples inhibin-A (pg/mL) Fp-hCG (iu/L)
10 52 207.0 (104.3-440.6) 45.2 (21.4-113.3)
11 318 174.0 (73.2-329.9) 41.0 (18.9-99.0)
12 325 168.6 (84.1-309.7) 34.0 (16.3-78.0)
13 105 146.6 (71.3-281.1) 30.0 (14.7-69.2)
6.3.2.2 Free fi-hCG results
Table 6.5 shows the levels of free (ThCG in the 800 control samples. As for inhibin-A
levels fell significantly across the gestations studied from 45.2 iu/L at 10 weeks to
30.0 iu/L at 13 weeks of pregnancy (p<0.001, Mann-Whitney U test).
In the Down's syndrome samples, the median (95% CI) free (ThCG level was 1.91
(1.68-2.31), significantly higher than the controls (p<0.0001, Mann-Whitney U test;
figure 6.2, page 90). For a given 5% false positive rate free (i-hCG alone would have
detected 28.9% of the Down's syndrome cases.
The free (3-hCG levels in the Down's syndrome samples, expressed as MoMs, were
significantly higher than the inhibin-A levels (figure 6.2; p<0.0001, paired t-test).
6.3.1.3 Correlation between inhibin-A andfree fi-hCG.
In both the control and Down's syndrome samples log10(inhibin-A MoM) was weakly
but significantly correlated with log10(free p-hCG MoM) (r=0.38, p=0.0001 for the
controls and r=0.32, p=0.004 for the Down's syndrome cases).
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Figure 6.2
Inhibin-A (#) and free phCG (O) levels, expressed as MoMs, in 76 singleton
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6.4 Discussion and conclusions
The studies in this chapter have explored in some detail the value of inhibin-A as a first
trimester marker of Down's syndrome and represent as extension of the small
preliminary study related in Chapter Four.
Study One reported here related extremely promising data with a median inhibin-A
level in the Down's syndrome pregnancies, at 11-13 weeks, almost 2.5x those in the
normal controls. This degree of elevation was greater than that found in the second
trimester where levels are 1.9x higher than normal (Cuckle et al 1996). This was
perhaps a little surprising since immunoreactive inhibin can differentiate between
normals and Down's syndrome cases in the second trimester (van Lith et al 1992,
Spencer et al 1993, Cuckle et al 1994) but not the first (Chapter Four, van Lith et al
1995) and levels of free inhibin a-subunit, relative to dimeric inhibin, are higher at the
earlier gestations (Illingworth etal 1996). However, in support of this finding are the
subsequent data of Spencer and his colleagues (1996) who observed that inhibin-A
levels in Down's syndrome pregnancies were higher in the early weeks of the second
trimester, compared to weeks 16-20. Together with the studies described in Chapter
Five, these data therefore suggested that inhibin-A might be a powerful new marker of
Down's syndrome in both the first and second trimesters.
Study Two explored this possibility further and suggested that while inhibin-A did
appear to be a potentially useful marker at 13-14 weeks of gestation, the levels at 7-10
weeks of gestation in the Down's syndrome pregnancies were not significantly
different from normal. In comparison, levels of intact hCG in the Down's syndrome
cases were not significantly different at either 7-10 or 13-14 weeks of pregnancy while
free (LhCG levels were significantly elevated at both time points, confirming previous
reports (Cuckle etal 1988, Macri etal 1993). This small study (14 Down's syndrome
samples only) therefore confirmed and extended the findings of Study One, suggesting
that effective first and second trimester Down's syndrome screening would indeed be
possible with inhibin-A, albeit to a lower gestational limit of approximately 11 weeks.
However, the data from Study Three, which involved much larger numbers of
samples, were not so encouraging. The median inhibin-A level was only 1.46 MoM in
the Down's syndrome samples, significantly lower than the levels observed in Studies
One and Two. Given the larger numbers of samples examined in Study Three it is
likely that this latter study is more representative of the overall population, an
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assumption that would be supported by a recent multicentre study of first trimester
markers (Wald et al 1996). In that study the median (95% CI) inhibin-A level was
1.19 (1.05-1.35) in 77 samples at 8-14 weeks of gestation, with no trends across
those weeks of pregnancy. While the four studies (ie three reported here and that of
Wald and colleagues) utilised different formats of the same inhibin-A ELISA, Studies
One and Two reported here and the study of Wald and his colleagues used essentially
the same format but with different calibrators. It is therefore unlikely that the format of
the assay is relevant to the differences between the studies and indeed, as discussed in
Chapter Seven, there is objective evidence to support this hypothesis, for the second
trimester at least.
It would therefore appear that the level of inhibin-A in Down's syndrome pregnancies
in the first trimester is not as elevated as first observed in Studies One and two.
Nonetheless, the degree of elevation is as high as AFP is low (Brambati et al 1986,
Sciosca et al 1987, Crandall et al 1991, Cuckle et al 1988, Brock et al 1990, Aitken et
al 1993) and the final value of inhibin-A will depend upon how much it adds to the
existing markers. In this regard, the data reported in the three studies here are again not
very promising. While inhibin-A and PAPP-A levels are independent, unlike in the
second trimester studies reported in this thesis (Chapter Five) levels of inhibin-A and
free (3-hCG are significantly correlated in the first trimester. This was also observed by
others (Wald etal 1996). Further, Studies Two and Three showed that inhibin-A is not
as good a marker of Down's syndrome as free (i-hCG, re affirming the latter as a
cornerstone of first trimester serum screening.
A first trimester marker of Down's syndrome so far not discussed is nuchal
translucency - a measurement taken, on ultrasound, from the nape of the fetal neck
(Nicolaides etal 1992). Large scale studies from the same group, in high (Nicolaides
et al 1994) and subsequently low risk populations (Snijders et al 1996), have
demonstrated that nuchal translucency (NT) is an excellent marker of Down's
syndrome with an overall detection rate as high as 80% for a 5% false positive rate.
While there is some concern that other centres have been unable to achieve similarly
outstanding results (Bewley et al 1995, Scott et al 1996) it remains likely that nuchal
translucency will find an important role in early pregnancy screening for Down's
syndrome.
Importantly, nuchal translucency and serum markers are independent in their
assessment of Down's syndrome risk (Noble et al 1995), and the addition of free
P-hCG to maternal age and nuchal translucency may afford detection rates as high as
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85-90% (Noble etal 1995) and while the further addition of PAPP-A has not yet been
reported, this combination may increase the detection rate yet further for a fixed false
positive rate. In such combinations it has been estimated, using modelling, that
inhibin-A might add less than 2% to any detection rates (Noble et al 1997).
In conclusion, while inhibin-A promises to be a most valuable new marker of Down's
syndrome in the second trimester of pregnancy, and it remains elevated in such
pregnancies in the first trimester, its is unlikely to find an application as a first trimester
serum marker. Rather, the data from all existing studies would suggest that inhibin-A
may become useful at approximately 13 weeks of pregnancy, when PAPP-A is losing
its power of discernment.
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7.1 Introduction
Chapter Two, Assay Methodology and Validation, (page 18) details the changes that
were successively made to the inhibin-A ELISA including the introduction of a
pre-assay boiling step, the use of a simplified signal detection reagent and the
calibration and introduction of a partially immunopurified standard preparation to
replace the recombinant human preparation that had been a gift from Genentech Inc,
USA. These modifications improved assay performance, reduced assay costs and
allowed widespread commercial distribution of the assay reagents, respectively.
However, it was apparent that the use of different assay formats, and the two different
inhibin standard preparations within those formats, resulted in considerable variation
in the absolute levels of inhibin-A reported, as is evident in the data reported in
Chapters Three, Four and Five. This has understandably made direct comparisons
between different series difficult, an issue of some concern when assessing the value
of inhibin-A as a possible prenatal marker of Down's syndrome (Spencer et al 1996).
Indeed, while no formal comparison was performed it appeared that the earlier studies
using the original ELISA format (Wallace et al 1995, Wallace et al 1996, Aitken et al
1996) afforded a better discrimination between Down's syndrome cases and controls
than the subsequent reports that used a modified format (Spencer et al 1996, Cuckle et
al 1996, Noble etal 1997). While it was likely that this latter observation was simply
due to either chance, regression to the mean, or to differences in the sample sets, an
effect related to the assay modifications could not be excluded.
In the hope of excluding the latter possibility, that the assay modifications had
detrimentally affected the performance of "inhibin-A" as a prenatal marker of Down's
syndrome, which if true would represent a significant problem, a simple, quick
"experiment" was performed. In this experiment the remaining aliquots from the
Down's syndrome samples used in the first large-scale study (reported in Chapter
Five, page 67 and in Aitken et al 1996) were retrieved from frozen storage in
Edinburgh and re-assayed using the fully modified assay format. Reflecting the
informal nature of this experiment the original controls were not re-assayed but instead
the samples used to define the normal range, as detailed in Chapter Three, page 35,
were used to calculate the median MoM for the Down's syndrome samples.
Unfortunately, rather than confirming that the median MoM remained unaffected by
the modifications the "new" Down's syndrome MoM was significantly lower than that
originally reported (1.43 v 2.28 for the same samples).
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Clearly, the approach to the potential format effect problem had not assisted in
clarifying the issue at all. Nonetheless, the results, even allowing for the confounding
problems of different controls and the extended frozen storage in an extremely small
sample volume, when considered with the drift apparent from the successive studies
(table 7.4, page 104) mandated a formal comparative study. This chapter details that
study and results.
7.2 Material and Methods
7.2.1 Inhibin-A ELISA formats
The original ELISA format and modifications, including the two different standard
preparations that have been used, are described in detail in Chapter Two. However,
for ease of reading the differences in the three formats (I-III) are briefly summarised
here.
Format I is the original ELISA method described by Groome and O'Brien (1993) and
subsequently validated for human serum (Groome etal 1994). Format II is identical to
the original method, except that a simplified and cheaper method of detection using a
non-amplified alkaline phosphatase substrate, p-nitrophenylphosphate (pNPP),
(Kirkegaard and Perry Laboratories, Maryland, USA), was used. This method was
validated in-house by Groome and first used in the study described in Chapter Four
and subsequently reported by Noble and her colleagues (Noble etal 1997). Format III
involves an additional sample preparation step, performed prior to oxidation, involving
heating the sample or standard in a waterbath at 100°C for 3 minutes after mixing with
2% (final w/v) sodium dodecylsulphate (SDS). Detection is afforded by the addition of
pNPP as detailed in format II. This format was validatedfor use in serum and amniotic
fluid as described in Chapter Three and has been used for inhibin-A measurement in
two separate series of Down's syndrome samples (Spencer et al 1996, Cuckle et al
1996).
The standard preparation used initially was a 32kD recombinant human (rh) inhibin
preparation generously supplied by Genentech Inc (CA, USA). This preparation was
used in a number of studies, including those reported in Chapters Four and Five and
those subsequently published (Wallace et al 1995, Aitken et al 1996, Cuckle et al
1995). This preparation has been denoted RH. The second preparation (IP) was
developed by Groome, allowing the commercial distribution of the assay. This is
partially immunopurified from human follicular fluid and was calibrated by Groome
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against the rh inhibin. Six possible permutations of the formats and standards are
therefore possible and all six were compared in this study: I-IP, II-IP, III-IP, I-RH,
II-RH, III-RH.
7.2.2 Serum samples
Second trimester maternal sera from 41 Down's syndrome pregnancies and 247
control samples, matched for gestation and duration of storage, were identified from
records and retrieved. The samples were generously supplied by Dr Kevin Spencer
and Dr David Aitken as a collaborative project. None of the Down's syndrome or
control samples had been assayed for inhibin-A previously and each sample was
assayed blinded to which group it was from. Each sample was assayed by all three
formats with both standards consecutively, without further freeze-thawing.
7.2.3 Statisticalanalyses
Statistical analyses were performed using the software packages Statview 4.1 (Abacus
Inc., Berkeley, CA, USA) and SPSS (SPSS Inc, Chicago, IL, USA).
Log10(inhibin-A) fits a Gaussian distribution, as previously described in Chapter Five
and therefore comparisons of absolute levels were made using log10 levels. Because
inhibin-A levels vary significantly with gestation, as described in Chapter Three,
regressed medians were calculated for each week of gestation, as previously described
in ChapterThree (page 37) and levels in the Down's syndrome samples expressed as
multiples of these normal medians (MoMs). MoMs obtained with different formats
were compared by Wilcoxon rank sums for paired tests. Distribution parameters were
calculated for inhibin-A for each of the formats by Dr Jenny Crossley (see
Acknowledgments, page viii). The mean was taken as log10median and the standard
deviation as the difference between the 10th and 90th centiles in logs, divided by 2.56
(Cuckle et al 1987). Comparative analyses were recorded as significant when p<0.05.
7.3 Results
An assay problem was encountered for the first batch of samples assayed with format I
(both standards). There was not sufficient sample volume to re-assay these samples
and so data are availablefor this format for fewer samples (both controls and Down's
syndrome) than the other two formats. Further, there was insufficient volume in
another Down's syndrome sample to perform all three assay formats and so there are
no data available on this sample assayed by format III.
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7.3.1 Chromosomally normal control samples.
Median inhibin-A levels in the control samples differed significantly between the three
formats. In particular, the levels obtained by format 1II-RH were approximately double
those of the other formats (Table 7.1).
Table 7.1.
Regressed median inhibin-A levels in 247 chromosomally normal pregnancies at 15-20
weeks gestation.
Gestation Format I Format II Format III
(weeks) n IP RH n IP RH n IP RH
15 49 134.7 146.5 96 120.4 139.3 96 134.1 357.9
16 33 133.0 146.0 64 111.8 129.6 64 129.0 341.9
17 49 145.6 162.1 65 113.6 132.6 65 127.4 339.0
18 7 172.4 194.6 12 125.8 148.5 12 129.2 349.0
19 3 213.4 243.5 5 148.8 177.1 5 134.4 371.9
20 5 181.6 218.6 5 143.0 407.8
The parameters of inhibin-A distribution in the control samples also varied between
formats with format III affording the narrowest width of distribution, irrespective of
the standard used (Table 7.2, page 99).
7.3.2 Down's syndrome samples
As with the control samples, the parameters of inhibin-A distribution in the Down's
syndrome samples varied between formats with format III affording the narrowest
width of distribution, irrespective of the standard used (Table 7.2, page 99). The
median inhibin-A level in the Down's syndrome samples, expressed as MoMs, was
significantly higher in formats II and III, when derived with the RH standard than
when derived with the IP standard (table 7.2, p<0.0001 for both). There were no
significant differences between standards for format I (p=0.09). For a given standard
preparation no particular format afforded persistently higher Down's syndrome MoMs
than the others although, for the RH standard, the median MoM was significantly
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higher when derived with format III than with format II (p=0.02) and for the IP
standard, higher with format I than with format II (p=0.01). There were no other
significant differences. Consistent with these trends, the distance from the control
mean, a measurement of separation, of Down's sample mean was greatest with format
III than the others.
Table 7.2.
Parameters of distribution of inhibin-A levels (MoM) in serum from 247
chromosomally normal and 41 Down's syndrome pregnancies. Mean and SD are of
log gaussian distributions. (Upper - controls, Lower - Down's syndrome)
n Median Mean SD Distance from
control mean (SD)
141 1.01 0.003 0.238 -
I - IP
19 1.73 0.239 0.392 0.99
247 1.02 0.006 0.293 -
II - IP
41 1.54 0.188 0.408 0.62
247 1.00 0.002 0.182 -
III - IP
40 1.72 0.236 0.203 1.29
141 1.02 0.008 0.377 -
I - RH
19 1.85 0.267 0.778 0.69
247 1.01 0.004 0.425 -
II - RH
41 1.83 0.262 0.629 0.61
247 1.01 0.002 0.2209 -
III-RH
40 1.88 0.275 0.2496 1.23
Table 7.3 (page 99) displays the correlation coefficients between Log10(inhibin-A)
levels in the control and Down's syndrome samples obtained by the different formats.
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The highest coefficients of correlation are between levels derived from the two
different standard preparations within a given assay format. Further, there is generally
a high level of correlation between the levels obtained with assay formats I and II
(irrespective of standard preparation), whereas the inhibin values derived with assay
format III correlate less well with those from the other two formats.
Table 7.3.
Correlation coefficients (r) between Log,0(inhibin-A) in Down's syndrome and
control samples for the three assay formats (I-III) and two standard preparations (IP,
RH). (Upper - controls, Lower - Down's syndrome)
II - IP Ill - IP I - RH II - RH III - RH
I - IP
0.86 0.61 0.94 0.79 0.62
0.92 0.45 0.80 0.87 0.46
II - IP
0.61 0.74 0.98 0.61
0.52 0.92 0.98 0.52
III - IP .
0.57 0.65 0.99
0.42 0.46 1.0
I - RH 0.78 0.57
0.91 0.43
II - RH 0.67
0.56
7.4 Discussion and conclusions
This study has afforded for the first time, formal comparative data from the different
inhibin-A ELISA formats. As was apparent from the previous studies related in
Chapters Three, Four and Five and reported in the literature (Wallace et al 1995,
Cuckleetal 1995, Aitken et al 1996, Wallace et al 1996, Spencer et al 1996, Cuckle et
al 1996, Noble et al 1997), the data reported here confirm that there are significant
differences in absolute levels of inhibin reported depending on the ELISA format and
standard preparation used (table 7.1). However, rather than simply confirming these
differences this study also affords some explanation for them.
Because the three ELISA formats remain highly specific for inhibin-A and because the
IP standard was calibrated against the RH standard, differences between the formats
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cannot have arisen from the detection of other inhibin moieties and must be due to
variations in the efficacy of the formats to detect inhibin-A. Biological fluids contain a
number of different molecular weight forms of inhibins (Schneyer et al 1990,
Robertson et al 1995, Robertson et al 1996) and it is now apparent that the higher
molecular weight inhibin-A forms, as well as probably being biologically inactive
(Mason et al 1996), are less immunoreactive in the inhibin-A ELISA used here than
32kDa inhibin-A (Good et al 1995, Priddle et al 1995). However, the
immunoreactivity of the larger forms can be increased approximately two-fold by
pre-assay boiling (Mason et al 1996), an effect that cannot be secondary to
degradation, because the large inhibin forms used were engineered to be non-
cleavable. The increased levels observed after boiling therefore, presumably arise
through improved epitope exposure, perhaps through protein unfolding. The extent of
this effect after boiling is very similar to the approximately two-fold increase in
inhibin-A levels observed in this study with format III compared to the other two
formats. It is therefore proposed that the differences evident here relate to changes in
epitope exposure following the SDS boiling step.
That these differences are only evident with III-RH, and not III-IP, is explained by the
composition of the two standard preparations. The RH standard, a recombinant
preparation, contains only 32kDa rh inhibin-A and thus boiling in SDS would not be
expected to change the already optimum antibody-epitope binding. However, boiling
would improve antibody binding to the epitopes of the larger molecular weight
inhibin-A forms present in the unknown samples. The net effect therefore is a relative
increase in the inhibin-A measured against the recombinant standards. The IP standard
however was derived from human follicular fluid which contains many different
molecular weight inhibins (Robertson et al 1995). Thus, when the IP standard is
employed to derive unknown values the effect of boiling is exerted on both the
standard and the sample resulting in minimal change in absolute inhibin levels. The
precise net effect is dependent on the relative concentrations of the different forms in
the standard (derived from follicularfluid) and sample (serum).
In Chapter Three, page 52, the ontogeny of inhibin-A in maternal serum in early
pregnancy is described in detail. The findings of Muttakrishna and her colleagues
(1995) are discussed in that chapter, relating how those authors used chromatography
to demonstrate that in pregnancy only 32kD inhibin-A circulated. However, if this
were true then the effects described above could not arise. The presence of only 32kD
inhibin in serum would mean that when assayed against the RH standard, the boiling
pretreatment would confer no changes (ie the inhibins in the standards and unknowns
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are identical). In contrast, when assayed against the IP standard inhibin-A levels
would fall (reflecting improved antibody affinity for the unfolded epitopes in the
standards compared to the unaltered affinity for the already optimum epitopes in the
unknowns). This is exactly the opposite of what is observed. Thus, the data reported
here provide indirect evidence that different molecular sizes of inhibin-A do circulate in
early pregnancy, supporting the preliminary observations made with two different
immunoreactive inhibin assays, as detailed in Chapter Four, page 60, and the
chromatographic data of Khalil and his colleagues (1995). It is likely therefore that in
the study of Muttakrishna and colleagues (1995) problems with sample collection and /
or storage resulted in in vitro degradation of the inhibin prior to chromatography.
However, the poor correlations between format III derived inhibin-A levels and format
I or II derived levels is probably not due to the differential detection of various
inhibin-A forms. If this was so then a poor correlation would be expected between the
levels derived with III-IP and those from III-RH. This was not observed. It is
therefore proposed that these differences relate to the release of erythrocyte catalase in
the venous samples. Catalase would remove the hydrogen peroxide added during
pretreatment and thus prevent modification of the inhibin (f-subunit and so impair
detection. This effect is evident in some samples, presumably depending on
storage/separation history, when assayed by formats I and II, but would be overcome
by the SDS boiling pretreatment in format III, probably through the denaturing of the
catalase. While catalase was not measured in the samples to confirm this directly,
indirect evidence is offered by the stability data related in Chapter Two, page 26.
These data showed that inhibin-A levels fell when samples were stored as whole blood
but not as serum, and that when the samples were boiled prior to assay the decline was
prevented. Thus, the changes observed with format II (no boiling) could not have been
due to dissociation of the inhibin dimer, because levels were stable with format III
(SDS boiling), but rather to an effect related to storage as whole blood, but not serum.
Importantly, a quenched inhibin-A signal was evident in the stability study samples
even without obvious haemolysis. These data therefore suggest that while the apparent
inhibin-A levels is stable in clinical samples, this is only so when using format III. In
the context of possible prenatal screening programmes, when samples might travel for
some distance and time prior to assay, this is an important observation. Indeed, there
have been important concerns about similar changes in fff-hCG levels after sampling
but prior to assay, concerns that may have limited the uptake of this analyte (Sancken
and Bahner 1995, Kardana and Cole 1997)
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Further support to the catalase hypothesis is given by finding that the correlation
coefficient between results from formats II-IP and III-IP can be increased by
recalculating using only those samples with an inhibin-A level of at least 70pg/mL in
formats I and II (r=0.76 v r=0.61). 70pg/mL approximates to the 10th centile (see
Chapter Three, page 40) and so excludes many samples that may have an inhibin-A
level artefactually lowered by catalase. Similarly, the tighter distribution of results with
format III compared to the other two formats is probably an effect of normalising the
levels in some samples with a quenched signal.
The high degree of correlation between the results derived with formats I and II
suggests that, while there may be small differences in absolute levels detected, the
method of detection of inhibin-A in the ELISA is not of critical importance, so long as
expected levels are above the sensitivity of the method employed. Therefore, given the
considerable cost savings afforded by the simple substrate detection method compared
to the amplification kits the former methodology appears preferable.
Lastly, in this study, the boiling pretreatment was associated with an apparent modest
improvement in the discrimination between Down's syndrome samples and controls
(table 7.2, page 97), the opposite of the concerns outlined in the Introduction to this
chapter that initiated this study. To aid interpretation of these data in the context of the
existing literature table 7.4 summarises the previous second trimester studies (some of
which have been described in earlier chapters), detailing the format used in each.
Interestingly, the most recent, and largest, of these studies utilised format III-IP
(Spencer et al 1996) and reported results less promising than the earlier studies using
format I (Wallace et al 1996, Aitken et al 1996), as outlined in Chapter Five.
Considering the biology underlying the differences between the formats and the
current understanding of inhibin-A in normal and Down's syndrome pregnancy
(Wallace and Healy 1996, Wallace et al 1997) it is unlikely that the assay format will
impact significantly upon detection rates (table 7.4). In support of this, two sample
sets reported from the same centre and analysed as work related to this thesis, one
analysed with format I (Cuckle etal 1995) and one with format III (Cuckleetal 1996),
showed no significant differences in terms of median MoMs.
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Table 7.4.
Inhibin-A ELISA method used and median affected inhibin-A MoM reported in




Cuckle et al 1995 I-RH 1.64
Wallace etal 1996 I-RH 2.6
Aitken et al 1996 I-RH 2.24
Wald etal 1996 I-RH* 1.79
Spencer et al 1996 III-IP 1.77
Cuckle et al 1996 III-IP 1.58
* the recombinant standard used by Wald et al differs from the rh-inhibin-A
preparation (RH) referred to in this chapter.
In conclusion, this is the first and only formal comparison of three different formats of
the inhibin-A ELISA. The data reported here demonstrate that while the absolute levels
of inhibin-A reported depend on the assay format used, the discrimination of Down's
syndrome cases from controls would not appear to be significantly affected.
Nonetheless, the boiling pretreatment affords significant improvements in assay
performance, particularly for samples stored as whole blood, and on this basis format
III would appear to be the most useful clinically. The introduction of an internationally
agreed inhibin-A standard will prevent other differences between laboratories but until
then a given institution should plan to use the same standard preparation for their long
term studies.
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8.1 Introduction
As described in Chapter Three, amniotic fluid contains significant amounts of both
inhibin dimers and inhibin precursor fragments, probably including free inhibin
a-subunits. Further, as discussed in that chapter and supported by indirect evidence, it
is likely that the source of these proteins in amniotic fluid is the chorionic trophoblast,
rather than the placenta. However, while it is also clear that, compared to normal
pregnancy, maternal serum levels of inhibin-A are elevated in Down's syndrome
pregnancies, in both the first (see Chapter Five', Wallace et al 1995, Noble et al 1997)
and second (see Chapter Six', Cuckle etcd 1995, Wallace etal 1996, Aitken et al 1996,
Spencer etal 1996, Cuckle et al 1996, Wald et al 1996) trimesters inhibin-A levels in
amniotic fluid in Down's syndrome pregnancy remains unexplored. If the production
and secretion of inhibins from the chorion and placenta are differentially regulated, as
suggested in Chapter Three, then it is conceivable that AF inhibin levels in Down's
syndrome may be normal. Therefore, to further explore the biology of inhibin
secretion in pregnancy AF levels of inhibin-A, inhibin-B and pro-«C containing
inhibins in chromosomally normal and Down's syndrome pregnancies have been
examined.
8.2 Materials and Methods
All samples for this study were generously supplied by Dr David Aitken and Dr Jenny
Crossley, Duncan Guthrie Institute, Glasgow (see Acknowledgments, page viii)
8.2.1 Control samples
One hundred and sixty-one chromosomally normal control pregnancies on which an
amniocentesis had been performed were identified from records and an aliquot of fluid
retrieved from storage at -20°C. Sixty-eight (42.2%) of these amniocenteses had been
performed for maternal age, 82 (50.9%) for a positive MS screening result, 1 (0.6%)
for an isolated elevated MS AFP and 10 (6.2%) for other miscellaneous reasons (eg
past history, maternal anxiety). Sample volume was sufficient in 150 of these control
aliquots to allow the measurement of inhibin-A, inhibin-B and pro-«C inhibins,
whereas in the remaining 11 samples only inhibin-A was measured.
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8.2.2 Down's syndrome samples
Similarly, 51 Down's syndrome pregnancies, from which AF had been collected
prospectively, were identified from records and an aliquot of fluid retrieved from
storage. Of these 51 pregnancies, 11 (21.6%) had an amniocentesis performed
because of maternal age and 40 (78.4%) because of an increased risk by AFP/age or
AFP/hCG/age screening. In six of the 51 aliquots, the sample volume was insufficient
for all three of the assays and only inhibin-A was measured in these. In the remaining
45, inhibin-A, inhibin-B and pro-aC inhibin levels are reported.
8.2.3 Inhibin assays
The three inhibin assays have been described and validated for amniotic fluid
previously (Chapter Three). Of the inhibin-A assay formats, format III was used in
this study. All samples were assayed blinded to whether the sample was from a
Down's syndrome or a normal pregnancy
8.2.4 Statistical analyses
Statistical analyses were performed using Statview 4.1 (Abacus Inc, Berkeley, CA,
USA) and SPSS for Windows (SPSS Inc, Chicago, IL, USA). AF inhibin-A and
inhibin-B levels increase significantly and linearly across the gestational window 14 to
20 weeks (Chapter Three ). The levels of these two proteins in both the Down's
syndrome and control pregnancies were therefore expressed as multiples of the normal
median (MoM), using the regressed median of the controls at the appropriate gestation.
The use of regressed medians corrects for the artefactual variation that arises secondary
to the small sample size and so affords more accurate MoM estimates for both the
control and Down's syndrome samples than using non-regressed medians. The
regressed medians were calculated, by Dr Jenny Crossley, using the weighted
regression equations:
Inhibin-A median = e(8 0649 - 35.045/gestation)
Inhibin-B median = e^8-4178 ~ 41.880/gestation)
Weighted regression of the pro-aC inhibin levels however did not generate an equation
that fitted the data well. Pro-aC inhibin MoMs have therefore been calculated using
raw, rather than regressed, medians. An analysis of both approaches showed no
significant differences in terms of the resulting comparison between controls and cases
(data not shown).
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8.3 Results
8.3.1 Control samples
78 (48.4%) of the 161 control AF samples were from pregnancies with a female fetus,
82(50.9%) were from a pregnancy with a male fetus and 1 (0.6%) was unknown. Of
the Down's syndrome samples, 18 (37.3%) and 32 (62.7%) were from pregnancies
with a female and male fetus respectively. There were no significant differences in
inhibin-A, inhibin-B or pro-cxC inhibin levels between the sexes for either controls or
Down's syndrome cases (data not shown) and so the data were subsequently analysed
by group, combining data for both sexes therein. Table 8.1 (page 108) displays the
number of control samples at each gestation and the median, 10th and 90th percentiles
for inhibin-A, inhibin-B and pro-aC inhibins in these samples.
Inhibin-A was weakly but significantly associated with inhibin-B (r=0.44, p=0.0001)
and pro-aC inhibins (r=0.34, p=0.0001) and inhibin-B was weakly but significantly
associated with pro-uC inhibins (r=0.24, p=0.005).
8.3.2 Down's syndrome samples
Table 8.1 (page 108) displays the number of Down's syndrome samples at each
gestation and the median, 10th and 90th percentiles for inhibin-A, inhibin-B and
pro-cxC inhibins in these samples. Expressed as MoMs the median (95% CI) level for
the three inhibins was 0.77 (0.68-0.89) for inhibin-A, 0.90 (0.52-1.57) for inhibin-B
and 0.79 (0.63-1.13) for pro-(xC inhibins. The level of inhibin-A in AF from the
Down's syndrome pregnancies was significantly lower than in the controls (p<0.0002
Mann-Whitney U test), whereas the level of neither of the other inhibins was
significantly lower than normal (p=0.35 and p=0.49, respectively; Mann-Whitney U
test).
In contrast to the controls, in the Down's syndrome samples, there was no significant
association between inhibin-A and inhibin-B (r=0.19, p=0.2I), whereas pro-aC
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8.4 Discussion and conclusions
This is the first study to examine AF levels of inhibin-A, inhibin-B and pro-cxC inhibins
in Down's syndrome and normal pregnancy and the results may shed some light on the
control of inhibin secretion in pregnancy.
While the ontogeny of inhibin and hCG in early pregnancy are similar (Tovanabutra et al
1993, Illingworth et al 1996), possibly reflecting reciprocal in vitro relationships
(Petraglia et al 1987), and maternal serum levels of both are elevated in Down's syndrome
(see Chapters Five and Six, van Lith et al 1992, Spencer et al 1993, Bogart et al 1987,
Chard and lies 1994), which for hCG at least is secondary to increased placental
production (Eldar-Geva etal 1995), there are important differences between the secretion
of hCG and inhibin in both normal and Down's syndrome pregnancies. In normal
pregnancy the intact hCG concentration is much lower in AF than in MS (Kletsky et al
1985) while inhibin-A concentrations in AF are significantly higher than in MS (Chapter
Three, page 44). Further, in Down's syndrome pregnancies while both intact hCG and
free phCG levels in AF are higher than in AF from normal pregnancies (Cuckle et al
1991, Spencer etal 1997), comparable with the differences reported in serum (Bogart et
al 1987, Chard and lies 1994), this study has shown that AF levels of inhibin-A in
Down's syndrome pregnancies are significantly lower than in normal pregnancy AF, the
reverse of what is observed in MS for this protein. Of course, since inhibin-B is
undetectable in maternal serum at this gestation (Chapter Three, page 42), no comparisons
between AF and MS can be made. There are currently no reports of MS levels of pro-«C
in Down's syndrome pregnancies although it has been suggested, based on indirect
evidence, that these will not be significantly different from normal (Wallace and Healy
1996).
The lower levels of AF inhibin-A observed in Down's syndrome compared to normal
may relate to changes in either the route of secretion of inhibin-A by the placenta, in
preference for MS, or in the rate of clearance of inhibin-A from the amniotic cavity. While
MS levels of several proteins and steroids are deranged in Down's syndrome, the AF
levels for each of these are similarly deranged (Cuckle et al 1985, Cuckle et al 1991,
Spencer et al 1997), indicative of neither an altered route of secretion nor selective
changes in clearance from AF. This explanation for the inhibin-A observations is
therefore unlikely. It is conceivable however, that dimeric inhibin-A, but not inhibin-B, in
AF, but not MS, may dissociate into separate subunits more rapidly in Down's syndrome
relative to normal pregnancy. Levels of free phCG and free uhCG subunits are much
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higher in AF than in MS while intact hCG levels are lower (Ozturk et al 1988). The
increased concentration of free hCG subunits in AF compared to MS could be accounted
for by an increased breakdown of intact hCG in AF but it is thought more likely that the
chorionic trophoblast preferentially secretes free subunits into AF and the placental
trophoblast secretes intact hCG into MS (Ozturk et cd 1988). In the first trimester of
pregnancy the major source of hCG in extra-embryonic coelom, and thereafter AF, is
probably chorionic, as opposed to placental, trophoblast (lies et al 1992, Chard et al
1995). It is therefore possible that in the second trimester the differences between MS and
AF in intact and free subunit hCG levels may represent different sources.
Thus, the source of AF inhibin-A may be different from that of MS, as previously
suggested (Chapter Three). If this were so then the data related here would indicate that
the abnormality in Down's syndrome underlying the elevated MS inhibin-A levels would
have to be differentially expressed in the placental and chorionic trophoblast. This would
be quite unlike hCG (either intact or free phCG).
The weak but significant associations between AF levels of inhibin-A, inhibin-B and pro-
«C inhibins in the control pregnancies is largely in keeping with the previous studies of
extra-embryonic coelomic fluid and AF in the first and second trimesters of
chromosomally normal pregnancies (Chapter Three). In the Down's syndrome
pregnancies however, inhibin-A and inhibin-B were not associated. While this may
simply be due to the smaller numbers of cases compared to controls, this observation,
together with the observation that the levels of inhibin-B and pro-aC inhibins were not
significantly lower than normal, may indicate that the abnormality underlying the
decreased inhibin-A levels is expressed specifically through the production or secretion of
the inhibin (fA subunit, rather than the other two subunits.
In conclusion, this study has demonstrated that the amniotic fluid inhibin-A, but not
inhibin-B or pro-«C, concentration in Down's syndrome is significantly lower than in
normal pregnancy. The precise explanation for these unexpected findings currently
remains obscure but the data are consistent with more than one significant source of
inhibins in mid-pregnancy and with differential control of these sources. Quantitative
assessment of the inhibin subunit messenger ribonucleic acids (mRNAs) and proteins in
fetal membranes in normal and Down's syndrome pregnancies may contribute to the
understanding of the changes in inhibin secretion in trisomy 21 pregnancies.
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9.1 Introduction
A number of maternal factors are known to affect the serum level of different Down's
syndrome markers and so potentially affect the predicted risk of having a Down's
syndrome fetus including race (Muller and Boue 1990, Simpson et al 1990, Kulch et
al 1993, Bogart et al 1991), cigarette use (Bernstein et al 1989, Cuckle et al 1990,
Battels et al 1993), early pregnancy bleeding (Salem etal 1984) and insulin dependant
diabetes mellitus (IDDM) (Wald et al 1979, Milunsky et al 1982, Reece et al 1987,
Wald et al 1992, Palomaki et al 1994). In particular, it has been reported that early
second trimester serum levels of AFP and hCG in women with IDDM are lower than
in non-diabetic women (Wald etal 1979, Milunsky etal 1982, Reece et al 1987, Wald
etal 1992, Palomaki etal 1994). On average, AFP levels have been found to be 70%
of those in non-diabetics which, while a small effect, may artefactually increase the
predicted risk of a given pregnancy. In contrast, the lower hCG level observed in
women with IDDM, on average levels are 95% of those in non-diabetics, might be
expected to decrease estimated risks.
Therefore, in view of the potential usefulness of inhibin-A as a prenatal marker of
Down's syndrome (see Chapter Five ) it was decided to compare early second
trimester inhibin-A levels in the serum of pregnant women with IDDM with those in
non-diabetic women.
9.2 Material and Methods
9.2.1 Serum samples
Maternal serum samples were collected prospectively as part of routine the West of
Scotland Down's syndrome and neural tube defects prenatal screening programme.
Each sample had been centrifuged and the serum separated within three days of
collection and stored at -20°C. 169 women with pre-existing IDDM and a
chromosomally normal, singleton pregnancy were identified from records and their
stored serum retrieved for analysis. These are a subset of 261 IDDM samples on
which hCG and AFP have been reported previously (Crossley et al 1996). Similarly,
sera from 432 non-diabetic women with a chromosomally normal singleton
pregnancy, matched for gestation and duration of storage with the 169 IDDM samples,
were identified and retrieved. These represent a subset of the normal pregnancy
samples reported in Chapter Three, page 35.
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Gestation, in completed weeks of pregnancy, was calculated from certain menstrual
dates or by an early pregnancy ultrasound scan.
9.2.2 Inhibin-A assay
Inhibin-A was measured using format III of the inhibin-A ELISA, as detailed in
Chapters Two and Seven.
9.2.3 Statistical analyses
Statistical analyses were performed using Statview 4.1 (Abacus Inc, Berkeley, CA,
USA) and SPSS for Windows (SPSS Inc., Chicago, IL, USA). Inhibin-A levels were
converted to multiples of the normal median for gestation, in completed weeks, using
regressed medians as previously described and validated in Chapter Three. As detailed
in Chapter Five inhibin-A MoM is log gaussian distributed. Therefore, to allow
comparisons, where appropriate, the mean and SD of logio(MoM) were calculated.
The mean was estimated as logio of the median and the SD as (logio(90th centile) -
logio(10th centile))/2.56 (Cuckle el al 1987). The correlation between inhibin-A and
hCG levels was examined using log(MoM) for each analyte.
To correct inhibin-A levels for maternal weight weighted log-linear regression of the
median inhibin-A MoM against median weight, in 10kg weight groups, was
performed. This generated the equation:
Weight corrected inhibin-A MoM = inhibin-A MoM /10(()-2488"() ()()40x weight)
The regression calculations, both for the median inhibin-A values and for the maternal
weight corrections were kindly performed by Dr Jenny Crossley (see
Acknowledgments, page viii).
9.3 Results
Table 9.1 (page 115) shows the number of samples, the 10^, 50^ and 90^
percentiles for inhibin-A in the 432 non-IDDM and 169 IDDM pregnancies by
completed week of gestation. Levels of inhibin-A fell from 15 weeks to 17 weeks
rising again to 20 weeks.
Table 9.2 (page 115) shows the median, mean and standard deviation of the inhibin-A,
expressed as MoMs, in both the control and IDDM pregnancies. There were no
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significant differences between the two groups when no adjustments were made for
maternal weight (p>0.05, Student's t-test).
Table 9.1.
Median (10th-90th percentile) maternal serum inhibin-A levels in 432 non-diabetic
women and 169 women with IDDM.
Gestation
(weeks) Controls IDDM
No. of samples Inhibin-A (pg/mL) No. of samples Inhibin-A (pg/mL)
123.5 126.9
15 75

















Medians, means and SDs of maternal serum inhibin-A in 432 normal and 169 IDDM
pregnancies.
Controls IDDM
Median Mean SD Median Mean SD significance
Inhibin-A (MoM) 1.01 0.003 0.240 1.05 0.022 0.250 ns
Inhibin-A (MoM)
(weight corrected)
1.02 0.010 0.219 1.17 0.068 0.241 p<0.01
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Maternal weight at sampling was available for 391 (91%) of the control samples and
151 (89%) of the IDDM samples. The median maternal weights of these two groups
were 63kg and 68kg respectively. Table 9.3 shows the median inhibin-A MoM for the
control samples, divided into 10kg weight bands, showing a decline in median MoM
with increasing weight. Table 9.2 shows the weight corrected median, mean and SD
inhibin-A MoM. When weight-adjusted, the inhibin-A level in the IDDM group was
significantly higher than that in the controls (p<0.01, Student's t-test).
Table 9.3.
Distribution, by weight, of 391 control pregnancies and the relationship between








<50 25 46.5 1.013
50 - 59.99 115 55.5 1.125
60 - 69.99 150 64.0 1.005
70 - 79.99 62 73.0 0.822
> 80 39 86.5 0.852
Weight corrected inhibin-A and hCG levels were significantly correlated (r=0.32,
p<0.001 and r=0.22, p<0.001 for the IDDM women and the controls respectively).
9.3 Discussion and conclusions
As detailed in the Introduction to this chapter it has been shown previously that,
compared to non-diabetic women, maternal serum levels of AFP and hCG may be
significantly lower in pregnancies complicated by IDDM (Wald et al 1979, Milunsky et
al 1982, Reeceetal 1987, Wald et al 1992, Palomaki et al 1994). While theoretically
such IDDM-related changes could alter risk estimations, and thereby impair the
performance of screening programmes, recently Crossley and colleagues (1996)
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reported that correction of the serum AFP level for maternal weight, which was on
average greater in the diabetic women, normalised the AFP levels in those women.
Further, the same authors demonstrated that in actual practice the effects of IDDM on
marker levels did not result in any significant alteration in screening follow-up rates
amongst diabetic women, suggesting that no formal correction of the minor effects
was required. The data reported here show that the serum inhibin-A level is not
significantly different between women with and without IDDM, when no adjustments
are made for maternal weight. However, the women with IDDM were on average 5kg
heavier than the non-diabetic women, as has been reported previously (Palomaki el al
1994, Crossley et al 1996), and the inhibin-A level was inversely and significantly
related to maternal weight, as is hCG (Suchy and Yeager 1990, Bogart et al 1991,
Bartels et al 1993). Correcting the inhibin-A level for this weight effect led to a
significantly higher level of inhibin-A in the IDDM women. This observation is in
direct contrast to the data recently reported by Wald and his colleagues (1996) who
reported that in diabetics the median inhibin-A level was significantly lower (0.88
MoM). When corrected for maternal weight, this effect was lessened and became
non-significant (0.91 MoM) (Wald et al 1996), but remained reduced rather than
increased. At present, it is difficult to explain these apparent contradictory results and
considering the in vitro and in vivo relationships between inhibin and hCG and the
relatively lower hCG levels in women with IDDM (Wald et al 1992, Palomaki et al
1994, Crossley etal 1996) it might appear that the data of Wald and his colleagues are
the more plausible. However, it is interesting that while Palomaki and his colleagues
(1994) reported lower hCG levels overall for the diabetic pregnancies, they found that
levels were actually higher (1.18 MoMs) in women who had "early-onset" diabetes,
diabetes onset prior to 19 years of age. Further, these women had a mean weight very
similar to the non-diabetic population (148 lbs v 151 lbs, respectively) whereas the
"late-onset" diabetics were significantly heavier (190 lbs). It is possible therefore that
differences in the duration of diabetes may exert subtle endocrine effects and in this
regard a significant association between maternal serum AFP and glycosolated
haemoglobin, a measure glycaemic control (Leslie et al 1978), has been reported
(Reece et al 1987).
An obvious explanation for the elevated inhibin-A might be changes in circulating
insulin and/or insulin-like growth factor (IGF) levels in the diabetic women. However,
this is an unlikely explanation for a number of reasons. Firstly, circulating IGF-I
levels are lower rather than higher in individuals with IDDM (Tan and Baxter 1986).
Furthermore, although fetal serum IGF-I and IGF-II levels are increased in diabetic
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pregnancies (Delmiset al 1992, Verhaeghe et al 1993), in vitro studies have failed to
show any effect of insulin, IGF-I or IGF-II on trophoblast secretion of
immunoreactive inhibin (Qu and Thomas 1995).
Flyperglycaemia may be the mechanism underlying the altered inhibin-A levels, as has
been suggested for AFP (Reece et al 1987), and in this regard it is interesting that
Petraglia and colleagues observed that maternal serum levels of activin-A, a protein of
the same family as inhibin-A (Ying 1988) which is secreted by the placenta (de Kretser
etal 1994, Qu and Thomas 1995, Knight et al 1996), are elevated approximately five
fold in the third trimester in women with gestational diabetes (Petraglia et al 1995).
Further, the activin-A levels normalised when insulin treatment was commenced and
euglycaemia was achieved. Activin-A is a homodimerof the Pa subunit, (Pa-PaX and it
is possible that the diabetes-associated elevations of activin-A and inhibin-A are
mediated entirely through the regulation of the pa-subunit. While this is entirely
speculative at present it is afforded indirect support by the suggestion that the
decreased AF inhibin-A levels observed in Down's syndrome pregnancies may reflect
specific changes in inhibin pa-subunit secretion (Chapter Eight).
In vitro, hCG stimulates inhibin secretion and inhibin suppress hCG secretion from
dispersed trophoblast cell cultures (Petraglia et al 1987, Mersol-Barg et al 1990).
Therefore, the data presented here may be the first in vivo evidence, albeit indirect, to
support an hCG suppressive role for inhibin. Arguing against this is the direct rather
than inverse relationship observed between hCG and inhibin, which was observed in
the studies reported in Chapter Five . Further, activin stimulates hCG secretion in vitro
(Petraglia etal 1995) and one would predict from these in vitro data that the changes in
activin-A levels that might be expected in the diabetic women would more than
compensate for the effects of the minimal changes in inhibin-A that were observed.
The control dataset analysed in this study also confirms the observation, made in
Chapters Three and Five that the absolute change in inhibin-A levels between 15 and
20 gestation, the window for second trimester aneuploidy screening, are small. This is
particularly true relative to established markers of Down's syndrome. The decline in
inhibin-A from 15 to 17 weeks was only 19% and the subsequent increase to 20
weeks 44%, whereas the levels of hCG and AFP approximately half and double,
respectively, over the same interval (Westergaard et al 1985). This consistent finding
suggests that inhibin-A would be less affected by inaccurate gestational dating than is
the case for other markers, a most beneficial property for a potential new marker of
Down's syndrome.
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Thus, it has been demonstrated that, at 15-20 weeks gestation, maternal serum
inhibin-A levels in women with insulin-dependent diabetes mellitus are similar to those
in non-diabetic women if not corrected for maternal weight. However, when weight
correction is made inhibin-A levels are significantly higher in diabetic women. The
underlying explanation for this observation currently remains obscure and whether this
elevation would exert any effects on screening performance in women with IDDM
should inhibin-A be introduced as a prenatal marker for trisomy 21 has not assessed. It
is suggested however that these observations may offer some new insights into the











Although the studies related in this thesis are all simple and observational in nature the
data derived from them have considerably aided the understanding of inhibin biology
in human pregnancy. In particular, it is now clear that the placenta is not the only
significant source of inhibins in pregnancy but rather that the chorionic trophoblast is
probably another source of some importance. Further, it would appear that these two
sources are both differentially regulated and secrete different inhibins.
It has also been shown for the first time that the male term fetus produces inhibin-B,
and it is possible that this inhibin has a role in the maturation of the male hypothalamo-
pituitary-gonadal axis during in utero development. This is particularly exciting
because in adults, recent studies have shown that inhibin-B promises to be a most
sensitive marker of Sertoli cell function. The presence of adult levels of inhibin-B in
the fetus therefore may offer an opportunity to explore more subtle effects of potential
environmental testicular toxins than previously possible and to gain an improved
understanding of normal and abnormal in utero testicular development.
The studies of inhibins in Down's syndrome have shown, for the first time, that
maternal serum levels of inhibin-A are significantly elevated compared to normal and
that this elevation is gestation dependent. Therefore, while it is likely that inhibin-A
will become a valuable prenatal marker of Down's syndrome in the second trimester,
adding approximately 10% to attainable detection rates, for a fixed false positive rate, it
is most unlikely that it will be useful before 13 weeks of pregnancy. The precise
gestation at which inhibin-A becomes a valuable marker has yet to be defined with
precision, something that will probably only be described from prospective study of
very large numbers of pregnancies.
Intriguingly, while inhibin-A levels in serum are elevated in Down's syndrome
pregnancy it was shown that they are decreased in amniotic fluid. This data from this
study suggest that for chorionic trophoblast, the abnormality in Down's syndrome
may be expressed through the inhibin u-subunit. Studies are currently under way in
the author's laboratory to explore this suggestion by quantifying inhibin subunit
mRNAs in normal and Down's syndrome trophoblast, both placental and chorionic.
The detailed assessment of the different inhibin-A ELISA formats in the context of
Down's syndrome screening was a useful exercise, affording reassurance about the
newer formats. However, almost more importantly, the study also confirmed, albeit
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indirectly, that maternal serum contains a large molecular weight forms of inhibin. The
author is currently exploring this issue further (see below).
The small studies exploring inhibin-A levels in twin and diabetic pregnancies simply
afforded data that will be important to screening laboratories should they wish to use
inhibin-A as a prenatal marker in the future.
10.2 Future prospects
It remains unclear what inhibins are present in maternal serum throughout pregnancy
and the author is currently exploring this in detail. It is hypothesised that with
increasing gestation the placenta, and probably the chorion, changes the inhibins
secreted reflecting changes in the relative amounts of mRNAs expressed. Further, the
inhibin sizes secreted by trisomic pregnancies remain entirely unexplored. It remains
possible that of the forms of inhibin-A detected by the ELISA used in these studies,
only specific ones are secreted in abnormal amounts in Down's syndrome, forms that
change in relative abundance across gestations. This hypothesis would explain why
the relative levels of inhibin-A in Down's syndrome pregnancies change between the
first and second trimester. If confirmed, then of course the implications for screening
are significant, and would encourage the development of new antibodies against
specific epitopes, allowing the detection of specific forms of inhibin-A.
It will be obvious that the studies described in this thesis are observational and
"phenomenological" in nature. Within these pages, as is true elsewhere, very little
consideration has been given to the possible roles for inhibins in pregnancy. As the
understanding of inhibins in human pregnancy increases and the possible clinical
applications become appreciated (Wallace and Healy 1996) it is clear that
understanding function will become a priority. The development of transgenic animal
strains, deficient in specific inhibins and activins will be a most important tool in this
area. Indeed, such studies have already afforded important insights into roles of
inhibins and activins in embryonic development. A transgenic mouse strain, with a
mutated u-inhibin gene (Matzuk et al 1992) show normal embryogenesis, without any
fetal abnormality, indicating that inhibin is not essential for developmental processes.
(The mice do however, invariably develop malignant ovarian or adrenal tumours).
Another transgenic strain (Vassalli et al 1994), mutant for the pB-subunit (ie
homozygotes have no active inhibin-B, activin-B and activin-AB) shows normal
mesodermal development but late developmental abnormality (eyelid closure failure).
Further, while the males exhibit normal fertility, the females do not labour
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appropriately and do not have normal milk-ejection and their pups die. The delayed
parturition is of extreme interest because activins have been implicated in human labour
(as discussed in Chapter One) and given that preterm labour is the single most
important cause of perinatal mortality (Creasey 1991) this area of perinatal research
should now be a priority.
The development of other mutant strains will hopefully help to elucidate other
important questions that remain, complementing human studies.
It is also clear that the functions of inhibins and activins differ fundamentally. While
activins probably have multiple growth factor functions, inhibins appear to have
traditional endocrine or paracrine roles in various tissues (Spencer et al 1992, Tuuri et
cd 1994) and it is likely that they have these functions in pregnancy. What these precise
functions are however, remain obscure although it is likely that they may change with
gestation. Studies exploring this area, addressing the regulation and effects of specific
inhibins in pregnancy would now be most useful, dissecting out gestation effects.
Most recently, new inhibin subunits have been described and it remains to be reported
whether they exist in humans and whether they form dimeric and biologically active
proteins. Should this be confirmed then their roles, both as new activins and inhibins,
in pregnancy will be intriguing. Likewise, the increasing understanding of inhibin
binding proteins in pregnancy (Woodruff and Mather 1995, Woodruff etal 1997) may
explain levels of regulation that are not apparent from simple circulating levels. Of
course, the identification and cloning of the inhibin receptor is eagerly awaited and this
event will likely afford opportunities not currently available.
In short, the increasing ability to detect specific inhibin and activin forms and to
explore their biological functions in consort with their binding proteins promises
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Summary
BACKGROUND AND OBJECTIVE Maternal serum immu¬
noreactive inhibin has been shown to be significantly
elevated in Down's affected pregnancies in the second
trimester, suggesting that it may be useful in prenatal
diagnosis. We have investigated whether it is similarly
elevated in the first trimester.
DESIGN Stored maternal sera from women with Down's
affected pregnancies and chromosomally normal control
pregnancies were retrieved for analysis. These sera had
been collected prospectively at either 11 or 12 weeks
gestation as a routine antenatal booking procedure.
SUBJECTS From records, 11 women were identified as
having had a Down's pregnancy. For each of these, 4
controls matched for gestation and duration-of-storage
were also identified.
MEASUREMENTS Two different inhibin immunoassays
were evaluated, one using an antibody raised against
31 kDa bovine inhibin and the other, a commercial two-
site assay, using two antibodies directed against two
distinct a-subunit epitopes.
RESULTS Neither assay detected a significant effect of
gestation on serum inhibin levels. After combining the
data from both gestations, no significant difference
between the Down's samples and controls for either
assay was detected. However, analysis of the data for
each gestation separately revealed that one assay
detected a significant difference in inhibin levels
between Down's affected and unaffected pregnancies at
11 weeks gestation (mean ± SEM 3186 ±195 vs
2020 ±172 ng/l, P < 0 01) but not at 12 weeks. The other,
commercial, assay did not detect a significant difference
Correspondence: Dr Euan M. Wallace, Department of Obstetrics
and Gynaecology, University of Edinburgh, Centre for
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at either gestation. In addition, there was poor associa¬
tion between the results of the two assays.
CONCLUSIONS These data suggest that immunoreactive
inhibin, as detected by these assays, will not be useful as
a late first trimester marker for Down's syndrome and
also that these two assays detect different inhibin species
in pregnancy serum.
Prenatal screening for Down's syndrome has become an
important and established part ofmodern antenatal care. At
present, most screening programmes depend upon maternal
age in combination with the measurement of human
chorionic gonadotrophin (hCG) and a-fetoprotein (AFP),
with or without unconjugated oestriol (uE3), in maternal
serum at 16 weeks gestation. Such an approach will detect
approximately 65% of Down's affected pregnancies for an
amniocentesis rate of 5% (RCOG, 1993). However, it has
long been hoped that improvements in screening might
increase this detection rate, while minimizing the amnio¬
centesis rate, and also allow testing to be performed earlier
in pregnancy. To this end, it was recently reported that
inhibin, a heterodimeric glycoprotein produced by various
tissues including the placenta, may be useful as a serum
marker for Down's syndrome in the second trimester (van
Lith et al., 1992, Spencer et al., 1993). In addition, a number
of fetal and placental proteins have undergone initial
evaluation of their usefulness as first, rather than second,
trimester maternal serum markers for Down's syndrome
(Macintosh & Chard, 1993 and references therein). We have
therefore assessed inhibin as a potential maternal serum
marker for Down's syndrome in the first trimester.
Subjects and methods
In Lothian, serum is routinely prospectively collected from
all women at the first hospital antenatal visit and stored at
—20°C. Eleven women (mean age 31-6 ± 51 years) were
identified from records of known Down's affected pregnan¬
cies (detected by maternal serum AFP at 16 weeks and
subsequent amniocentesis), allowing their stored serum to
be retrieved. The serum from 5 of these women had been
collected at 11 completed weeks of gestation and the other 6
at 12 completed weeks. These gestations were calculated
from first trimester ultrasound scans, performed on the day
of sampling. Similarly, for each Down's affected sample 4
483
484 E. M. Wallace et at. Clinical Endocrinology (1994) 41
control women, matched for gestation (ultrasound deter¬
mined) and duration of storage, were identified (mean age
27-5 ± 4-9 years) and their samples retrieved.
Hormone assays
Inhibin was assayed using two different assays. First, a
heterologous radioimmunoassay using an antibody (1989)
raised against 31 kDa bovine inhibin and a tracer of
iodinated 31 kDa bovine inhibin was performed (McLach-
lan et al., 1987). Recombinant human inhibin A (rhlNH-R-
90/1) was used for standards with the results expressed as
ng/1. The sensitivity of the assay was 780ng/l and the
coefficients of variation of intra-assay and interassay were
6-6 and 11-5% respectively. This assay is now distributed by
the National Institute of Child Health and Human
Development (NICHD).
Secondly, a commercial solid-phase two-site immunoen-
zymatic assay (Medgenex, High Wycombe, UK) was used to
assay the same samples. The two antibodies employed in this
assay were directed against distinct epitopes of the a-subunit
of human inhibin. The standards were prepared from
purified human follicular fluid. One unit was defined as
the average serum concentration of 20 healthy males and the
results were expressed as U/ml. The sensitivity of the assay
was OT U/ml and the coefficients of variation of intra-assay


















Fig. 1 Maternal serum immunoreactive inhibin levels in #,
Down's affected (n = 11) and O, control (n = 44) pregnancies
obtained using a, NICHD; b, Medgenex assays.
significant difference between Down's syndrome and normal
pregnancies (2821 ±267 and 2317 ±138 ng/1 respectively,
NS). However, analysing each gestation separately, at 11
weeks the mean serum immunoreactive inhibin levels in
Down's syndrome and control pregnancies were 3186 ± 195
and 2020 ± 172 ng/1 respectively (Fig. 2). The mean inhibin
level at 11 weeks gestation was significantly higher in the
Down's affected pregnancies when compared to the controls
(P < 0-01). No significant differences existed at 12 weeks
(2517 ±441 and 2561 ± 198 ng/1) (Fig. 2).
Statistical analysis
Neither assay gave normally distributed results. To allow
statistical comparisons to be performed, square root and
logarithmic transformations were used for the results
derived from the NICHD and Medgenex assays respec¬
tively. Analysis of variance (ANOVA) was then performed
on the transformed, normally distributed data to assess the
effects of gestation and Down's syndrome on the maternal
serum inhibin levels. Where significance was detected, a
post-hoc analysis was performed.
Results
NICHD assay
The mean (± SEM) maternal serum immunoreactive inhibin
at 11 and 12 weeks gestation in the Down's syndrome
samples were 3186 ±195 and 2517 ±441 ng/1 and in the
controls 2020 ± 172 and 2561 ± 198 ng/1 respectively. The
mean immunoreactive inhibin levels at the two gestations
were not significantly different for either group. Figure 1
shows the data from both gestations combined, revealing no
Medgenex assay
The mean (± SEM) maternal serum immunoreactive inhibin
levels at 11 and 12 weeks gestation in the Down's syndrome
samples were 2-46 ±0 56 and 2-35 ± 0-62 U/ml and in the
controls I-84 ±0-17 and 2-20 ± 0-33 U/ml respectively. The












Fig. 2 Maternal serum immunoreactive inhibin levels (NICHD
assay) in #, Down's affected and O, control pregnancies at a, II
(P < 0 01 Down's vs controls) and b, 12 weeks gestation.
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Fig. 3 Regression plot of maternal serum immunoreactive inhibin
levels derived from Medgenex and NICHD assays, r = 0-28;
P> 0-5.
were not significantly different for either group. Figure 1
shows the data from each gestation combined, revealing no
significant difference between Down's syndrome and normal
pregnancies (2-4 ±0-4 and 2-04 ± 0-19 U/ml respectively,
NS). Analysis of each gestation separately also revealed no
significant effect on inhibin levels exerted by Down's
syndrome (data not shown).
Comparison between NICHD and Medgenex assays
There was poor correlation between the results derived from
the two assays (r = 0-28) (Fig. 3).
Discussion
Established screening programmes for Down's syndrome
are currently timed for the second trimester of pregnancy
(RCOG, 1993), utilizing maternal age in combination with
the measurement of maternal serum hCG and AFP, with or
without unconjugated oestriol (uE3). More recently it was
reported that inhibin may be a useful second trimester
marker for Down's syndrome (van Lith et al., 1992, Spencer
et al., 1993). Indeed, the data of Spencer et al. suggest that
inhibin alone might offer a detection rate of 66% for a false
positive rate of 5-3%. As reviewed by Macintosh and Chard
(1993), a number of fetal and placental products have also
been investigated as putative first trimester markers. We
have therefore described the first data for inhibin as a
marker for Down's syndrome in the first trimester, derived
from two different assays for immunoreactive inhibin. These
data show that, at 11 and 12 weeks gestation, no significant
effect of gestation on maternal serum immunoreactive
inhibin levels was demonstrated by either assay. Further¬
more, when the data for these two gestations were
combined, there was no significant difference between
Down's affected and normal pregnancies in either assay.
However, one of the assays detected a significant difference
in maternal serum inhibin levels between Down's affected
and normal pregnancies at 11 but not at 12 weeks gestation.
In addition, our finding of a lack of correlation between the
results of the two assays suggests that they are detecting
different inhibin species in these pregnancy samples.
Interestingly, we have not observed a similar disagreement
between these two assays in samples from non-pregnant
women (unpublished data) and so the current data may
reflect changes in inhibin secretion specific to pregnancy.
The NICHD assay detects free a-subunit and the related pro
q-C fraction (Schneyer et al., 1990) in addition to intact
inhibin in serum. If in pregnancy the relative circulating
concentrations of different inhibin species vary, compared
to non-pregnancy, this might explain some of the differ¬
ences. It was also reported recently that a2-macroglobulin
has been found to bind inhibin in peripheral plasma
(Vaughan & Vale, 1993), altering immunoreactive detect¬
able levels by masking different epitopes. Levels of a2-
macroglobulin rise by approximately 30% in pregnancy
(Studd et al., 1970) and it is conceivable that this could
differentially interfere with antigen-antibody binding in one
or other of these two assays.
Furthermore, while the isolated significant elevation in
serum immunoreactive inhibin at 11 weeks, and not at 12
weeks, is surprising when the previous reports of screening
in the second trimester are considered (van Lith et al., 1992,
Spencer et al., 1993), these published second trimester
results were obtained using the Medgenex assay. Our new
finding of a lack of correlation between results derived from
the two assays suggests that it is possible that the NICHD
assay is detecting inhibin species, not detected by the
Medgenex antibodies, that are elevated in Down's syndrome
in the first trimester. Nonetheless, this isolated finding at 11
weeks gestation suggests that inhibin is unlikely to be a
useful marker.
Importantly, we did not observe any storage related
trends in our sample results derived from either assay
(results not shown) suggesting that degradation changes
were not responsible for artefactual differences. Further¬
more, the samples were control-matched for storage.
In summary, this is the first report of first trimester
maternal serum immunoreactive inhibin levels in Down's
affected pregnancies using both these assays. Although a
significant elevation in circulating maternal serum immuno-
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reactive inhibin in Down's affected pregnancy at 11 weeks
gestation compared to normal pregnancy was detected by a
radioimmunoassay utilizing an antibody against 31 kDa
bovine inhibin, this was not apparent at 12 weeks gestation.
Also, using a different two-site assay (with both antibodies
directed against a-subunit epitopes) no significant elevation
was apparent. It also appears that these two assays do not
detect identical inhibin species in pregnancy, as suggested by
the poor correlation of results between the assays. We suggest
that these data do not confirm inhibin, as detected by these
two assays, as a useful marker for Down's syndrome in the
first trimester. However, the results at 11 weeks gestation
should encourage the assessment of the assays at other,
earlier gestations. The remaining uncertainty about which
inhibin proteins are being detected in pregnancy also merits
the evaluation of other inhibin assays in the detection of
Down's syndrome in the first trimester, in particular, those
specific for dimeric inhibin or the /3-subunit.
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SUMMARY
While second-trimester prenatal screening programmes for Down's syndrome have become established in prenatal
care, it would be advantageous to be able to offer screening in earlier pregnancy. To this end, we have evaluated a
new potential maternal serum marker, dimeric inhibin A, as a possible first-trimester marker. Dimeric inhibin A was
measured in prospectively collected maternal serum from 23 cases of Down's syndrome and matched chromosomally
normal controls, at 11-13 weeks' gestation. Levels of this protein were significantly elevated in the Down's
pregnancies compared with the control pregnancies. The median multiple of the normal median (MOM) for the
Down's samples was 2-46 (95 per cent confidence interval: 2-11-3-26, f<0 0001 vs. controls). These results suggest
that dimeric inhibin A is a useful discriminator of Down's-affected pregnancies from normal pregnancies in the first
trimester and that sensitive screening in combination with maternal age and other possible markers may be
practicable in the first trimester.
key words: Down's syndrome; inhibin; dimeric inhibin A; first trimester; maternal serum
INTRODUCTION
Down's syndrome (trisomy 21) is the single most
common recognized cause of mental handicap.
Not surprisingly therefore, prenatal screening for
Down's syndrome has become an important and
established part of modern prenatal care (Royal
College of Obstetricians and Gynaecologists
(RCOG), 1993). At present, screening programmes
utilize maternal age in combination with the
measurement of human chorionic gonadotrophin
(hCG) and alpha-fetoprotein (AFP), with or with¬
out unconjugated oestriol (uE3), in maternal serum
at 15-20 weeks' gestation. Such an approach
detects approximately 60-70 per cent of Down's-
affected pregnancies with an amniocentesis rate, or
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approximate false-positive rate, of 5 per cent
(RCOG, 1993). However, it would be desirable if
sensitive and specific screening could be applied in
the first trimester, affording earlier termination of
pregnancy if indicated. To this end, a number of
fetal and placental proteins have undergone initial
evaluation of their usefulness as first-trimester
maternal serum markers for Down's syndrome
(Macintosh and Chard, 1993). Also, it has been
recently reported that immunoreactive inhibin, a
glycoprotein of placental origin in pregnancy (Abe
et al., 1990; Tovanabutra et al., 1993). did not
appear useful in first-trimester screening for
Down's syndrome (van Lith et al., 1994; Wallace
et al., 1994), although some potential value in the
second trimester has been suggested (van Lith
et al., 1992; Spencer et al., 1993; Cuckle et al.,
1994). We report here the successful application of
a new sensitive assay specific for dimeric inhibin A
in the detection of Down's syndrome in the first
trimester of pregnancy.
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SUBJECTS AND METHODS
In Lothian, serum is routinely collected prospec¬
tively from all women at the first hospital prenatal
visit and stored at — 20°C. Twenty-three women
(mean age 32-1 years, range 22-44 years) were
identified from records of all known Down's-
affected pregnancies, allowing their stored serum
to be retrieved. The sera from eight of these
women had been collected at 11 completed weeks
of gestation, eight at 12 completed weeks, and
seven at 13 completed weeks. These gestations had
been calculated from ultrasound scans performed
on the day of sampling. Similarly, for each
Down's-affected sample four control women,
matched for gestation (ultrasound-determined)
and duration of storage, were identified and their
samples retrieved (mean age 27-7 years, range
19-38 years). Three control samples, each one
matched for three different 11-week Down's
samples, were unable to be used due to insufficient
sample volume, making 89 control samples
available for assay.
The assay for dimeric inhibin A has been previ¬
ously described (Groome and O'Brien, 1993) and
validated for human serum (Groome et al., 1994).
Briefly, serum samples or standards are oxidized
with 1 per cent (final w/v) hydrogen peroxide for
30 min prior to assay. Samples were diluted 1:4
prior to assay. The assay is an enzyme-linked
two-site immunoassay using an immobilized anti-
//A-inhibin subunit monoclonal antibody (E4) as
a capture antibody. This is coupled covalently
through Fc carbohydrate residues to treated
hydrazide microplates (Avidplate-HZ). The Fab
fraction of a mouse anti-a-inhibin subunit mono¬
clonal antibody (R1), conjugated to alkaline phos¬
phatase. is then used to bind to the a-subunit of the
captured dimeric inhibin. A sensitive amplified
enzyme assay then allows detection. Recombinant
32 kD human inhibin A (Genentech) was used for
standards with the results expressed as pg/ml. The
sensitivity of the assay was 8 pg/ml and the intra-
plate and inter-plate coefficients of variation were





























Completed Weeks of Gestation
Fig. 1—The 10th, 50th, and 90th percentiles of maternal serum
inhibin A MOMs of 89 chromosomally normal pregnancies
with levels from 23 individual Down's-affected pregnancies
(279-9-402-7) pg/ml, and 263-6 (218-7-308-4) pg/
ml, respectively. There was no significant differ¬
ence between the levels at 11 and 12 weeks
(R=0-054, Mann-Whitney [/-test) but the mean
level at 13 weeks was significantly lower than that
at 11 weeks (P=0-0004, Mann-Whitney [/-test),
though not 12 weeks (P = 0-055). The MOMs for
both Down's and controls were therefore calcu¬
lated from the controls for each gestation sepa¬
rately. Figure 1 shows the Down's cases from the
three gestations against the 10th. 50th. and 90th
centiles of the control MOMs. The median (95 per
cent CI) MOM for the Down's samples was 2-46
(2-11-3-26) (/)<0.0001 vs. controls. Mann-
Whitney [/-test). Table I displays the number of
affected and unaffected pregnancies at different
MOMs. In this series, for a given false-positive rate
of 4 per cent (4/89), 65 per cent (15/23) of the
Down's cases were detected. Maternal serum
inhibin A w-as not associated with maternal age
(r= 1 -0, P-0-49).
The mean (95 per cent confidence interval (CI))
maternal serum immunoreactive dimeric inhibin A
at 11, 12, and 13 weeks' gestation in the control
samples was 389-5 (34f-3—437-7) pg/ml, 341-3
DISCUSSION
Inhibin is a heterodimeric glycoprotein, consist¬
ing of an a-subunit combined to one of two
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Table I—Number (percentage) of affected and un¬
affected pregnancies with a given MOM above different
arbitrary levels
No. (%) of No. (%) of
MOM affected pregnancies unaffected pregnancies
0-5 23 (100) 86 (97)
10 22 (96) 42 (47)
1-5 19 (83) 18 (20)
2-0 15 (65) 6 (7)
2-5 10 (43) 1 (1)
3-0 9 (39) 1 (1)
3-5 5 (22) 0 (0)
4-0 4 (17) 0 (0)
4-5 3 (13) 0 (0)
/J-subunits, /?A or /?B. Inhibin A is the dirtier of the
a-subunit and the ySA-subunit. In early pregnancy,
inhibin is secreted from both the corpus luteum
and the placenta, although the placenta becomes
the major source after approximately 10-12 weeks'
gestation (Abe et al., 1990; Tovanabutra et al.,
1993), when peripheral plasma levels have reached
a peak (Abe et al., 1990).
The data presented suggest that maternal serum
dimeric inhibin A may be a useful serum marker of
Down's syndrome in the first trimester of preg¬
nancy. For a given false-positive rate of 4 per cent
in this series, 65 per cent of the Down's cases were
detected with dimeric inhibin A. This compares
very favourably with similar data obtained for free
/ThCG in the first trimester (Spencer et al., 1992;
Aitken et al., 1993). Figure 1 suggests that there
may be a slight gestation effect, with better dis¬
crimination of Down's cases at 13 weeks than at 11
or 12 weeks. However, the number of cases
reported is small and there is not a consistent trend
across the three gestations. Further analysis of
larger numbers will hopefully clarify this.
Maternal serum immunoreactive inhibin levels
have previously been shown to be elevated in
Down's-affected pregnancies in the second (van
Lith et al., 1992; Spencer et al., 1993; Cuckle et al.,
1994) but not the first trimester (van Lith et al.,
1994; Wallace et al., 1994). Importantly, the assays
used in these studies utilize antibodies directed
against epitopes only on the a-subunit of inhibin
and so are unable to specifically detect intact
dimeric inhibin. Indeed, it has been shown that
such assays will detect inhibin a-subunit precursors
in addition to free a-subunit and dimeric inhibin
(Schneyer et al., 1990). Recently, it was also
reported that there was a poor correlation between
immunoreactive inhibin levels measured in the
same pregnancy samples by two different assays
utilizing anti-a-subunit antibodies (Wallace et al.,
1994). This would suggest that these assays were
detecting relatively different amounts of the vari¬
ous inhibin species circulating free in peripheral
blood. This phenomenon might also explain some
of the heterogeneity of results reported using one
of these assays in the second trimester (Cuckle
et al., 1994). However, the novel assay reported
here is specific for dimeric inhibin A and this is the
first report of its application in pregnancy. As
detailed above, recombinant human inhibin A is
used for standards in the inhibin A assay and
results are expressed as pg/ml. Of the other two
inhibin assays previously reported, one (National
Institute of Child Health and Human Develop¬
ment, U.S.A.) uses the same standard preparation
while the other (Medgenix, Brussels) uses a par¬
tially purified form of inhibin derived from human
follicular fluid ('human inhibin') expressed as U/ml
(Wallace et al., 1994). Considering the differences
between the antibodies and standards used in the
three inhibin assays, a direct comparison of inhibin
levels across the assays is not appropriate. Indeed,
the lack of correlation between the results from the
two non-specific inhibin assays would confirm this.
Thus, it would appear from the limited and
indirect data available at present that it is likely
that the peripheral serum levels of only certain
inhibin species, such as inhibin A, will be different
in chromosomally normal and abnormal preg¬
nancies. An understanding of the biology of
inhibin and the development of assays specific for
different inhibin species is therefore fundamental
to future progress in this area.
In summary, these promising preliminary
inhibin A data have important implications for the
future development of first-trimester Down's syn¬
drome screening programmes. Certainly, larger
prospective studies, allowing full evaluation of this
novel marker, in combination with maternal age
and established markers, are now merited.
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Summary
BACKGROUND AND OBJECTIVE Prenatal maternal
serum screening for Down's syndrome has become an
important and established part of modern antenatal care.
Previously it has been reported that non-specific immu-
noreactive inhibin may be useful in this context. Using a
novel assay we have evaluated dimeric inhibin A as a
possible second trimester marker of Down's syndrome.
METHODS From 1992-1993 records, stored sera from
women with Down's affected pregnancies and chromoso-
mally normal control pregnancies were identified and
retrieved for analysis. These sera had been prospectively
collected at 15, 16 and 17 weeks gestation.
SUBJECTS Records revealed 21 women who had had a
Down's syndrome pregnancy and who also had serum
available for analysis. Sera from 150 chromosomally
normal controls, matched for gestation and duration of
storage, were also retrieved
MEASUREMENTS Dimeric inhibin A was measured using
a recently developed two-site enzyme-linked immuno¬
assay. This employs a capture anti inhibin /3A-subunit
monoclonal antibody, covalently bound to a microtitre
plate and a second anti inhibin a-subunit antibody con¬
jugated to alkaline phosphatase, allowing detection.
RESULTS The mean (95% CI) maternal serum dimeric
Correspondence: Dr E. M. Wallace. Department of Obstetrics
and Gynaecology. University of Edinburgh. Centre for
Reproductive Biology. 37 Chalmers Street. Edinburgh EH3 9EW.
Scotland. UK. Fax: OH 44 31 229 2408.
inhibin A in the samples from control pregnancies was
237 (201-5-273-4) ng/l, 266 9 (235-4-298-5) ng/l and 207-2
(178-5-235-9) ng/l at 15, 16 and 17 weeks gestation
respectively. Expressing the results from the Down's
samples as multiples of the normal median (MoM), the
median (95% CI) MoM was 2-6 (2-25-3-57), significantly
higher than the controls (P < 0-0001, Mann-Whitney U-
test). In the sample set tested, for a given false positive
rate of 5-3% inhibin A alone afforded a detection rate of
62%, detecting cases previously undetected by routine
screening.
CONCLUSIONS Dimeric inhibin A appears to be a prom¬
ising new marker for the prenatal detection of Down's
syndrome. Further prospective evaluation and assess¬
ment with other established markers would now be
merited.
Down's syndrome (trisomy 21) is the single most common
recognized cause of mental handicap in the United King¬
dom. Not surprisingly therefore, prenatal screening for this
condition is now a common and integral part of modern
obstetric practice. Such screening utilizes a risk calculation
based upon maternal age in combination with the measure¬
ment of human chorionic gonadotrophin (hCG), or free /?-
hCG, and a-fetoprotein (AFP), with or without uncon¬
jugated oestriol (uEj). in maternal serum at 15-21 weeks
gestation. Amniocentesis targeted by such screening will
detect 60-70% of Down's affected pregnancies with an
overall amniocentesis rate, or approximate false positive
rate, of 5% (RCOG, 1993). Thirty to 40% of affected cases
therefore remain undetected by this approach and. because
amniocentesis carries an excess risk of miscarriage of
approximately 1% (Tabor el al., 1986). a significant number
of normal pregnancies are iatrogenically lost. A variety of
other screening methods have therefore been reported
(Benacerraf et al.. 1985, Cuckle et al.. 1990, Macintosh &
Chard. 1993). Recently. Van Lith et al. (1992) reported that
immunoreactive inhibin may be useful as an additional
maternal serum marker for Down's syndrome in the second
trimester although this was not confirmed by others (Spencer
et al.. 1993. Cuckle et al., 1994). The development of a new
sensitive assay for intact dimeric inhibin A has enabled us to
evaluate this specific inhibin species, rather than non-specific
immunoreactive inhibin, as a potential marker for Down's
syndrome in the second trimester of pregnancy.
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Subjects and methods
In south-east Scotland prenatal screening for Down's
syndrome is offered to all women booking antenatally
with a singleton pregnancy. This is performed at 16-21
weeks gestation, using maternal age in combination with
maternal serum hCG and AFP levels. An aliquot of each
serum sample collected for this programme is routinely
stored at —20°C. Of the known Down's affected pregnancies
during 1992-1993 there were 21 women from whom stored
serum was available and these sera were retrieved. All these
women had been at 15, 16 or 17 completed weeks of
pregnancy at the time of sampling, as calculated from a first
or early second trimester ultrasound scan. Fourteen of the
21 (67%) had been detected prenatally by the screening
programme. One hundred and fifty control samples from
women with a chromosomally normal pregnancy matched
for gestation (within one week as determined by ultrasound)
and duration of storage, were identified and retrieved.
Forty-five of the control samples were at 15 completed
weeks. 55 at 16 completed weeks and 50 at 17 completed
weeks of pregnancy.
Table 1 Mean (95% CI) maternal serum dimeric inhibin A levels in
150 chromosomally normal singleton pregnancies at 15-17 weeks
gestation.
Week of gestation /! Inhibin (ng/1)
15 45 237-0 (201-5-273-4)
16 55 266-9 (235-4-298-5)
17 50 207-2 (178-5-235-9)
multiples of the normal median (MoM) to allow non-
parametric comparison between the two groups. Each
MoM, for both control and Down's samples, was calculated
from the normal median of the respective gestation. The
MoMs for all the Down's samples and controls were then
pooled separately allowing comparison. Median MoMs
for the Down's samples were expressed with 95% con¬
fidence intervals. The software package Statview was used
throughout.
Results
Dimeric inhibin A assay
The assay for dimeric inhibin A has been previously described
(Groome & O'Brien, 1993) and validated for human serum
(Groome et al., 1994). Briefly, serum samples (diluted 1:4) or
standards are oxidized with 10% (w/v) hydrogen peroxide
for 30 minutes prior to assay. The assay is an enzyme-linked
two-site immunoassay using an immobilized anti inhibin
/3A-subunit monoclonal antibody (E4) as a capture anti¬
body. This is coupled covalently through Fc carbohydrate
residues to treated hydrazide microplates (Avidplate-HZ).
The Fab fraction of a mouse anti inhibin a-subunit
monoclonal antibody, conjugated to alkaline phosphatase,
is then used to bind to the a-subunit of the captured dimeric
inhibin. A sensitive amplified enzyme assay (Ampak. Dako
UK) affords detection. Recombinant 32-kDa human inhibin
A (Genentech) was used for standards with the results
expressed as ng, 1. The sensitivity of the assay was 8 ng 1 and
the intraplate and interplate coefficients of variation were
2-5 and 7-0% respectively.
Statistical analysis
xosomte inhibin values for the control samples at each
vena rate gestation were compared using ., non-parametric
-.est. die Mann Whitney (. -test. Since a significant differ¬
ence across gestation of pregnancy \\a. tetectcd in the
-octroi s. the 1 )ov\ n s sum pies and controls v ere expressed as
The maternal serum levels of dimeric inhibin A in the
chromosomally normal pregnancies are reported as means

























Fig. 1 The IOth. M)tti and 90th percentiles ot maternal serum
inhibin A MoMs of 150 chromosomally normal pregnancies with
levels from 21 individual Down's syndrome pregnancies.
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Table 2 Number (percentage) of affected and unaffected
pregnancies with a given MoM above different arbitrary levels
Number (%) of Number (%) of
MoM affected pregnancies unaffected pregnancies
0-5 21 (100) 135 (90)
1-0 21 (100) 76(51)
1-5 21 (100) 28 (19)
2-0 14 (67) 11 (7)
2-5 11 (52) 4(3)




distribution with standard deviation of log|0 inhibin of 0-27
in the controls and 0 20 in the Down's syndrome cases. The
mean log|() inhibin A in the Down's syndrome cases was
0-41. For a given false positive rate (FPR) of 5-3% (8/150),
62% (13/21) of the Down's syndrome samples would be
detected at a cut-off MoM of 2-2. Table 2 shows the detec¬
tion rates and corresponding FPRs at different arbitrary
MoMs.
Of the seven Down's samples that had been undetected by
the routine screening programme two had dimeric inhibin A
levels above 2-2 MoM while three Down's samples with
levels below this arbitrary detection limit had been detected
by screening (Table 3).
separately (Table l). The level at 17 weeks gestation was
significantly lower than that at 16 weeks (P < 0 02, Mann-
Whitney (7-test). There were no other significant differences.
In all the Down's syndrome samples the dimeric inhibin
levels were above the normal median (Fig. 1). The median
(95% CI) MoM was 2-6 (2-25-3-57) which was significantly-
higher than the controls (P < 0-0001, Mann-Whitney Li¬
test). The inhibin data fitted a log Gaussian frequency
Table 3 Maternal serum dimeric inhibin A levels (MoM) in 21
Down's affected pregnancies compared with the result from routine
screening
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Discussion
Inhibin is a heterodimeric glycoprotein, consisting of an
a-subunit combined to one of two 3-subunits, (3A or JB.
Inhibin A is the dimer of the a and dA subunits. The
placenta is the major source of inhibin during pregnancy
(Abe et al. 1990. Tovanabutra et al.. 1993). Maternal serum
inhibin levels have previously been shown to be elevated in
Down's affected pregnancies in the second trimester (Van
Lith et al., 1992: Spencer et al.. 1993: Cuckle et al.. 1994).
However, the absolute inhibin levels in the controls and the
degree of elevation in the Down's cases reported in these
three studies varied so considerably that Cuckle et al. (1994)
suggested that immunoreactive inhibin, as detected, was
unlikely to prove a valuable marker of Down's syndrome.
All these previous reports relate to a commercial assay that
utilizes two distinct antibodies, both directed against the
a-subunit of inhibin (Medgenix, UK).
There are a number of possible inhibin species circulating
in peripheral blood including the two 31-kDa dimeric forms
(inhibin A and inhibin B). larger dimeric forms (58-73kDa).
large free precursor a-subunits and the free processed
a-subunit (Robertson et al.. 1995). By the nature of the
antibodies employed, the Medgenix assay is unable to
specifically detect intact dimeric inhibin A but probably also
detects free inhibin a-subunits and the related pro q-C and
pro a-C-pro a-N fractions (Schneyer et al., 1990). It is
possible that this non-specificity may account for the very-
heterogeneitv of the results that has caused some concern
(Cuckle et al., 1994). Further, both Spencer et al. (1993) and
Cuckle et al. (1994) noted that the distribution of levels of
inhibin detected by the Medgenix assay in pregnancy was
wide. This would also argue against inhibin being likely to
be a valued marker of Down's syndrome. Recently it was
reported that two immunoassays, both utilizing anti inhibin
a-subunit antibodies, appeared to recognize different inhibin
species in the same pregnancy samples, possibly due to
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differing antibody affinities for different species (Wallace el
ill., 1994). Further, serum factors that are known to interfere
with immunoreactive inhibin detection (Vaughan & Vale.
1993) increase in pregnancy (Studd et al., 1970). It is clear
therefore that the usefulness of inhibin in prenatal screening
for Down's syndrome may crucially depend on which
inhibin species are being detected and thus on the antibodies
utilized in the assay(s) applied. Indeed, while non-specific
immunoreactive inhibin has not been shown to be a good
marker for Down's syndrome in the first trimester (Van Lith
el al., 1994: Wallace el ill., 1994). dimerie inhibin A has been
shown to be significantly elevated in Down's syndrome
pregnancies at this gestation (Wallace et cii, 1995). In this
regard it is important that the data reported here relate
specifically to intact dimeric inhibin A species. The assay
used displays no cross reactivity with inhibin B. or free
subunits or their free precursors (N. P. Groome, unpub¬
lished data).
Despite the wide distribution of inhibin noted previously,
however, using the Medgenix inhibin assay Van Lith et al.
(1992) reported a preliminary detection rate of 40% with a
false positive rate of 5% and a median MoM (95°/oCI) of 1-3
(0-9-1-9) for inhibin alone across a gestational range of
14 -18 weeks. Our corresponding detection rate of 62% for
5-3°o and median MoM (95% CI) of 2-6 (2-25—3-57) for
intact dimeric inhibin A at 15-17 weeks gestation would
appear to compare very favourably with non-specific
immunoreactive inhibin. Also, in the series reported here
the standard deviations of log!0 inhibin in both the controls
and the Down's cases show that inhibin A levels are less
widely distributed than those for non-specific immunoreac¬
tive inhibin previously reported. This phenomenon could
explain the improved detection performance of intact
dimeric inhibin A relative to immunoreactive inhibin. It is
also possible that only some of the circulating inhibin
species are discriminatory with regard to Down's syndrome.
If the less specific assays were detecting some of the non¬
discriminatory inhibin species, undetected by the dimeric
assay, then poorer detection performance would be observed.
However, until the processed free a-subunit. both dinters
and circulating precursors can all be detected specifically
and separately this remains speculation.
Finally, the finding that dimeric inhibin A detected
Down's affected samples that had previously screened
negative with traditional markers suggests that this inhibin
species may have a useful role as an adjuvant marker in the
second trimester, increasing detection rates. Further assess¬
ment of inhibin A in combination with other established
markers will clarify this but it is clear that these novel data
may have important implications for future screening pro¬
grammes. We therefore propose that further prospective
assessment of this new marker in the second trimester is now
required.
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Abstract Background. In screening for Down's syn¬
drome in the second trimester of pregnancy, the con¬
centrations of alpha-fetoprotein, the p subunit of human
chorionic gonadotropin, and intact human chorionic go¬
nadotropin in maternal serum are widely used markers.
We investigated a new marker, dimeric inhibin A, and
compared its predictive value with that of the established
markers.
Methods. Serum samples were obtained at 7 to 18
weeks of gestation from 58 women whose fetuses were
known to be affected by Down's syndrome, 32 whose fe¬
tuses were affected by trisomy 18, and 438 whose fetus¬
es were normal, and the samples were analyzed for each
marker. Individual serum concentrations of each marker
were converted to multiples of the median value at the ap¬
propriate length of gestation in the women with normal
pregnancies, and rates of detection of Down's syndrome
by screening for inhibin A in various combinations with the
other markers were estimated by multivariate analysis.
Results. In the women with fetuses affected by
Down's syndrome, the serum inhibin A concentrations
were 2.06 times the median value in the women with nor-
THE sensitivity and specificity of screening forDown's syndrome have improved in recent years
with the identification of new biochemical markers of
this disorder. Since the observation that serum levels of
alpha-fetoprotein were reduced in women with fetus¬
es affected by chromosomal abnormalities,' numerous
other fetoplacental markers in maternal serum have
been found to have altered levels in pregnancies with
fetuses affected by aneuploidy. The most useful mark¬
ers for screening in the second trimester are intact hu¬
man chorionic gonadotropin,2 the (3 subunit of human
chorionic gonadotropin,3,4 unconjugated estriol,5,6 and
alpha-fetoprotein.7'8 The serum levels ol all these mark¬
ers overlap in affected and unaffected populations, how¬
ever, and so the odds that a particular value is associat¬
ed with an affected pregnancy are used to modify the a
priori risk specific to maternal age.9 The most effective
approach to screening is to use combinations of markers
(taking into account correlations between markers), and
most protocols use alpha-fetoprotein and either intact
human chorionic gonadotropin or its (3 subunit, with"'
or without"'12 unconjugated estriol. In clinical practice,
approximately two thirds of pregnancies in which the
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mal pregnancies (P<0.001). This compared with 2.00
times the median for the p subunit of human chorionic go¬
nadotropin, 1.82 times the median for intact human chori¬
onic gonadotropin, and 0.72 times the median for aipha-
fetoprotein. The serum concentrations of inhibin A in the
women with fetuses affected by Down's syndrome did not
appear to be significantly elevated above normal until the
end of the first trimester and were not significantly differ¬
ent from normal in the women with fetuses affected by tri¬
somy 18 (P = 0.17). The rate of detection of Down's syn¬
drome was 53 percent and the false positive rate was
5 percent when alpha-fetoprotein, the p subunit of human
chorionic gonadotropin, and maternal age were used to¬
gether as predictors. The detection rate increased to 75
percent when inhibin A was added (P = 0.002).
Conclusions. In the second trimester of pregnancy,
measuring inhibin A in maternal serum, in combination
with measurements of alpha-fetoprotein and the p sub-
unit of human chorionic gonadotropin, significantly im¬
proved the rate of detection of Down's syndrome. (N Engl
J Med 1996;334:1231-6.)
©1996, Massachusetts Medical Society.
fetuses are affected by Down's syndrome can be detect¬
ed in the 3 to 5 percent of the screened population with
the highest risk.13-17 Fetuses affected by trisomy 18, which
is associated with very low levels of intact human cho¬
rionic gonadotropin and its /3 subunit, may also be
identified with the use of a separate protocol.18'19
Efforts to improve biochemical screening further
have centered on the investigation of screening in the
first trimester and on the search for better markers.
The performance of certain markers varies between the
first and the second trimesters. For example, intact hu¬
man chorionic gonadotropin, a widely used marker in
the second trimester, is a poor marker in the first,20,21
whereas the (3 subunit of human chorionic gonadotro¬
pin is a useful marker during both stages of pregnan¬
cy.21'22 Recent investigations of inhibin, a dimeric glyco¬
protein of placental origin composed of one a and one
/3A or f3B subunit, found elevated serum levels in wom¬
en in the second trimester of pregnancy whose fetuses
were affected by Down's syndrome23-25 but no differenc¬
es between women with such pregnancies and those
with unaffected pregnancies during the first trimes¬
ter.26'2' These studies used an enzyme immunoassay
with antibodies directed against epitopes on the inhibin
a subunit. Further studies using a new assay specific for
dimeric inhibin A (a-j3A) have suggested a possible
role for dimeric inhibin A as a screening marker, since
elevated serum levels have been found in women with
fetuses affected by Down's syndrome in both the first
and the second trimesters.28'29
In this study, we extended the investigation of inhib¬
in A to a larger group of women with fetuses affected
by Down's syndrome or trisomy 18 and compared its
Reprinted from The New England Journal of Medicine
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performance in screening with that of the established
markers alpha-fetoprotein, intact human chorionic go¬




All aliquots of maternal serum used in this study came from sam¬
ples collected between 1987 and 1994 by the prenatal screening serv¬
ice in western Scotland. To avert repeated freeze-and-thaw cycles,
which might affect marker levels in future studies, frozen serum sam¬
ples from women whose fetuses were confirmed as being chromoso-
mally abnormal were routinely retrieved from storage, thawed, divid¬
ed into aliquots, and returned to a freezer bank for long-term storage
pending further analyses. A total of 528 samples were analyzed, in¬
cluding 58 samples from women whose fetuses had Down's syndrome,
32 samples from women whose fetuses had trisomy 18, and 438 con¬
trol samples from women with unaffected pregnancies at 7 to 18 weeks'
gestation. For each trisomic sample, three to six control samples were
selected and matched for the same completed week of gestation and
length of time in frozen storage (within six months). Additional con¬
trols, selected on the basis of length of gestation, were added to sup¬
plement the small number of matched serum samples collected earlier
in gestation. Fourteen of the Down's syndrome samples, which were
collected at 7 to 14 weeks' gestation, were part of a series previously
investigated for alpha-fetoprotein, unconjugated estriol, the P subunit
of human chorionic gonadotropin, and pregnancy-associated plasma
protein A.21'30 The remaining 44 Down's syndrome samples were col¬
lected between 15 and 18 weeks' gestation; 35 of these were part of a
previous series of 37 reported in a prospective study.16 Four of the tri¬
somy-18 samples collected at 8 to 12 weeks' gestation were also in¬
cluded in previous studies.21'30 The remaining 28 trisomy-18 samples
were collected at 15 to 18 weeks' gestation. The length of gestation
was estimated by calculating the number of completed weeks from the
date of the last menstrual period or by ultrasound scanning. If two
different estimates were obtained for the same pregnancy, reliable in¬
formation on the menstrual cycle was used as the primary determi¬
nant, unless the ultrasound estimate was one or more completed
weeks greater than or two or more completed weeks less than the
length of gestation as determined from the last menstrual period, in
which case the ultrasound estimate was used.16
Marker Analyses
Serum dimeric inhibin A was measured with a two-site enzyme-
linked immunosorbent assay (ELISA) that uses an immobilized mon¬
oclonal antibody (E4) against the /3A subunit of inhibin as the cap¬
ture antibody. This was coupled covalently through Fc carbohydrate
residues to treated hydrazide microplates (Avidplate-HZ, UniSyn
Technologies, Tustin, Calif.).31,32 The Fab fraction of a mouse mono¬
clonal antibody (Rl) against the a subunit of inhibin, conjugated to
alkaline phosphatase, was then used to bind the a subunit of the cap¬
tured dimeric inhibin. A sensitive amplified-enzyme assay (Ampak,
Dako, High Wycombe, United Kingdom) allowed detection of the
bound second antibody. Recombinant 32-kd human inhibin A (Ge-
nentech, South San Francisco) was used for standards, with results ex¬
pressed in picograms per milliliter. The intraplate and interassay co¬
efficients of variation were 2.5 percent and 7.0 percent, respectively,
and assay sensitivity was 8 pg per milliliter.
The p subunit of human chorionic gonadotropin was measured by
ELISA as previously described.33 Intact human chorionic gonadotro¬
pin was measured with the use of a commercial immunoradiometric
assay (MAIA Clone, Serono, Biodata, Rome, Italy), after a 1:500 di¬
lution of samples.16 Alpha-fetoprotein was measured with the use of a
sensitive immunoradiometric assay developed in our institution21
Aliquots of serum samples from all the selected women were
obtained from frozen storage in Glasgow, coded, randomized, and
shipped in dry ice to the Centre for Reproductive Biology in Edin¬
burgh to be assayed for inhibin A. All other analyses of markers were
performed in Glasgow. Alpha-fetoprotein and intact human chorionic
gonadotropin were measured prospectively as part of the routine
screening program in the second-trimester samples16 and retrospec-
Table 1. Serum Concentrations of Inhibin A, Intact Human Cho¬
rionic Gonadotropin, the p Subunit of Human Chorionic Gonad¬
otropin, and Alpha-Fetoprotein in Control Women and Women




Marker (weeks) controlsf Syndrome Value!
multiples of the median
(no. of women)
Inhibin A 7-11 1.00 (148) 0.98 (8) 0.68
13-14 1.00 (58) 2.60 (6) 0.002
15-18 1.00 (202) 2.24 (44) <0.001
Combined 7-18 1.00 (438) 2.06 (58) <0.001
Intact human chorionic 7-11 1.08 (148) 0.95 (8) 0.62
gonadotropin 13-14 0.93 (58) 1.19 (6) 0.09
15-18 1.03 (202) 2.04 (44) <0.001
Combined 7-18 1.03 (438) 1.82 (58) <0.001
P Subunit of human chori¬ 7-11 1.00 (140) 1.79 (8) 0.02
onic gonadotropin 13-14 0.94 (58) 2.15 (6) 0.002
15-18 1.03 (112) 2.05 (44) <0.001
Combined 7-18 1.00 (340) 2.00 (58) <0.001
Alpha-fetoprotein 7-11 0.99 (148) 0.70 (8) 0.10
13-14 0.96 (58) 0.59 (6) 0.02
15-18 0.95 (202) 0.74 (44) <0.001
Combined 7-18 0.95 (438) 0.72 (58) <0.001
*Values are expressed in multiples of the median among the women with normal pregnancies.
fCombined numbers include 30 controls studied at 12 weeks' gestation. The controls stud¬
ied for the (3 subunit of human chorionic gonadotropin were a subgroup of the 438 controls.
fP values were determined by the Mann-Whitney test.
tively in the first-trimester samples.21 The P subunit of human chori¬
onic gonadotropin was measured in all samples retrospectively. All
data were collated in Glasgow, and sample decoding and data analysis
were performed only after all assays had been completed.
Statistical Analysis
For inhibin A, the median level at each completed week of gestation
was calculated from the results of the analyses in the control women's
serum samples and used to convert individual marker values to mul¬
tiples of the normal gestational median. Multiples of the median for
alpha-fetoprotein, intact human chorionic gonadotropin, and the
P subunit of human chorionic gonadotropin were calculated with the
use of medians previously determined in a larger series of women with
normal pregnancies from which the 438 controls were selected (Table
1). Goodness of fit to log gaussian distributions for the marker values
in the women with normal fetuses and in those with chromosomally
abnormal fetuses was assessed by probability plot and the Kolmogor-
ov-Smirnov test. The measures of the distribution (means and stand¬
ard deviations) for each marker in the control women and in women
whose fetuses were affected by Down's syndrome were calculated by
taking the log10 of the median as the mean and the difference between
the 10th and 90th percentiles in logs divided by 2.56 as the standard
deviation.7 Correlations between pairs of markers were estimated with
the use of log-transformed values.
Detection rates for Down's syndrome and corresponding false pos¬
itive rates were calculated with gaussian models of the distribution of
likelihood ratios and the age distribution of pregnancies in western
Scotland. First, the proportion of fetuses affected by Down's syn¬
drome that would be expected at each individual maternal age was
calculated from the age-related risk8 and the proportion of pregnan¬
cies at each age in the population. Next, likelihood ratios were calcu¬
lated for each marker and combination of markers for all samples
from women with fetuses affected by Down's syndrome and from the
control women with the use of the variables derived in this study.9 A
specific risk threshold was then selected to define a high-risk group,
and cutoff likelihood ratios were calculated from the age-specific
risks. The distribution of likelihood ratios for the samples from wom¬
en whose fetuses had Down's syndrome was then used to calculate the
predicted detection rate at each maternal age. This detection rate was
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multiplied by the proportion of fetuses affected by Down's syndrome
expected for that age, and the overall detection rate was obtained by
summation. Similarly, the corresponding false positive rates at each
threshold risk were obtained with the use of the distribution of likeli¬
hood ratios for the control samples and the proportion of pregnancies
at each individual maternal age in the population of pregnant women
in western Scotland.
Results
Serum concentrations of inhibin A in women with
normal pregnancies rise to a median of about 550 pg
per milliliter at 8 to 9 weeks' gestation, followed by a
decline that levels out at about 180 pg per milliliter at
15 weeks' gestation. The serum levels of inhibin A were
elevated in the women whose fetuses were affected by
Down's syndrome, with an overall median value 2.06
times the median among the women with normal preg¬
nancies (by the Mann-Whitney test, P<0.001). The
distribution of results according to length of gestation
(Fig. 1) shows a rising trend, from a median value 0.98
times the median among the women with normal preg¬
nancies at 7 to 11 weeks' gestation (P = 0.68) to 2.24
times the median among the women with normal preg¬
nancies at 15 to 18 weeks' gestation (P<0.001) (Table
1). This trend appears similar to that for intact human
chorionic gonadotropin but contrasts with that for the
/3 subunit of human chorionic gonadotropin, which is
associated with elevated levels in women with fetuses
affected by Down's syndrome both early and later in
gestation (Table 1). Alpha-fetoprotein levels are re¬
duced in the first and second trimesters in women with
fetuses affected by Down's syndrome.
The means and standard deviations of the log gaus-
sian distributions for inhibin A, intact human chorionic
gonadotropin, the (3 subunit of human chorionic go¬
nadotropin, and alpha-fetoprotein are summarized in
Table 2. The goodness of fit for inhibin A in women
with fetuses affected by Down's syndrome and in con¬
trol women at 15 to 18 weeks of gestation was exam¬
ined with the use of probability plots. Neither log-
transformed nor untransformed values gave a perfectly
straight line, but the fit to the log gaussian distributions
was better, as assessed by the Kolmogorov—Smirnov
test (P = 0.51 for Down's syndrome; P = 0.06 for normal
pregnancies), and subsequent statistical analyses were
based on the assumption of log normality. Previous
studies of alpha-fetoprotein, intact human chorionic go¬
nadotropin, and the [3 subunit of human chorionic go¬
nadotropin have shown that these markers fit log gaus¬
sian distributions.8'"'12
Correlation coefficients for inhibin A with the /3 sub-
unit of chorionic gonadotropin, intact human chorion¬
ic gonadotropin, alpha-fetoprotein, and maternal age
both in women with normal pregnancies and in those
with fetuses affected by Down's syndrome are sum¬
marized in Table 3. The strongest correlation was
with intact human chorionic gonadotropin; there was
no significant correlation between inhibin A and the
13 subunit of human chorionic gonadotropin in the
second trimester in either the control women (P = 0.11)
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Figure 1. Serum Concentrations of Inhibin A, Expressed in Mul¬
tiples of the Median Value in Women with Normal Pregnancies,
in 58 Pregnant Women with Fetuses Affected by Down's Syn¬
drome and 32 with Fetuses Affected by Trisomy 18 at 7 to 18
Weeks' Gestation.
(P = 0.13). Intact human chorionic gonadotropin and
the (3 subunit of human chorionic gonadotropin were
strongly correlated.
Using the statistical characteristics of the distribu¬
tions of each marker in the control women and in those
whose fetuses were affected by Down's syndrome at 15
to 18 weeks' gestation, we calculated detection rates at
a fixed 5 percent false positive rate for each marker in
combination with maternal age, and for various groups
of markers in combination with maternal age, in a typ¬
ical screened population (Table 4). We obtained the
highest predicted detection rate (75 percent at a 5 per¬
cent false positive rate) by adding inhibin A to the com¬
bination of alpha-fetoprotein and the /3 subunit of hu¬
man chorionic gonadotropin. This protocol resulted in
a 22 percent increase in the detection of Down's syn¬
drome when tested against both the population model
and the actual study cases (two-tailed P = 0.002 by
McNemar's test).
The serum concentrations of inhibin A in women
whose fetuses were affected by trisomy 18 were slight¬
ly reduced at 0.84 times the median in the women
with normal pregnancies (P = 0.17). There were too few
Table 2. Measures of the Log Gaussian Distribu¬
tions of Each Serum Marker, Expressed in Multi¬
ples of the Median Values in Samples from Control
Women and Women with Pregnancies Affected by
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measurements at earlier gestational
ages to permit examination of the
values in relation to the length of
gestation (Fig. 1), but for this chro¬
mosomal trisomy, inhibin A was
clearly different from the other mark¬
ers. The median values of intact
human chorionic gonadotropin and
its /3 subunit were 0.30 and 0.14
times the medians in the women with
normal pregnancies, respectively
(P<0.001), and for alpha-fetoprotein
the median value was 0.53 times the
median in the women with normal
pregnancies (P<0.001).
Discussion
Table 4. Detection Rates and 95 Percent Confidence Intervals (CI) for Down's Syn¬
drome at a Constant 5 Percent False Positive Rate for Various Combinations of Se¬
rum Markers and Maternal Age.
Alpha-fetoprotein and age
Intact human chorionic gonadotropin and age
f3 Subunit of human chorionic gonadotropin and age
Inhibin A and age
Alpha-fetoprotein, intact human chorionic gonadotropin, and age
Alpha-fetoprotein, f3 subunit of human chorionic gonadotropin,
and age
Alpha-fetoprotein, inhibin A, and age
Intact human chorionic gonadotropin, inhibin A, and age
/3 Subunit of human chorionic gonadotropin, inhibin A, and age
Intact human chorionic gonadotropin, /3 subunit of human chorionic
gonadotropin, and age
Alpha-fetoprotein, intact human chorionic gonadotropin, inhibin A,
and age
Alpha-fetoprotein, (3 subunit of human chorionic gonadotropin,
inhibin A, and age
Alpha-fetoprotein, intact human chorionic gonadotropin, f3 subunit of













Inhibin is a heterodimeric glyco¬
protein with a molecular weight of
32,000, composed of one a subunit
and one of two related /3 subunits
(/3A or /3B). Inhibin A (a-/3A) and —
inhibin B (a-f3B) are synthesized by
the gonads and regulate the secretion by the pituitary
of follicle-stimulating hormone.34 In addition to these
mature dimers, forms of inhibin with greater molecular
weights, representing partially processed or unproc¬
essed dimers and processed or unprocessed free a sub-
units, circulate in the peripheral blood.35 In pregnancy,
the main source of inhibin secretion switches from the
corpus luteum to the placenta,36 and the level of immu-
noreactive and bioactive inhibin is significantly higher
than that in nonpregnant women.37,38
Until recently, studies of immunoreactive inhibin in
pregnancy have depended on assays using antibodies
directed against epitopes only on the a subunit.37'39
Such assays detect the mature dimers and all unproc¬
essed or partially processed molecules containing the
a subunit.39 A commercially available assay (Medgenix,
Brussels, Belgium) with this type of inhibin specificity
has been used in three separate studies to measure in-
Table 3. Coefficients of Correlation (r) between Serum Inhibin A and Other Variables
in Control Women and Women with Fetuses Affected by Down's Syndrome at 15 to
18 Weeks' Gestation.*
Inhibin A and intact human chorionic gonadotropin
Inhibin A and (3 subunit of human chorionic
gonadotropin
Inhibin A and alpha-fetoprotein
Inhibin A and maternal age
Intact human chorionic gonadotropin and (3 subunit
of human chorionic gonadotropin
Intact human chorionic gonadotropin and alpha-
fetoprotein
(3 Subunit of human chorionic gonadotropin and
alpha-fetoprotein



















r P value r P value
0.27 <0.001 0.39 0.008
0.15 0.11 0.23 0.13
0.24 0.001 0.24 0.11
-0.03 0.69 0.25 0.10
0.87 <0.001 0.76 <0.001
0.23 0.001 0.25 0.11
0.15 0.12 0.20 0.19
hibin levels in maternal serum from second-trimester
pregnancies affected by Down's syndrome.23"25 Inhibin
values that were 1.9,23 3.6,24 and 1.325 times the median
values in the women with normal pregnancies were re¬
ported.
Inhibin levels in women with first-trimester pregnan¬
cies affected by Down's syndrome have also been inves¬
tigated in two studies with the commercial assay. No
differences were found between women with fetuses af¬
fected by trisomy 21 and control women.26,27 In our study
with a new assay specific for dimeric inhibin A,31,32 the
increase in the concentration of inhibin A associated
with affected pregnancies did not occur until the end of
the first trimester. Recently, however, significant increas¬
es in inhibin A as early as 11 weeks' gestation have been
reported,28 although there was some evidence of an ef¬
fect of the length of gestation; there was a better rate of
detection of Down's syndrome at 13 weeks than at 11 or
12 weeks. It is clear that larger num¬
bers of samples are required to deter¬
mine more accurately the levels of
inhibin A in women with fetuses af¬
fected by Down's syndrome before
15 weeks' gestation. The greater in¬
crease in the serum concentration of
inhibin A from women with fetuses
affected by Down's syndrome later
in gestation is similar to the trend
noted previously for other placental
markers, including intact human
chorionic gonadotropin,21 pregnan¬
cy-specific /3| glycoprotein,4'1,41 and
pregnancy-associated plasma pro¬
tein A.30 The exception to this rule
appears to be the (3 subunit of hu¬
man chorionic gonadotropin, which
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is elevated in women with fetuses affected by Down's
syndrome in both the first and the second trimesters,21,42
although it is not known whether the increases are of
the same magnitude throughout gestation.
Two studies of the same series of 19 women with
second-trimester pregnancies affected by Down's syn¬
drome20,29 provide a comparison of the performance of
the commercial (Medgenix) assay with that of the spe¬
cific assay for dimeric inhibin A used in the present in¬
vestigation. Overall median values 1.3 times the medi¬
an value for immunoreactive inhibin25 and 1.6 times the
median value for dimeric inhibin A in the women with
normal pregnancies29 were obtained, suggesting (hat
the latter is more specific for Down's syndrome. One
other study using an inhibin assay with the same anti¬
body specificity as our own reported a median value
1.88 times the control median value in 20 women with
second-trimester pregnancies affected by Down's syn¬
drome and a strong correlation between inhibin and in¬
tact human chorionic gonadotropin.43
In this study, we found a statistically significant 22
percent increase in the rate of detection of Down's syn¬
drome when inhibin A was added to the established
screening protocol including alpha-fetoprotein, the
/8 subunit of human chorionic gonadotropin, and mater¬
nal age. This compares with detection rates estimated at
54 percent for the combination of alpha-fetoprotein, in¬
tact human chorionic gonadotropin, and maternal age
and 53 percent for the combination of alpha-fetoprotein,
the (3 subunit of human chorionic gonadotropin, and
maternal age. These results are consistent with those of
previous retrospective studies with respect to alpha-
fetoprotein, intact human chorionic gonadotropin, and
maternal age1"'12 but lower than those reported in some
studies with respect to alpha-fetoprotein, the /3 subunit
of human chorionic gonadotropin, and maternal age.3,12
The confidence limits of our estimates are wide, howev¬
er, because of the small size of the sample.
The inclusion of inhibin A in multimarker screening
protocols did not, however, contribute to the detection
of trisomy 18. In contrast to the elevated levels found
in women with second-trimester pregnancies affected
by Down's syndrome, levels of inhibin A associated
with trisomy 18 were not significantly different from
normal, whereas levels of intact human chorionic go¬
nadotropin and the /3 subunit of human chorionic go¬
nadotropin were both significantly reduced.
A practical advantage of the use of inhibin A as a
screening marker is the very small change in average
levels of inhibin A with increasing lengths of gestation
between 15 and 18 weeks in women with unaffected
pregnancies. Inaccuracies in estimating the length of
gestation will therefore have a much smaller effect on
the calculation of risk estimates than would be the case
with a marker such as unconjugated estriol, whose lev¬
els change rapidly during gestation.44 If the improved
detection rate provided by inhibin A is confirmed in a
larger series, then screening for inhibin A, alpha-feto¬
protein, and the /3 subunit of human chorionic gonado¬
tropin, in combination with maternal age, will be a very
effective method for detecting Down's syndrome in the
second trimester.
We are indebted to Genentech for generously supplying its recom¬
binant 32-kd inhibin A.
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SUMMARY
To assess the value of inhibin A as an additional second-trimester maternal serum marker of Down's syndrome
we studied 56 affected and 280 unaffected pregnancies matched for gestational age. The median level in the cases was
1-62 multiples of the gestation-specific median (MOM) in the controls, with 95 per cent confidence limits of
1-34—1 -96. The distribution of inhibin levels in affected and unaffected pregnancies was approximately log Gaussian,
with means about 1 standard deviation apart. This degree of separation was similar to that for human chorionic
gonadotropin (hCG), free /f-hCG, and unconjugated oestriol (uE3), but about double that of alpha-fetoprotein
(AFP) measured in the same samples. Inhibin was largely uncorrelated with AFP and uE3, whereas the log
correlation coefficient with hCG was 0-29 (P=0-19) for Down's syndrome and 0-41 (P<0-0001) for unaffected
pregnancies; with free //-hCG, it was 0-18 (P=0-38) and 0-38 (P<0-0001), respectively. On the basis of these results
and other pubished studies, we estimate that measuring inhibin A in addition to AFP and hCG or free /J-hCG (with
or without uE3) will increase the detection rate for a fixed 5 per cent false-positive rate by about 7 per cent.
key words: Down's syndrome; inhibin; maternal serum; second trimester
INTRODUCTION
Several studies have shown that maternal serum
inhibin levels are raised on average in second-
trimester pregnancies with Down's syndrome
(Van Lith et a/., 1992; Spencer et al., 1993; Cuckle
et al., 1994; Cuckle et al., 1995; Canick et al., 1994;
Wallace et al., 1996; Wald et al., 1996; Aitken
et al., 1996). The intact inhibin molecule is a dimer
with two possible forms (A and B) with a common
a subunit and two distinct ft subunits. The reported
studies have used two types of assay, either an
'immunoreactive' assay which detects several
inhibin species or one which is specific for inhibin
A (a-flA). One study compared both methods in 19
Down's syndrome pregnancies and found that the
level of inhibin A was significantly higher than
with the immunoreactive assay (Cuckle et al.,
1995). Whichever method is used, the potential of
inhibin in Down's syndrome screening will ulti¬
mately turn on how much additional information
it provides to existing markers. We carried out a
study to assess this specifically for inhibin A.
MATERIALS AND METHODS
A series of maternal serum samples were selected
for inhibin A measurement from a bank of samples
which had been stored at — 25°C or cooler. A total
of 56 pregnancies affected by Down's syndrome
were studied together with 280 unaffected control
pregnancies. The gestational ages of the affected
pregnancies in completed weeks were 13 (4 cases),
CCC 0197-3851/96/121095-06
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14(5), 15(28), 16(12), 17(3), 18(2), 19(1), and 21
(1). Five controls were individually matched with
each case for gestational age, which was based on
ultrasound in all but three pregnancies. Serum
samples were taken either routinely as part of the
Down's syndrome screening programmes in Hull
and Leeds or specifically for research purposes
prior to an invasive diagnostic procedure or when
there was a high Down's syndrome risk. The
samples from cases comprised 52 taken for screen¬
ing, three taken prior to prenatal diagnosis (two
for ultrasound indications and one because of a
family history of neural tube defects), and one
because ultrasound indicated a high risk of
Down's syndrome but prenatal diagnosis was
refused.
All tests were carried out without knowledge of
which sample was from an affected pregnancy and
which a control. The inhibin results for 19 of the
cases and their 95 controls have previously been
reported (Cuckle et al., 1995) using the inhibin A
method described by Groome and O'Brien (1993).
A modified assay was used for the remaining 37
cases and 185 controls. The standards were made
from an in-house immunopurified preparation
which was calibrated against the original recom¬
binant human inhibin A preparation. Samples and
standards (100 /d) were boiled for 3 min with 50 //I
of 6 per cent (w/v) sodium dodecyl-sulphate (SDS),
cooled, and oxidized with 10 per cent hydrogen
peroxide (final v/v) for 30 min prior to assay. The
assay methodology was thereafter as previously
described except that detection was afforded by
colour change of a simple alkaline phosphatase
substrate (pNNP, Kierkegaard and Perry Labora¬
tories, Maryland, U.S.A.), reading at 405 nm,
rather than by the amplified detection system
(Ampak, Dako, U.K.) used previously. The modi¬
fied assay yielded inhibin concentrations about
double those of the existing method, despite
the similar gestations in the two sets of samples
(medians of 15 weeks 4 and 3 days). To overcome
this, we standardized inhibin values by dividing
each one by the overall median concentration
among controls in the appropriate set: 411 and
181 U/ml, respectively. The standardized values
were then used to calculate normal medians for
each gestational week and a regression analysis
was performed, weighted for the number tested
each week, so that multiples of the normal median
(MOM) could be calculated for each day of gesta¬
tion. A quadratic equation fitted best, giving
9-44 — 0-144 day+ 0-000606 day2. Finally, to adjust
for maternal weight, the MOMs were divided
by the expected value for the weight (in kg) from
the log10 regression equation: 0-0173-0-000268
weight.
Each of the 336 samples had been previously
tested for alpha-fetoprotein (AFP) and unconju¬
gated oestriol (uE3), with human chorionic gona¬
dotropin (hCG) also measured in 154 samples and
free /LhCG in the remainder. The tests on samples
taken for screening were done prospectively and
the research samples were tested in the next routine
analytical batches after collection. Different com¬
mercial assay kits were used over the period of
sample collection: immunoradiometric assay (IDS,
Tyne and Wear, U.K.), radioimmunoassay
(Amerlex-M, Johnson & Johnson Diagnostics Ltd,
Amersham, U.K.; Biotecx, Texas, U.S.A.) or time-
resolved fluorescent assay (Wallac Oy, Turku,
Finland). The levels of all four analytes were
expressed in MOM using gestation-specific
medians for the appropriate period and
laboratory, and adjusted for maternal weight.
Detection and false-positive rates were estimated
by standard statistical modelling techniques
(Royston and Thompson, 1992) for different com¬
binations of inhibin A with AFP, uE3, hCG, and
free /?-hCG. The model components are the mater¬
nal age distributions of affected and unaffected
pregnancies and the frequency distributions of the
markers. The age distributions were derived by
applying published age-specific rates of Down's
syndrome (Cuckle et ciL, 1987) to the maternities in
England and Wales for the period 1989-1993
(Office of Population Censuses and Surveys, 1991 —
1995). The existing marker distributions fit a multi¬
variate log Gaussian distribution over a specified
range. The fit of inhibin A alone and in combi¬
nation with existing markers was tested using the
Shapiro-Wilks test after excluding outliers exceed¬
ing 3 standard deviations from the mean. In the
model, for the existing markers the multivariate
distribution parameters were based on meta¬
analysis of published studies (Cuckle et al., 1995).
For inhibin, the parameters were first estimated
from the current series as follows: the means from
the medians, the standard deviations by dividing
the tenth to 90th centile range by 2-563, and the
correlation coefficients by first excluding outliers
exceeding 3 standard deviations from the mean.
These estimates were then entered into a meta¬
analysis with values from four other published
series (Canick et al., 1994; Wallace et al., 1996;
Wald et al., 1996; Aitken et al., 1996). For each
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Table I—Inhibin and existing markers: tenth, median, and 90th centiles (MOM) in affected
and unaffected pregnancies
Down's syndrome Unaffected
Marker* 10th Median 90th 10th Median 90 th
Inhibin A 0-83 1-62 3-60 0-56 1-00 1-80
AFP 0-49 0-85 1-32 0-68 1-00 1-61
uE, 0-41 0-70 1-09 0-64 1-00 1-51
hCG 0-81 1-54 3-37 0-52 1-00 1-75
Free /t-hCG 0-97 1-82 4-25 0-47 1-00 2-00
*Measured in all 56 cases and 280 controls except for hCG (26 cases. 128 controls) and free /t-hCG
(30 and 152, respectively).
parameter the average value was used, weighted
for the number in each study.
RESULTS
There was a highly statistically significant ele¬
vation in inhibin A levels among Down's syn¬
drome pregnancies (PcOOOOl, Wilcoxon rank sum
test). Table I shows the tenth, median, and 90th
centiles in affected and unaffected pregnancies for
inhibin and the other markers. The median inhibin
level for Down's syndrome was 1-62 MOM with a
95 per cent confidence limit of 1 -34 1 -96 and was
similar when using the existing and modified
assays (1-64 and 1-58 MOM, respectively). There
was no obvious tendency for the median to vary
with gestation: at 13-14. 15-16, and 17-21 weeks,
it was 1-72 (9 cases), 1-62 (40), and 1-48 (7) MOM,
respectively.
The standard deviation of log10 inhibin was 0-25
and 0-20 for the cases and controls, respectively, so
that the log median was elevated by 0-9 standard
deviation (the average for affected and unaffected
pregnancies). By comparison, the hCG and
free /J-hCG were raised by 0-8 and IT standard
deviations, respectively, with reductions in uE3
and AFP of TO and 0-5 standard deviation,
respectively.
A correlation analysis between the logarithm of
the marker levels showed that inhibin tended to
have a positive association with AFP and the two
species of hCG. The correlation coefficients for
affected and unaffected pregnancies were respect¬
ively 0-08 (P = 0-57) and 0-11 (P=0-06) for AFP,
0-29 (P=0.19) and 0-41 (P<0-0001) for hCG, and
0-18 (/)=0-38) and 0-38 (P<0-0001) for free
/i-hCG. There was a tendency for a negative
association with uE3: r- — 0-08 (P=0-58) and
>•=-0-02 (P=0-78) in affected and unaffected
pregnancies, respectively.
Figure 1 is a probability plot for each inhibin A
level. In such a diagram, a straight line indicates
that the values follow a log Gaussian frequency
distribution. Thus, the figure shows that for both
affected and unaffected pregnancies there is little
deviation from log Gaussian fit over a wide range
of values. Formal testing confirmed this (P=0T1)
for Down's syndrome and P=0-07 for unaffected
pregnancies) and no significant deviations from
multivariate fit were seen for inhibin together with
AFP, uE3, and free /FhCG (P=0-61 and 0-47 for
affected and unaffected pregnancies, respectively);
AFP, uE3, and hCG (P=011 and 0-28); or AFP
and free /?-hCG (T>=0T3 and 0-41).
Table II summarizes the inhibin parameters in
this series and in three other publications together
with the overall values from the meta-analysis.
Based on this, the estimated detection rate for a
fixed 5 per cent false-positive rate is 65-0 per cent
for AFP, uE3, and free /i-hCG; 60T per cent for
AFP, uE3, and hCG; and 61-7 per cent for AFP
and free /i-hCG. The corresponding rates when
inhibin is used as an additional marker are 71-6,
67-6 and 69-0 per cent, respectively. Therefore the
use of inhibin is likely to increase detection by
about 7 per cent.
DISCUSSION
In keeping with four other studies we found
that the level of maternal serum inhibin A is
raised on average in second-trimester pregnancies
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Fig. 1—Probability plot of inhibin A levels (in MOM) against the normal
deviate of rank in 56 Down's syndrome ( + ) and 280 unaffected pregnancies
(■)
Table II—Inhibin parameters (log,0 MOM) for the multivariate Gaussian distributions in affected and unaffected
pregnancies from four second-trimester case-control studies*
R value
Gestation
Study (weeks) Women Mean SD AFP uE3 hCG Free /f
Canick et al., 1994* 15-20 Case 20 0-27 0-26 0-28 0-20 0-57 —
Control 100 0-00 0-23 0-24 0-02 0-36 —
Wallace et al., 1996 15-17 Case 21 0-41 0-20 — — — —
Control 150 0-00 0-27 — — — —
Wald et al., 1996 13-22 Case 77 0-25 0-14 0-15 -0-15 0-36 0-50
Control 385 0-00 0-22 008 0-02 0-19 0-23
Aitken et al., 1996 15-18 Case 44 0-35 0-35 0-24 — 0-39 0-23
Control 206 000 0-29 0-24 — 0-27 0-15
Present 13-21 Case 56t 0-21 0-25 0-08 -0-08 0-29 0-18
Control 280 000 0-20 011 -0-02 0-41 0-38
Overall Case 218 0-28{ 0-23 0-16 -0-08 0-38 0-36
Control 1221 000 0-24 0-14 000 0-27 0-24
*And J. Canick, personal communication.
tTwenty-six cases had been tested for hCG and 30 for free /?-hCG; similarly for 128 and 152 controls, respectively.
JEquivalent to 1-91 MOM.
with Down's syndrome. Whilst the extent of
elevation was slightly lower than that reported in
the other studies, this is likely to be due to
chance since the median hCG and free /ThCG
levels in the cases were also lower than found
elsewhere. The best estimate of the average
inhibin A level in Down's syndrome can be
derived from the studies combined. The geo¬
metric mean MOM value weighted for the
number of affected pregnancies in each study
is T91 MOM (95 per cent confidence interval
T74-2-08).
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Modifications were made to the original inhibin
A assay method in order to improve analytical
performance: a new standard preparation, a more
cost-effective substrate detection system, and a
pretreatment boiling step. A formal comparative
study of these various changes has been performed
and has confirmed that while absolute levels
change, there remains a high degree of between
method correlation except for the pretreatment
step (Wallace, unpublished observations). Pre¬
treatment allows the detection of inhibin A in
haemolysed samples, which was not previously
possible, and as a consequence leads to a poorer
correlation with other methods. None the less, all
the assay formats detect similar inhibin A species,
which is not the case for the different imrnuno-
reactive inhibin assays. Moreover, the median
MOM value was similar for Down's syndrome
pregnancies tested with the original and modified
assays.
The value in Down's syndrome screening of
any marker is dependent on the amount of over¬
lap between the distribution of values in affected
and unaffected pregnancies. In our inhibin series,
the degree of separation in terms of the number
of standard deviations between the medians was
similar to that of hCG, free /i-hCG and uE3, but
about double that of AFP. The value of a marker
in addition to established markers will depend on
its correlation with them. For inhibin, the degree
of correlation is not great and statistical model¬
ling predicts that its use will increase the Down's
syndrome detection rate by about 7 per cent.
This estimate is necessarily provisional, due to
the relatively small number of cases in the pub¬
lished series and the retrospective design of the
studies. It is likely that in prospective screening
the spread of inhibin results will be wider and the
associations with the other markers smaller.
None the less, it is reasonable to conclude that
the use of inhibin A as an additional second-
trimester Down's syndrome marker will be of
material benefit.
Our study was confined to the second trimester
of pregnancy. First-trimester inhibin levels have
been reported for three series of pregnancies with
Down's syndrome. One study used inhibin A and
found that in 23 affected pregnancies the median
value was 2-5 MOM (Wallace et al., 1995). The
others used immunoreactive inhibin assays which
yielded medians of T3 MOM in 23 cases (van Lith
et al., 1994) and 1-2 MOM in 11 (Wallace et al.,
1994). A further study of inhibin A included
samples over a 7- to 18-week range but tabulated
results in three gestational groups (Aitken et al.,
1996). The median value was 0-98 MOM in 8 cases
at 7-11 weeks, 2-60 MOM in 6 at 12-14 weeks, and
2-24 MOM in 44 at 15-18 weeks. Much more data
will be required before any conclusions can be
drawn about the discriminatory power of inhibin
in relation to well-established first-trimester
markers of Down's syndrome such as free /1-hCG
and pregnancy-associated plasma protein A
(PAPP-A). Its role in first-trimester multimarker
screening will depend on any correlations with
these markers. Our preliminary results on 69
unaffected pregnancies indicate a high correlation
with free /J-hCG (r = 0-6, /><0 0001) but not with
PAPP-A (r=01).
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SUMMARY
Initial studies of immunoreactive inhibin using a commercial assay have shown levels to be increased in three
second-trimester series of maternal samples from Down's syndrome-affected pregnancies. This assay detected
non-specifically all forms of circulating inhibin, dimeric and free alpha subunits, whether fully or partially processed.
More recently, a new specific assay for dimeric inhibin-A has shown elevated results in both a first-trimester and a
second-trimester series of cases. In order to assess the value of dimeric inhibin-A as a potential marker in the second
trimester, we have analysed 157 Down's syndrome cases and used 367 unaffected cases across the gestational range
14—20 weeks to establish control medians and population parameters. In our series, the median MOM in Down's
cases was 1-77, significantly higher than in the controls. At a 5 per cent false-positive rate, dimeric inhibin-A alone
identified 37 per cent of cases. When used in conjunction with maternal age and other marker combinations,
mathematical modelling showed detection rates rising from 48 per cent (inhibin-A plus age) to 61 per cent
(inhibin-A, free beta hCG, age) and 68 per cent (inhibin-A, AFP, free beta hCG, age). Our data suggest that dimeric
inhibin-A may have greater potential earlier in gestation when median levels at 14-16 weeks are T92 compared with
1-46 at 17-23 weeks. Dimeric inhibin-A may be a valuable addition to screening protocols, particularly in early
gestations.
key words: dimeric inhibin-A; second-trimester serum screening; Down's syndrome screening
INTRODUCTION
Inhibin is a member of the transforming growth
factor beta (TGF/?) superfamily (Massague, 1990)
and is characterized by its ability to suppress
follicle-stimulating hormone (FSH) secretion
(Ying, 1988). Fully processed inhibin is a dimer
with a molecular mass of 32 kD, composed of an
alpha subunit and one of two similar but distin¬
guishable beta subunits. The resulting possible
mature forms are dimeric inhibin-A (a-fiA) and
dimeric inhibin-B (a-//B), of which only dimeric
inhibin-A is present in pregnancy sera (Wallace,
1995, unpublished observations; Illingworth et al.,
1996). In addition to these, however, a number of
other partially processed and free a subunit forms
may circulate peripherally (Schneyer et al., 1990;
Robertson et al., 1995). Like placental
gonadotropin-releasing hormone (Petraglia et al.,
1987), in pregnancy inhibin has been postulated to
have a role in the feedback control of placental
human chorionic gonadotrophin (hCG) secretion
(Healy et al., 1990).
In pregnancies affected by Down's syndrome,
levels of hCG (either free beta hCG or total hCG)
are increased in amniotic fluid (Spencer et al.,
1993a) and maternal serum (Spencer, 1993); as a
result, free beta hCG is the most discriminating of
the biochemical markers (Spencer, 1994a). In
order to assess further the mechanisms involved in
hCG regulation in cases of trisomy 21, we have
previously investigated levels of immunoreactive
inhibin using a commercial assay (Spencer et al.,
1993b). Using this same commercial assay, two
other studies (Van Lith et al., 1992; Cuckle et al.,
1994) have also demonstrated increased levels
of immunoreactive inhibin in maternal serum
samples from Down's syndrome-affected
CCC 0197-3851/96/121101-10
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pregnancies. The commercial assay will detect non-
specifically all forms of circulating inhibin, dimeric
and free alpha subunits, whether fully or partially
processed (Schneyer et al., 1990). More recently, a
new specific assay for dimeric inhibin-A has been
developed (Groome and O'Brien, 1993; Groome
et al., 1994) and in studies of a first-trimester
(Wallace et al., 1995) and two second-trimester
(Cuckle et al., 1995; Wallace et al., 1996) series of
Down's cases, levels of inhibin-A have been shown
to be elevated. In order to assess the value of
dimeric inhibin-A as a potential marker of Down's
syndrome in the second trimester, we have studied




The Down's study population consisted of
women who presented through the NTD and
Down's syndrome screening programme of the
Romford centre. The serum collected from each
woman was aliquoted and stored at — 20°C after
being analysed in routine serum alpha-fetoprotein
(AFP) and free beta hCG assays. The samples were
collated on the basis of abnormal birth outcome
or cytogenetic confirmation after mid-trimester
amniocentesis as a result of an increased risk
Down's syndrome screen report. A total of 157
singleton pregnancies associated with Down's
syndrome were identified with maternal serum
samples taken between 14 and 23 weeks' gestation
and before amniocentesis. In order to provide a
control population, 367 samples from unaffected
pregnancies of the same gestational range were
selected to establish the median value at each
gestational week. Table I summarizes the study
population. Both control and Down's syndrome
samples had undergone only one previous freeze-
thaw cycle.
Analytical methods
AFP was measured using a polyethylene
glycol-assisted radioimmunoassay (Spencer and
Carpenter, 1985) and free beta hCG was measured
using a highly specific solid-phase two-site
immunoradiometric assay (ELSA-FbHCG; CIS
(U.K.) Ltd, High Wycombe, Bucks, U.K.). The
specificity, precision, and performance of this
assay have been previously documented (Spencer,











1991a; Macri et al., 1993). Dimeric inhibin-A was
measured with a solid-phase sandwich microtitre
plate ELISA (Groome and O'Brien, 1993; Groome
et al., 1994) with some minor modifications. Sam¬
ples and standards were mixed with 6 per cent
(w/v) sodium dodecyl sulphate, boiled for 3 min,
cooled, and incubated at room temperature with
10 per cent (w/v) hydrogen peroxide for 30 min.
The performance of this assay has been previously
documented (Wallace et al., 1995). The standard
preparation used in this study was derived from
immunopurified human follicular fluid, calibrated
against previously used recombinant 32 kD human
inhibin-A (Genentech, U.S.A.).
Statistical analysis
All results for each analyte were expressed in
multiples of the median (MOM) for unaffected
pregnancies at the same gestational age, derived
from regressed weighted medians for each analyte
when appropriate. Statistical analysis of the data
was performed using Astute, a statistical software
add-in for Microsoft Excel 5 (DDU Software,
University of Leeds, U.K.). Calculation of the
multivariate risk of Down's syndrome using com¬
binations of various biochemical parameters, in
addition to a priori maternal age risk (Cuckle et al.,
1987), was performed according to standard pro¬
cedures as outlined by Reynolds and Penney
(1990). To establish further the validity of various
screening protocols applied to mass population
screening, standard statistical modelling tech¬
niques (Royston and Thompson, 1992) were used.
Population means and standard deviations were
obtained in the manner used previously (Spencer
et al., 1992). Using the previously established
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Fig. 1—Variation of dimeric inhibin-A with gestational age in the second trimester.
♦ = fifth centile; ▲ = 95th centile
x =median;
population parameters for AFP and free beta hCG
(Spencer et al., 1992) updated by the inclusion of
data from a further 367 Down's syndrome cases
and 49 858 unaffected cases, and the inhibin
parameters established in this study, a series of
random MOM values were selected from within
the distributions of the affected and unaffected
distributions. These values (without the use of
truncation limits) were then used to calculate like¬
lihood ratios and the expected Down's syndrome
detection rate was calculated at a given false-
positive rate (5 per cent) assuming the maternal
age distribution of births in England and Wales
(Office of Population Censuses and Surveys, 1991-
1994). Repeated simulations through the model
enabled confidence intervals to be established.
RESULTS
Figure 1 shows the median value (50th centile)
and fifth and 95th centiles of the dimeric inhibin-A
values at each gestational week. The results indi¬
cated almost no variation of the median value
across the 14th to 20th week of pregnancy. When
the levels at 14 weeks were compared consecutively
with those in the 15th to 20th week using the
Mann-Whitney U-test, no significant difference
between medians at each week could be demon¬
strated (P>0-01). Since gestational variation did
not appear to be statistically significant, all subse¬
quent MOM calculations were performed using
the total population median (106-3 pg/ml).
Dimeric inhibin-A in both the affected and the
unaffected cases was shown to fit a Gaussian
distribution well after logl0 transformation. The
Kolmogorov-Smirnov D statistic for the Down's
cases was 0-6288, and for the unaffected popu¬
lation 0-5831, neither significant at the 0-001 level.
Figures 2 and 3 show the cumulative probability
plots for these two populations. The log10 mean
and standard deviation of the unaffected cases
were 0-0117 and 0-1945, respectively, and for the
Down's cases 0-2377 and 0-2284.
There was no evidence of any association of
dimeric inhibin-A with maternal age. Correlation
of log10 dimeric inhibin-A MOM with maternal
age showed a correlation coefficient of — 0-03 in
the unaffected population and — 0-007 in the
Down's population.
Log10 dimeric inhibin-A showed a small but
significant negative variation with maternal weight
(log inhibin MOM = 0-133 - (0-0019 x maternal
weight in kg), r = 0T311). This variation follows
the same pattern seen with other biochemical
markers and relates to an increase in the volume of
distribution of the analyte as the maternal weight
increases.
Dimeric inhibin-A in the unaffected population
showed a median MOM of 1-00 [95 per cent
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Fig. 2—Cumulative normal probability plot of logl0 dimeric inhibin-A (MOM) in the unaffected cases
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Fig. 3—Cumulative normal probability plot of log10 dimeric inhibin-A (MOM) in the Down's
syndrome cases
confidence interval (CI) 0-94—l 07] with a tenth to
90th centile of 0-61—1 -80 and a fifth to 95th centile
of 0-50-2-11. In the Down's syndrome population,
the median MOM was 1-77 (95 per cent CI I -60—
1-97), significantly greater (/><0-0001, Mann-
Whitney test) than in the unaffected population.
The tenth to 90th centile was 0-87-3-18 and the
fifth to 95th centile was 0-75-3-95. Table II shows
the distribution of affected and unaffected preg¬
nancies with dimeric Inhibin-A at specific MOM
cut-off values. Figure 4 shows the individual
MOM values obtained in each of the Down's
syndrome cases. At a fixed 5 per cent false-positive
rate (2-11 MOM cut-off), dimeric inhibin-A alone
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Table II—Distribution of affected and unaffected
pregnancies at various dimeric inhibin-A MOM cut-off
values
Down's cases Unaffected cases
(n = 157) (n -361)
MOM No. % No. %
5=0-50 153 98-1 350 94-9
5=0-75 149 95-6 280 76-3
5=100 134 85-3 186 50-6
54-25 116 73-8 124 33-7
51-50 98 62-2 78 21-1
51-75 82 52-6 42 11-3
52-00 63 39-8 26 6-9
52-50 36 22-5 10 2-5
53-00 22 13-5 6 1-4
54-00 8 4-5 0 0
would have identified 59 of 157 cases (37-2 per
cent) of Down's syndrome.
When the Down's syndrome cases were split
into two groups based on those with a gestational
age of 14-16 weeks (n= 102) and those 17 weeks
and older (w = 55), there was an apparently higher
median (1-92 MOM) amongst the cases at the
earlier gestation compared with those at the later
gestation (1-46 MOM). This was significant at the
0-0196 level using Mann-Whitney test statistics.
The corresponding log10 mean and standard
deviation (SD) were 0-262 and 0-238 at the
earlier gestation and 0-195 and 0-205 at the later
gestation.
When the dimeric inhibin-A MOM values were
compared with previously measured AFP and free
beta hCG values, a significant positive correlation
was observed with free beta hCG in both the
unaffected (r = 0-2373) and the Down's syndrome
group (r=0-3925). With AFP, the level of corre¬
lation was much smaller, with r equal to 0-1483 in
the unaffected group and 0-0583 in the Down's
group.
In the statistical modelling exercise, various
combinations of the biochemical markers were
used in conjunction with maternal age, and the
population parameters for dimeric inhibin-A from
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Fig. 4—Dimeric inhibin-A (MOM) in 157 cases of Down's syndrome
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Table III—Expected Down's syndrome detection rates
at a fixed 5 per cent false-positive rate for various
combinations of biochemical markers and maternal age,
using the England and Wales population model and
repeated estimations through the simulation («= 10)
Detection rate
Test combination (%) 95% CI
Inhibin/age 47-8 45-9-49-7
Free beta/age 55-5 53-7-57-3
AFP/inhibin/age 55-9 54-0-57-8
Free beta/inhibin/age 60-5 58-8-62-2
AFP/free beta/age 64-5 62-8-66-2
AFP/free beta/inhibin/age 67-5 65-7-69-3
CI =confidence interval.
previously established for AFP and free beta hCG
(Spencer et al., 1992) corrected for population
estimates in the extended series (log10 mean AFP
controls = 0-0, logl0 SD AFP controls = 0-1650,
log10 mean AFP Down's= — 0-1427, logI0 SD
AFP Down's = 0T868, log10 mean free beta con-
trols = 0-0, logl0 SD free beta controls = 0-2347,
log10 mean free beta Down's = 0-3848, log10 SD
free beta Down's = 0-2988, correlation con-
trols = 0-0172, correlation Down's= -0-0894, con¬
trols number = 52 720, Down's number = 457). The
results of the simulation exercise are shown in
Table III. The data indicated that in combination
with maternal age, using dimeric inhibin-A along¬
side AFP and free beta hCG would increase
Down's syndrome detection rates by no more than
3 per cent.
DISCUSSION
Our gestational median data are consistent with
other published series which have similarly shown
little or no variation of dimeric inhibin-A across
the second-trimester 15- to 20-week period (Cuckle
et al., 1995; Canick et al., 1994; Aitken et al., 1996;
Wald et al., 1996). The overall median value from
the control data set was 106-3 pg/ml; this is some¬
what lower than the 181 pg/ml observed by Cuckle
et al. (1995) and the 180 pg/ml observed by Aitken
et al. (1996) using a similar assay calibrated
directly with the recombinant inhibin-A. The
median observed in the Wallace et al. (1996) study
was higher at 237 pg/ml when using the same assay
and recombinant inhibin-A calibrator as Cuckle
et al. (1995) and Aitken et al. (1996). Wald et
al. (1996), using the same assay as Cuckle et al.
(1995), Wallace et al. (1996), and Aitken et al.
(1996), but calibrated with a different recombinant
inhibin-A preparation, found even higher median
values at 346 pg/ml. The median observed by
Canick et al. (1994), however, was significantly
lower (67 pg/ml), although no details of the specific
assay or calibration method were mentioned. The
differences between the absolute inhibin-A levels
reported in these various studies are a major cause
for concern. Not only do they reflect differences in
the various calibrator preparations in use, but they
also reflect minor but important differences in
assay formats which may be contributing to the
absolute values of measured dimeric inhibin-A
and, more importantly, to the levels of clinical
discrimination of these various assay formats. Fur¬
ther studies are ongoing to evaluate the impact of
changes in assay format and we await the pro¬
duction of an agreed international reference
preparation for inhibin-A.
There was no evidence of any association of
dimeric inhibin-A with maternal age, confirming
previous studies in the first trimester (Wallace
et al., 1995) and the second trimester (Wald et al.,
1996).
The correlation with free beta hCG was not as
high as had been observed previously (Spencer et
al., 1993b) with immunoreactive inhibin or as high
as noted by Canick et al. (1994) when comparing
intact hCG. The size of our correlation with free
beta hCG was closely similar to that of Cuckle et
al. (1995) when comparing intact hCG, which was
much less than when the same samples were com¬
pared with immunoreactive inhibin (Cuckle et al.,
1994). Compared with the recent publication by
Wald et al. (1996), the correlation with free beta
hCG in the Down's group was lower in our study.
Aitken et al. (1996), however, found a significantly
lower level of correlation between inhibin-A and
free beta hCG in both the controls and the Down's
syndrome group, being almost half that observed
in this study. Similarly, with intact hCG, these
workers also found a much lower correlation than
has been reported in other studies.
The median MOM value in our large Down's
series was lower than that noted in a small prelimi¬
nary series (Spencer et al., 1993b) using a non¬
specific inhibin assay (T77 vs. 3-60) but higher
than noted by Cuckle et al. (1994) using the same
non-specific assay (1-3) and closely similar to that
initially published by Van Lith et al. (1992), again
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using the same non-specific assay (1-9). Doubts
have already been expressed about the contri¬
bution of the non-specific inhibin assay to the wide
variation of results between these three studies
(Cuckle et al., 1994).
Cuckle et al. (1995), in re-analysing their
samples using the more specific dimeric inhibin-A
assay, found a small but significantly higher
median MOM and their observed median of
1-6 MOM is of similar magnitude to that seen in
our larger series. Canick et al. (1994), in a study of
20 Down's cases, found a similar median MOM of
1-88 and observed a similar distribution in both
affected and unaffected populations (log10 SD
unaffected 0-231, affected 0-261), although they
reported a much higher degree of correlation with
intact hCG in both affected and unaffected popu¬
lations. The exact details of the dimeric inhibin-A
assay used were not provided. Wallace et al.
(1996), in a small study of 21 Down's cases, found
a median of 2-6 MOM and observed a similar
distribution in both affected and unaffected popu¬
lations (logi0 SD unaffected 0-27, affected 0-20).
Ward et al. (1996), in their recent study, found a
median of 1-79 MOM, which is closely similar to
our study. However, our value of 1-77 MOM is
lower than that reported by Aitken et al. (1996) in
a study of 44 cases in the 15- to 18-week period.
The logi0 SD quoted by Wald et al. (1996) for
inhibin-A in the unaffected group was 0-2188,
similar to our figure of 0-1945, both being lower
than the 0-2967 observed by Aitken et al. (1996). In
the Down's syndrome group, Aitken et al. (1996)
similarly observed a much wider distribution of
inhibin-A levels (log]0 SD = 0-3521) and both con¬
trol and affected data sets showed more than a 50
per cent increase in the width of the distribution,
compared with our study. In the Wald et al. (1996)
study, for the Down's group the authors quote a
log10 SD of 0-1417 derived from an adjustment to
the observed Down's data based on the differences
between the variance and covariance for the
matched control population and a newly collected
set of unaffected samples. Examination of Table I
in the Wald et al. paper shows a tenth to 90th
centile in the Down's group of approximately 4-00
to TOO; using the Wald et al. (1992) method of
calculating SD shows that prior to this correction
the SD approached 0-235, which is more consistent
with all other published data. Wald et al.'s data
also show considerable deviation in the tails of the
unaffected and affected distributions, resulting in
the authors suggesting data linearity only between
0-4 and 3-5 MOM. They suggest that in the
Down's group they calculated the SD by only
considering the population within the tenth to 70th
centile; from their Table I, using the available data
of the 7-8 centile (TOO MOM) to the 71-8 centile
(2-25 MOM), this should have produced an SD
prior to their adjustment for variance and covari¬
ance differences between the older sample set and
the fresh sample set of:
SD = (log10 2-25 - logl0 T00)/2 x 0-915 (the z value
at 64 per cent of the normal distribution)
= 0-1924
As has been pointed out previously (Spencer and
Macri, 1994), this sample set was collected some 20
years ago (1973-1983) and has undergone repeated
freezing and thawing, which may possibly affect
the results. Our data clearly show linearity in the
Down's samples from 0-6 MOM to 6-00 MOM
and down to 0-3 MOM in the unaffected data set,
with a better fit to linearity than that observed by
Aitken et al. (1996) or Wald et al. (1996).
Clearly from our large study we can confirm
that dimeric inhibin-A levels are increased in preg¬
nancies affected by Down's syndrome, and when
used alone (without maternal age), they can iden¬
tify 37 per cent at a 5 per cent false-positive rate. In
comparison with other markers, however, the
extent of this elevation is less than with free beta
hCG, which detects 46 per cent of cases, and
similar to total hCG, which can detect 38 per cent
of cases, but better than AFP or unconjugated
oestriol (Spencer et al., 1992). Our data are not as
encouraging as the initial series from Wallace et al.
(1996), who found a 62 per cent detection rate at a
5-3 per cent false-positive rate. Wald et al. (1996),
however, only found a 24-7 per cent detection rate
at a 5-5 per cent false-positive rate. The study by
Aitken et al. (1996) did not report on the detection
rate using the marker inhibin-A alone without
maternal age, but from the standard deviation of
the control and affected distributions it is possible
to estimate from their data that at a 5 per cent
false-positive rate (3-92 MOM) a detection rate of
25-5 per cent would have been achieved.
When combined together with maternal age and
other biochemical marker combinations, math¬
ematical simulation studies suggest that an
increase in detection rate of little more than 3 per
cent can be expected by adding dimeric inhibin-A
to a simple two-analyte protocol of AFP and free
beta hCG, which alone can be expected on average
to give detection rates of 65 per cent and for which
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prospective screening performance year on year
seems to consistently show rates of 70-75 per cent
to be achievable (Spencer, 1994b). If the popu¬
lation parameters for the inhibin-A log10 SD in the
Down's group in the Wald et al. (1996) study are
an underestimate, the net effect of this will have
been to bias the results on detection efficiency
towards showing an even greater benefit for the
addition of inhibin-A. Our detection rates for the
inclusion of inhibin-A are less optimistic than
those of Aitken et al. (1996), who showed a
projected 75 per cent detection rate using AFP/free
beta hCG/inhibin-A/maternal age, being some¬
what 22 per cent higher than that observed with
only AFP/free beta hCG/maternal age. The poorer
performance of the simple two-analyte protocol
was some 12 per cent lower than detection rates
observed in other studies and was noted by Aitken
et al. as being a contributing factor to this per¬
formance differential. It is difficult to reconcile the
wide observed standard deviations for inhibin-A in
the Aitken et al. study with the projected 22 per
cent increase in performance when inhibin-A is
included.
On the basis of our predicted 3 per cent increase
in detection rate, it is unlikely to be enough benefit
to warrant the addition of a third and complex
assay to such a simple two-analyte screening pro¬
tocol as AFP and free beta hCG. The additional
errors in the estimate of risk as more analytes
are added to the risk algorithm have been well
demonstrated both theoretically (Spencer, 1991b,
1994c) and practically (Seth et al., 1995), and it is
unlikely, as with the use of unconjugated oestriol
(Spencer, 1994c), that such marginal benefits could
be practically realized.
In the first trimester, dimeric inhibin-A using
the more specific assay has been shown to be
significantly elevated in one small study of 23 cases
(Wallace et al., 1995), contrary to two observations
using assays measuring immunoreactive inhibin
(Wallace et al., 1994; Van Lith et al., 1994). At this
time, there is the same degree of correlation
between free beta hCG and dimeric inhibin-A
(r=0-6 in Down's and 0-16 in controls) as in the
second trimester but no correlation with
pregnancy-associated plasma protein-A (PAPP-
A) 0"=0-052 in Down's and 0-0005 in controls)
(Wallace, 1995, unpublished observations). The
recent study of Aitken et al. (1996), however,
has shown no elevation of dimeric inhibin-A in a
small study of eight cases in the 7- to 11-week
period.
Dimeric inhibin-A MOM in Down's cases
appears significantly higher in the earlier weeks of
gestation in the second trimester (as also observed
in the data of Aitken et al., 1996); this mirrors that
seen for free beta hCG (Macri et al., 1990; Spencer
et al., 1993c), and may lead to higher detection
rates in the 14- to 16-week period. It may be that
dimeric inhibin-A will have an important role to
play in the late first and early second trimester at a
time when other potential first-trimester markers
of Down's syndrome such as PAPP-A are rapidly
losing their effectiveness (Aitken et al., 1994).
Future work on dimeric inhibin-A must await
clarification of how the different assay formats and
the various calibrators contribute to the wide
variation in published medians (67-346 pg/ml) and
whether these differences also contribute to
variation in the Down's syndrome detection rate.
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Abstract
Recently, inhibin-A has been shown to be a useful new
prenatal marker of Down's syndrome, significantly in¬
creasing detection rates. While the placenta is believed to
be the major source of inhibin in pregnancy, there are
actually very limited data available on specific inhibin
dimers in pregnancy. Using a sensitive and specific ELISA
we have measured the inhibin-A content of amniotic fluid
(AF) to investigate further the biology of inhibin-A in
chromosomally normal and abnormal pregnancies. AF
from 51 Down's syndrome and 161 chromosomally normal
pregnancies between 16 and 19 weeks of gestation were
analysed, blinded as to whether the sample was from a
Down's syndrome or normal pregnancy. There were no
sex differences in inhibin-A content in either the control
or Down's syndrome pregnancies. The median (10th—90th
percentiles) inhibin-A level in the control pregnancies
increased from 339-6 (175-2—649-1) pg/ml at 16 weeks
to 592-9 (256-4-1027-3) pg/ml at 19 weeks of gestation.
The median (95% confidence interval) inhibin-A in the
Down's syndrome pregnancies, expressed as multiples of
the median (MoM) to correct for gestation, was 0-77
(0-68-0-89) MoM, significantly lower than the controls
(T<0-001, Mann—Whitney U test).
We believe that these data are compatible with more
than one source of inhibin-A in pregnancy and suggest
that the fetal membranes may be contributing significantly
to AF inhibin-A content. Further, our data would suggest
that the endocrine function of the placenta and the other
inhibin source(s) are differentially regulated.
journal of Endocrinology (1997) 152, 109-112
Introduction
Inhibins are dimeric glycoproteins characterised by their
ability to suppress follicle-stimulating hormone secretion
from the anterior pituitary gland (Ying 1988). Two fully
processed forms of inhibin exist — inhibin-A (an a-(3A
dimer) and inhibin-B (an Ct-PB dimer) and while the ovary
secretes both of these forms during the normal menstrual
cycle (Groome et al. 1994, 1996), the principal source of
inhibin in pregnancy, the placenta, only secretes inhibin-A
(Muttukrishna et al. 1995, Illingworth et al. 1996, Wallace
et al. 1996a).
It has recently been shown that, compared with normal
pregnancy, maternal serum (MS) inhibin-A levels are
elevated in Down's syndrome pregnancies, in both the first
(Wallace et al. 1995) and second (Cuckle et al. 1995,
Aitken et al. 1996a, Wallace et al. 1996b) trimesters.
Further, when combined with maternal age and other MS
markers of Down's syndrome, inhibin-A will add a further
10—20% detection to current established marker combina¬
tions (Aitken et al. 1996a, Wald et al. 1996). Inhibin-A
would thus appear to be a promising new prenatal marker
of Down's syndrome.
To explore the biology of inhibin-A secretion in
pregnancy further we have studied inhibin-A levels in
amniotic fluid (AF) in chromosomally normal and Down's
syndrome pregnancies.
Materials and Methods
Fifty-one Down's syndrome pregnancies, from which AF
had been collected prospectively as part of the West of
Scotland prenatal diagnosis service, were identified from
records and an aliquot of fluid retrieved from storage
at — 20 °C. Of these 51 pregnancies, 11 (21-6%) had an
amniocentesis performed because of maternal age and 40
(78-4%) because of an increased risk by a-fetoprotein
(AFP)/age or AFP/human chorionic gonadotrophin
(hCG)/age screening. Similarly, 161 chromosomally
normal control pregnancies on which an amniocentesis
had been performed were identified from records and
an aliquot of fluid retrieved. Sixty-eight (42-2%) of
these amniocenteses had been performed for maternal age,
82 (50-9%) for a positive MS screening result, one (0-6%)
for an isolated elevated MS AFP and 10 (6-2%) for
Journal of Endocrinology (1997) 152, 109-112 © 1997 Journal of Endocrinology Ltd Printed in Creat Britain
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Table 1 Inhibin-A levels (pg/ml) in AF from 161 chromosomally normal and 51 Down's






















other miscellaneous reasons (e.g. past history, maternal
anxiety).
Inhibin-A was measured in each sample using an ELISA
specific for inhibin-A (Groome & O'Brien 1993), blinded
as to whether the sample was from a Down's syndrome or
a normal pregnancy. The original assay method was
modified and validated for AF as previously reported
(Wallace et al. 1996a).
Statistical analyses were performed using Statview 4-1
(Abacus Inc, Berkeley, CA, USA) and SPSS for Windows
(SPSS Inc, Chicago, IL, USA). AF inhibin-A levels
increase significantly and linearly across the gestational
window of 14 to 20 weeks (Wallace et al. 1996a). The
inhibin-A levels in both the Down's syndrome and control
pregnancies were therefore expressed as multiples of the
normal median (MoM), allowing a comparison between
the two groups. MoMs, for both the Down's syndrome
and control samples, were calculated from the regressed
median of the controls at the appropriate gestation. The
use ol regressed medians corrects for the artefactual
variation that arises secondary to the small sample size and
so affords more accurate MoM estimates for both the
control and Down's syndrome samples than using
non-regressed medians. The regressed medians were
calculated using the weighted regression equation:
median=e(80649-35 045/Bestatlon).
Results
Seventy-eight (48-4%) of the 161 control AF samples were
from pregnancies with a female fetus, 82 (50-9%) were
from a pregnancy with a male fetus and one (0-6%) was
unknown. Of the Down's syndrome samples, 18 (37-3%)
and 32 (62-7%) were from pregnancies with a female and
male fetus respectively. There were no significant differ¬
ences in inhibin-A levels between the sexes for either
controls or Down's syndrome cases (data not shown) and
so the data were subsequently analysed by group, com¬
bining data for both sexes therein. Table 1 displays the
number of control samples at each gestation and the
median, 10th and 90th percentiles for inhibin-A in these
samples. The median inhibin-A level at 19 weeks of
gestation was significantly higher than at the other periods
of gestation (P<0'01, Mann-Whitney U test). Figure 1
shows the regressed medians, 10th and 90th percentiles
across the gestations.
Table 1 shows the median inhibin-A levels in the 51
Down's syndrome samples by week ofgestation. Expressed
as MoMs, the median (95% confidence interval) inhibin-A
level for the Down's syndrome pregnancies was 0-77
(0-68-0-89) MoM (Fig. 2). The level of inhibin-A in AF
from the Down's syndrome pregnancies was significantly
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Figure 1 AF inhibin-A levels (regressed medians, 10th and 90th
centiles) in 161 chromosomally normal pregnancies at 16-19
weeks of gestation.
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Figure 2 AF inhibin-A levels, expressed as multiples of the
regressed normal median (MoMs), in 51 Down's syndrome
pregnancies.
Discussion
The ontogeny of inhibin-A secretion in early pregnancy is
similar to that of hCG with levels peaking at approxi¬
mately 9—10 weeks of gestation (Aitken et al. 1996a,
Illingworth et al. 1996). Levels then decline to a nadir at 17
weeks (Muttukrishna et al. 1995, Aitken et al. 1996a,
Wallace et al. 1996a), rising thereafter such that the highest
levels are achieved by term (Muttukrishna et al. 1995). It
is generally accepted that the principal source ofinhibin in
pregnancy is the placenta (reviewed by Qu & Thomas
1995). Although the control of placental inhibin secretion
has yet to be fully elucidated, hCG stimulates inhibin
secretion from in vitro trophoblast cell cultures and,
reciprocally, inhibin suppresses hCG secretion (Petraglia
et al. 1987).
MS hCG is elevated in Down's syndrome (Bogart et al.
1987, Chard & lies 1994), reflecting increased production
of both hCG subunits by the placenta (Eldar-Geva et al.
1995). Considering the in vitro and in vivo relationships of
hCG with inhibin it is not unexpected that MS immuno-
reactive inhibin (van Lith et al. 1992, Spencer et al. 1993),
and more specifically inhibin-A (Cuckle et al. 1995,
Wallace et al. 1995, 1996b, Aitken et al. 1996a, Wald et al.
1996) levels are also higher than normal in pregnancies
complicated by Down's syndrome. However, despite
these apparent similarities there are important differences
between the secretion of hCG and inhibin in both normal
and Down's syndrome pregnancies. In normal preg¬
nancy the intact hCG concentration is much lower in
AF than in MS (Kletsky et al. 1985) while inhibin-A
concentrations in AF are significantly higher than in MS
(Wallace et al. 1996a). In Down's syndrome pregnancies,
while both intact hCG and free (3hCG levels in AF are
higher than in AF from normal pregnancies (Cuckle et al.
1991, Aitken et al. 1996b), comparable with the differ¬
ences reported in serum (Bogart et al. 1987, Chard & lies
1994), we have shown that AF levels of inhibin-A in
Down's syndrome pregnancies are significantly lower than
in normal pregnancy AF, the reverse of that which is
observed in MS for this protein. There are a number of
possible explanations for this unexpected finding for
inhibin-A.
The lower levels of AF inhibin-A observed in Down's
syndrome compared with normal pregnancies may relate
to changes in either the route of secretion of inhibin-A by
the placenta, in preference for MS, or in the rate of
clearance of inhibin-A from the amniotic cavity. While
MS levels of several proteins and steroids are deranged in
Down's syndrome, the AF levels for each of these are
similarly deranged (Cuckle et al. 1985, 1991), indicative of
neither an altered route of secretion nor selective changes
in clearance from AF.
Dimeric inhibin-A in AF may dissociate into separate
subunits more rapidly in Down's syndrome relative to
normal pregnancy. Levels of free PhCG and free ahCG
subunits are much higher in AF than in MS while intact
hCG levels are lower (Ozturk et al. 1988, Aitken et al.
1996b). The increased concentration of free hCG subunits
in AF compared with MS could be accounted for by an
increased breakdown of intact hCG in AF but it is thought
more likely that the chorionic trophoblast preferentially
secretes free subunits into AF and the placental trophoblast
secretes intact hCG into MS (Ozturk et al. 1988). In the
first trimester of pregnancy the major source of hCG in
extra-embryonic coelom, and thereafter AF, is probably
chorionic, as opposed to placental, trophoblast (lies et al.
1992, Chard et al. 1995). It is therefore possible that in the
second trimester the differences between MS and AF in
intact and free subunit hCG levels may represent different
sources.
Thus, the source ofAF inhibin-A may be different from
that of MS. Indeed, it has been previously suggested that
the placenta may secrete inhibin-A primarily into MS
while the chorion is probably the main source of inhibin-A
in AF (Wallace et al. 1996a). However, if this were so then
our data would indicate that the abnormality in Down's
syndrome underlying the elevated MS inhibin-A levels
would have to be differentially expressed in the placental
and chorionic trophoblast. This would be quite unlike
hCG (either intact or free PhCG).
lournal of Endocrinology (1997) 152, 109-112
112 em Wallace and others Inhibin-A in amniotic fluid
In summary, we have demonstrated that the AF
inhibin-A concentration in Down's syndrome is signifi¬
cantly lower than in normal pregnancy. The precise
explanation for this unexpected finding currently remains
obscure but our data are consistent with more than one
significant source of inhibin-A in mid-pregnancy and with
differential control of these sources. Studies exploring
changes in mRNA for the three inhibin subunits in the
placenta and fetal membranes in normal and Down's
syndrome pregnancies would afford some clarification of
this possibility and would certainly now be worthwhile.
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ABSTRACT
Using new specific and sensitive enzyme-linked immunosorbent
assays for inhibin A and inhibin B, we measured these proteins in
amniotic fluid (AT), maternal serum (MS), and umbilical cord serum
in normal pregnancies.
Inhibin A levels in AF rose from a median (10-90th percentile)
level of 615 (158.2-1124.6) pg/mL at 14 weeks to 1336.0 (489.4-
2084.1) pg/mL at 20 weeks, and inhibin B rose from 216.6(67.4-554.6)
to 1078.2 (439.3-2482.2) pg/mL over the same period. In MS, inhibin
A levels fell from a median (10-90th percentile) level of 177.5 (101.4-
290.7) pg/mL at 10 weeks to a nadir of 111.9 (59.5-200.3) pg/mL at 17
weeks, rising again to 180.3 (74.1-327.2) pg/mL at 20 weeks. No
inhibin B was detectable in MS. In 47 pairs of matched samples
(14-16 weeks gestation) there was no correlation of inhibin A levels
in AF with those in MS (r = 0.19; P > 0.05). In 45 term umbilical cord
serum samples, no dimeric inhibin was detectable in serum from
female babies, but inhibin B was detectable in male sera; the median
(10-90th percentile) concentration was 167.4 (111.2-224.8) pg/mL.
These data suggest that for the gestation periods studied, although
the placenta secretes inhibin A, another source, probably the fetal
membranes, secretes both inhibin A and inhibin B. Further, the
presence of inhibin B in male fetuses is consistent with a testicular
origin, suggesting that inhibin B may be important in the develop¬
ment of the fetal hypothalamo-pituitary-testicular axis. (J Clin En¬
docrinol Metab 82: 218-222, 1997)
INHIBINS ARE glycoproteins that belong to the transform¬ing growth factor-^ superfamily (1) and are character¬
ized by their ability to suppress FSH secretion (2). They are
composed of an a-subunit and one of two j3-subunits, fiA or
PB, giving rise to two mature 32-kDa inhibins: inhibin A
(a-f3a) and inhibin B (a-/3B) (2). Although inhibins were orig¬
inally identified from gonadal tissue, messenger ribonucleic
acids (mRNAs) for the inhibin subunits are expressed in
many nongonadal sites (3), including the placenta (4). In¬
deed, very high circulating levels of inhibin have been re¬
ported during pregnancy, significantly higher than those in
nonpregnant subjects (5-8), which then rapidly decline after
delivery (6, 8, 9). Current evidence derived from clinical
studies (4-11), from the localization of inhibin subunit
mRNA (4, 12) and proteins (4, 13), and from trophoblast cell
culture experiments (12) suggests that the placenta is prob¬
ably the principal source of inhibin during pregnancy (14).
Until recently, the available assays for inhibin were unable
to differentiate between dimeric forms and partially pro¬
cessed free a-subunits or between dimers (15-17). Thus, our
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current understanding of inhibins in pregnancy is largely
based upon these nondiscriminatory immunoreative inhibin
assays (14). However, the development of sensitive and spe¬
cific enzyme-linked immunosorbent assays (ELISAs) for in¬
hibin A (18) and inhibin B (19) and their subsequent appli¬
cation have offered novel and important insights into inhibin
biology in chromosomally abnormal pregnancies (20-22). To
gain further insight into the biology of inhibin in normal
pregnancy, therefore, we measured inhibin A and inhibin B
in different pregnancy compartments.
Materials and Methods
Samples
Amniotic fluid (AF). Aliquots of AF were obtained from the regional
cytogenetics laboratory in Edinburgh, Scotland. These had been col¬
lected prospectively as part of a clinical amniocentesis service. AF was
separated from fetal epithelial squamous cells by centrifugation at 250 X
g within 24 h of collection, and an aliquot of each sample was stored
specifically for this study at — 20 C until assay. The karyotype from each
sample was reported subsequently.
Maternal serum (MS). Blood samples were collected prospectively as part
of the West of Scotland Down's Syndrome and Neural Tube Defects
Prenatal Screening Program and from an ongoing first trimester study
of serum markers. Each sample was centrifuged, and the serum was
separated within 3 days of collection and stored at -20 C. Information
from early pregnancy karyotyping, where performed, and birth records,
where karyotyping is not performed, is routinely used to identify chro¬
mosomally abnormal babies. Through the exclusion of these, sera from
chromosomally normal pregnancies were identified and retrieved from
storage. To gain sex details from this normal group, a cohort of case
records was retrieved and analyzed.
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Matched MS and AF. In 47 women venepuncture was performed, with
informed consent, immediately before amniocentesis (14-16 weeks ges¬
tation). The blood was centrifuged, and the serum was separated on the
day of collection and stored at -20 C until assay. The AF was processed
as detailed above. In each case, a normal karyotype was subsequently
reported.
Umbilical cord serum. In 45 normal pregnancies, at term (37-41 weeks)
and in normal spontaneous labor, umbilical blood (arterial and venous)
was collected after consent was obtained. After the delivery of each baby,
the cord was double clamped, and blood was taken after delivery of the
placenta. Blood was centrifuged on the day of collection, and serum was
separated and stored at — 20 C until assay.
For each sample, AF, MS, or umbilical cord serum, the time of ges¬
tation at sampling, in completed weeks, was calculated from certain
menstrual dates or from an early pregnancy ultrasound scan. Ethical
approval was granted by the Lothian research ethics committee.
Assays
Inhibin A. Inhibin A was measured using a two-site ELISA (18) that has
been previously validated for human serum (23) but with some mod¬
ifications. Before assay, samples (and standards) underwent two pre¬
paratory steps. Each was mixed with 2% (final wt/vol) SDS and heated
in a water bath at 100 C for 3 min. After cooling, each sample or standard
was mixed with 1% (final wt/vol) hydrogen peroxide, incubated at room
temperature for 30 min, and then diluted 1:1 in assay diluent (0.1 mol/L
Tris-HCl, 0.15 mol/L NaCl with 5% Triton X-100, 10% BSA, and 5%
normal mouse serum, pH 7.5). The assay uses an immobilized anti-/3A-
inhibin subunit monoclonal antibody (E4) as a capture antibody, co-
valently coupled to hydrazide microplates (Avidplate-HZ, UniSyn
Technologies, Tustin, CA). The Fab fraction of a mouse anti-a-inhibin
subunit monoclonal antibody (Rl) is used as a second antibody diluted
in assay diluent. This is conjugated to alkaline phosphatase, allowing
detection by the addition of an alkaline phosphatase substrate, p-nitro-
phenylphosphate (Kirkegaard and Perry Laboratories, Gaithersburg,
MD). Inhibin, immunopurified from follicular fluid and calibrated
against recombinant 32-kDa human inhibin A (Genentech, South San
Francisco, CA), was used as a standard preparation. Plates were read at
405 nm in a microplate reader (Thermomax, Molecular Devices Corp.,
Menlo Park, CA) using dedicated software (Softmax, Molecular Devices
Corp.). Results are expressed as picograms per mL, with an assay sen¬
sitivity of 23 pg/mL. The intra- and interplate coefficients of variation
were 4.3% and 5.6%, respectively. The cross-reactivity of this assay with
activin A, activin B, follistatin, purified human pro-aC, and inhibin B is
less than 0.1%. The recovery of recombinant human inhibin A spiked
into AF was quantitative (mean ± sem, 108 ± 13%; n = 10). Serial
dilution of AF samples gave dose responses parallel to that of the
immunopurified standard (Fig. 1).
Inhibin B. Inhibin B was measured using a similar two-site ELISA as
previously described (19). A monoclonal antibody (C5) raised against
the human inhibin /3B-subunit was used as a capture antibody, biotin-
ylated, and immobilized on streptavidin-coated microplates (Life Sci¬
ences International, Basingstoke, UK). The same second antibody (Rl)
as that used in the inhibin A assay was employed. Samples and stan¬
dards were also pretreated as detailed above, but in this assay the signal
was detected using an alkaline phosphatase amplification kit (Life Tech¬
nologies, Paisley, UK). The same immunopurified inhibin preparation
as that detailed above was used as a standard but calibrated against
recombinant human inhibin B, with results expressed in picograms per
mL. Plates were read at 490 nm using the same apparatus and software
as those described for the inhibin A assay. The assay detection limit was
less than 5 pg/mL. Activin A, activin B, follistatin, and purified human
pro-aC had less than 0.1% cross-reaction, whereas recombinant inhibin
A had 0.5% cross-reaction. The intra- and interplate coefficients of vari¬
ation were 7.6% and 8.1%, respectively. Recovery of recombinant human
inhibin A spiked into AF was quantitative (mean ± sem, 88 ± 11%; n =
8). Serial dilution of AF gave a dose response parallel to that of the
immunopurified standard (Fig. 1).
Statistical analyses were performed using Statview 4.1 (Abacus,
Berkeley, CA) and SPSS for Windows (SPSS, Chicago, IL). Regressed































Fig. 1. Dose-response relationships for immunopurified inhibin
standards with serially diluted amniotic fluid samples in the inhibin
A (a) and inhibin B (b) ELISAs.
compartment, and multiples of the median (MoM) were used to correct
for gestational changes, allowing group comparisons across gestations.
The regression equations calculated were: AF inhibin A: median =
e(i i .3209- 84.616 / gestation). AF inhibin B: median = e^93254 "41 •656/sestation); MS
inhibin A: median = -0.0129006*5 + 0.988003*4 - 29.6031*3 + 434.528x2
- 3136.00* + 9078.01 (where x is weeks gestation).
Results
AF
AF samples from 618 consecutive amniocenteses were
available for measurement of inhibin A content. In 15 (2.4%),
karyotyping was abnormal, and these were excluded from
this study. Of the 603 AF samples analyzed, 388 (64.3%) were
unselected with regard to placental function [tests were per¬
formed for reasons of maternal age (n = 350), maternal anx¬
iety (n = 19), or past history (n = 19)] and were grouped
together (group A). The remaining 215 (35.7%) amniocente¬
ses (group B) had been performed after an abnormal ultra¬
sound scan (n = 15) or after positive MS screening, based on
maternal age and MS levels of intact hCG and alphafeto-
protein, had indicated an increased risk of fetal trisomy 21
(n = 200).
Inhibin A levels were analyzed for groups A and B sep¬
arately by completed week of gestation and by fetal sex.
There were no significant differences in inhibin A levels
between the two groups (P > 0.05, by Mann-Whitney U test;
data not shown) or between sexes in either group A or B (P >
0.05, by Mann-Whitney U test; data not shown). Data from
all AF samples were, therefore, combined regardless of in-
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dication for sampling or fetal sex and analyzed by gestational
age. Table 1 details the median and 10th and 90th percentiles
for inhibin A in AF in these 603 pregnancies. Levels increased
steadily across the gestational window of 14-20 weeks, as
evidenced by the regressed medians (Fig. 2).
Inhibin B assays were performed on 189 of the 603 AF
samples. Where possible (weeks 14-18 inclusive), all samples
were from group A, with 15 samples for each sex at each
gestation. At 19 and 20 weeks, however, there were insuf¬
ficient numbers in group A alone, and 7 samples at each
gestation (1 female and 6 males at 19 weeks and 3 females and
4 males at 20 weeks) were derived from group B. There were
no significant differences in inhibin B levels between the 23
AF samples from group A and the 7 from group B at 19 weeks
gestation or between the sexes at any time of gestation (P >
0.05, by Mann-Whitney U test; data not shown). The data
were, therefore, grouped by gestation, combining both sexes
within each group. Table 2 details the median and 10th and
90th percentiles for inhibin B in these 189 pregnancies. Levels
increased steadily across the gestational window, as shown
in Fig. 2.
There was significantly more inhibin A than inhibin B at
14-16 weeks gestation (P < 0.001, by Mann-Whitney U test),
but because the levels of inhibin B rose more rapidly, this
became nonsignificant at 17 weeks (Fig. 2). There was a
significant, but weak, association between the levels of in¬
hibin A and B in the 189 amniotic fluid samples (r = 0.42; P =
0.0001).
MS
Sera from 807 chromosomally normal singleton pregnan¬
cies from 10-20 completed weeks of pregnancy were ana¬
lyzed for inhibin A and inhibin B. Table 3 details the distri¬
bution of these sera by gestation and the median (10th and
90th percentiles) inhibin A levels. Levels fell significantly
from 10 weeks to a nadir at 17 weeks (P < 0.0001, by Mann-
Whitney U test), rising again to 20 weeks (P < 0.0001, by
Mann-Whitney U test; Fig. 2).
Sexing information was available from the case records of
165 of the 807 pregnancies, 91 males and 74 females. When
expressed as multiples of the median (MoM), correcting for
gestation, there were no sex differences (1.02 MoM vs. 1.04
MoM for males and females, respectively; P = 0.88, by Mann-
Whitney U test).
Inhibin B was undetectable in MS.
Matched MS and AF
Inhibin A was measured in matched maternal sera, and AF
samples were collected from 47 women at 14-16 weeks ges¬
tation. The median (10—90th percentiles) inhibin A levels in
MS and AF were 123.7 (79.0-196.1) and 802.5 (250.6-1731.4)
pg/mL, respectively; the levels in AF were significantly
higher than those in MS (by paired t test, P < 0.001). Inhibin
A levels in the AF and MS samples were not significantly
correlated (r = 0.19; P > 0.05).
Umbilical cord serum
Cord blood was obtained from 45 pregnancies at term
(37-41 weeks gestation), 24 with a female baby and 21 with
a male, as evident on examination. Inhibin A was undetect¬
able in all 45 samples, both arterial and venous. Inhibin B was
undetectable in the cord serum from all female babies, but
was present in serum from all 21 male babies, with no dif¬
ferences between arterial or venous blood levels. The median
(10—90th percentile) inhibin B level in the umbilical vein was
167.4 (111.2-224.8) pg/mL. There was no association be¬
tween cord inhibin B level and either gestation (r = 0.005; P =
0.98) or birth weight (r = 0.11; P = 0.6).
Discussion
Immunoreactive inhibin levels throughout pregnancy
have been extensively reported using inhibin a-subunit-
based assays (5-9). Serum levels of immunoreactive inhibin
rise from ovulation to a peak at 9-10 weeks gestation, falling
to a plateau at approximately 15 weeks and thereafter rising
in the third trimester to another peak at term (5-8). A similar
biphasic ontogeny for inhibin A has been recently described
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Fig. 2. Regressed median inhibin A levels in 807 maternal serum
samples at 10-20 weeks gestation (•) and in 603 amniotic fluid
samples at 14-20 weeks gestation (A) and regressed median inhibin
B levels in 189 amniotic fluid samples at 14-20 weeks gestation (O).
TABLE 1. Median and 10th and 90th percentile inhibin A levels (picograms per mL) in amniotic fluid from 603 chromosomally normal
singleton pregnancies
Weeks gestation
14 15 16 17 18 19 20
73 117 87 133 137 47 9~
10th percentile 158.2 183.7 206.9 212.7 322.8 282.0 489.4
50th percentile 615 680.2 728.7 997.8 1195.9 1130.7 1336.0
90th percentile 1124.6 1438.8 1389.4 2156.0 2717.4 2608.2 2084.1
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TABLE 2. Median and 10th and 90th percentile inhibin B levels (picograms per mL) in amniotic fluid from 189 chromosomally normal
singleton pregnancies
Weeks gestation
14 15 16 17 18 19 20
No. 30 30 30 30 30 30 9
10th percentile 67.4 116.0 133.1 114.0 255.6 280.4 439.3
50th percentile 216.6 334.6 261.4 631.8 775.4 1089.2 1078.2
90th percentile 554.6 884.4 1451.8 1738.4 1887.5 2874 2482.5
TABLE 3. Median and 10th and 90th percentile inhibin A levels (picograms per mL) in maternal serum from 807 chromosomally normal
singleton pregnancies
Weeks gestation
10 11 12 13 14 15 16 17 18 19 20
No. 75 75 75 75 75 75 75 75 75 75 57
10th 101.4 88.8 86.8 62.3 73.8 73.2 54.2 59.5 67.3 61.2 74.1
50th 177.5 164.3 159.1 133.9 157.4 142.5 119.2 111.9 156.0 146.2 180.3
90th 290.7 277.8 253.5 212.2 295.0 261.2 189.4 200.3 291.2 277.4 327.2
previously reported, our findings confirm the biphasic pro¬
file, but show that inhibin A levels rise at 18 weeks gestation,
earlier than previously reported (24). Contrary to our find¬
ings, Qu et al. (26) showed a steady rise in bioactive inhibin
levels without the biphasic profile. It would now appear that
these bioactive inhibin data have been confounded by either
other FSH-regulating peptides in MS, such as activin (27), or
by inadequate stripping of the very high levels of circulating
sex steroids that exist in pregnancy (26). Our studies also
demonstrate that inhibin B is not detectable in MS at 10-20
weeks gestation, extending the finding of a previous report
that inhibin B was absent in MS up to 11 weeks gestation (25).
This is the first report of specific inhibin dimers in AF. The
higher level of inhibin A in AF than in MS is consistent with
existing reports of immunoreactive inhibin levels in these
compartments (28, 29). It is perhaps surprising that AF levels
of inhibin A are higher than those in MS because hCG, which
is also secreted by the placenta, is significantly lower in AF
than in serum (30, 31), consistent with secretion from the
placenta into the maternal circulation. Our data suggest that
either inhibin A is preferentially secreted by the placenta into
the AF, rather than the maternal circulation, which is un¬
likely considering anatomical relationships, or that there is
another significant source of inhibin during pregnancy. The
lack of correlation of AF inhibin A with MS inhibin A and the
differing ontogenies of inhibin A in MS and AF support the
latter explanation, suggesting that different sources contrib¬
ute to different compartments. Furthermore, the presence of
inhibin B in AF, but not in MS, and the finding that AF levels
of inhibin A and inhibin B are only weakly associated are also
consistent with the presence of at least two independent
sources of inhibin.
Potential sources of inhibin in pregnancy include the de-
cidua, the fetus, and the fetal membranes, which all express
inhibin subunit mRNAs (32-34). The decidua is an unlikely
candidate, as it preferentially expresses /3B-subunit mRNA
(32), suggesting that it would secrete more inhibin B than
inhibin A, the converse of our observations. Further, if de-
cidually derived, it might be expected that inhibins would be
detectable in both MS and AF, similar to other decidual
products, such as PRL and placental protein 14 (30, 35, 36),
but inhibin B is not detectable in MS. It is possible that the
inhibins in AF may be fetally derived, as alphafetoprotein,
which is of fetal origin, is found in higher concentrations in
AF than MS (37), similar to inhibin A. Previous studies of
immunoreactive inhibin in cord serum concluded that the
fetus was not a significant source of inhibin (5, 6, 8), and
although we were unable to collect fetal blood at 10-20
weeks, we demonstrated that there is no inhibin A in the fetal
circulation at term, which would argue against a fetal source
for the inhibin A in AF. The fetal membranes are, therefore,
the likely origin of the inhibin A in AF at the gestation periods
studied. Of these, the amnion selectively expresses j3B-sub-
unit mRNA (34), which is more indicative of activin pro¬
duction, but the chorion expresses mRNA for both the pA-
and a-subunits (34), consistent with inhibin A secretion.
The fetal membranes are also the probable source of the
inhibin B detected in AF. We found no sex differences in AF
inhibin B levels, which is not consistent with our umbilical
cord data or previous midgestation data for immunoreactive
inhibin (38). This would argue against a significant fetal
contribution to the inhibin B content of AF, although, as for
inhibin A, we were unable to collect fetal blood at the earlier
gestation times, and we cannot exclude the fetus as a con¬
tributor of inhibin B to AF.
In cord serum from female babies, neither inhibin A nor
inhibin B was present, but in the males, we found levels of
inhibin B comparable to those in adult men (39). This differs
from a previous report that no dimeric inhibins are present
in cord serum (40). That Billiar and colleagues (40) found no
inhibin B can be explained by the capture antibody (E4) used
in their ELISA-B assay, which is an antiinhibin /3A-subunit
antibody displaying no significant affinity for the inhibin
/3B-subunit. The fetal testis expresses mRNA for the inhibin
subunits, whereas the ovary does not (32), in keeping with
inhibin B being of testicular origin, rather than from another
source common to both sexes, such as the adrenals. There¬
fore, these data may be novel evidence that the human fetal
testis secretes dimeric inhibin. It is likely that the majority of
the inhibin detected in cord serum by the inhibin a-subunit
assays used in previous studies (5, 6, 8) is free a-subunit (40).
Although there are no sex differences in immunoreactive
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inhibin levels in cord serum at term (6,8, 41), at 26-28 weeks,
immunoreactive inhibin levels are higher in males than in
females (38). In light of our data, the immunoreactive inhibin
findings at earlier periods of gestation may represent relative
changes in inhibin B, particularly when at these times of
gestation FSH levels in males are significantly lower than
those in females (38, 42, 43). This sex difference in circulating
FSH has been previously explained by the higher circulating
levels of testosterone in males (42, 43), but it is possible that
it may at least in part be due to inhibin B, being evidence of
negative feedback by inhibin B on fetal pituitary FSH secre¬
tion at these periods of gestation.
In summary, our data offer some clarification of the biol¬
ogy of inhibin in early to midpregnancy, providing evidence
to challenge the concept that the placenta is the only signif¬
icant source of inhibin A in pregnancy. We suggest that the
placenta secretes inhibin A primarily into the maternal cir¬
culation, whereas the fetal membranes are the likely major
source of both inhibin A and inhibin B in AF. Our data also
show for the first time that the fetal testis may secrete inhibin
B.
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Objective To determine the relation between maternal serum inhibin-A and free p-hCG concentrations in
chromosomally normal pregnancies and to compare the two biochemical markers for their sensitivity
in identifying trisomy 21 pregnancies.
Sample Inhibin-A and free P-hCG were measured in maternal serum samples from 800 chromosomally
normal singleton pregnancies at 10 to 14 weeks of gestation and 76 singleton pregnancies with fetal
trisomy 21.
Results In the normal group maternal serum inhibin-A was significantly associated with both maternal
weight and gestational age (F = 11-2, P < 0-0001). In pregnancies with trisomy 21 the maternal
serum inhibin-A and free p-hCG concentrations were significantly increased (mean difference
inhibin = 0-51 SD, F = 18, P < 0 0001 and mean difference free P-hCG = 113 SD, F = 80,
P < 0-0001). For a 5% false positive rate, the sensitivity of maternal serum free p-hCG in identifying
pregnancies with trisomy 21 was 28-9% compared with 12-8% for maternal serum inhibin-A. Delta
inhibin-A was significantly associated with delta-free P-hCG (r = 0-345, P < 0-01) and the deviation
from the normal mean for free p-hCG was significantly greater than the deviation for inhibin-A
(f = 4-0, P < 0-0001). For a 5% false positive rate, the sensitivity achieved by combining information
from delta inhibin-A and delta free P-hCG was similar to the sensitivity of free P-hCG alone (30-3%
compared with 28-9%)
Conclusion At 10 to 14 weeks of gestation fetal trisomy 21 is associated with increased maternal serum
inhibin-A and free p-hCG levels. However, the degree of elevation of inhibin-A is less than that of
free P-hCG, and there is a significant association between levels of the two proteins. The sensitivity
for trisomy 21 achieved with the combination of maternal serum inhibin-A and free p-hCG is not
significantly different from that achieved with maternal serum free p-hCG alone.
INTRODUCTION
Inhibin is a heterodimeric glycoprotein formed by the
combination of an P-subunit with either a pA-subunit
(inhibin-A) or a pB-subunit (inhibin-B); additionally
there are circulating nonbioactive free-subunits1-2. In
pregnancy the major source of inhibin in maternal
serum is thought to be the placenta3.
The first immunoassay for inhibin used antibodies
directed at the P-subunit only and could therefore not
distinguish between inhibin A, inhibin B and the free-
P-subunits1. More recently, immunosorbent assays
(ELISA) specific for each dimer have been intro¬
duced4-3. Studies using these specific assays have
reported that inhibin-B is not detectable in maternal
Correspondence: Professor K. H. Nicolaides, Harris Birthright
Research Centre for Fetal Medicine, King's College Hospital
Medical School, Denmark Hill, London SE5 8RX, UK.
serum in early pregnancy6, whereas the levels of
inhibin-A which mirror those found with the nonspe¬
cific assays, increase with gestation to reach a peak at
10 to 12 weeks; they subsequently decline to a
plateau in the second trimester but they rise again in
the third trimester to maximum levels at term6-8.
Studies using the nonspecific inhibin (immuno-
reactive) assays have reported that in trisomy 21
maternal levels are increased in the second9-10 but not
in the first trimester of pregnancy". Studies with the
specific assay have reported that levels of inhibin-A
in trisomy 21 are increased both during the first and
the second trimesters12-13. Furthermore, in the second
trimester inhibin-A is more sensitive than immuno-
reactive inhibin in the detection of trisomy 2114, and
in the second trimester there is no significant correla¬
tion between inhibin-A and free p-hCG so that when
data from both proteins were combined inhibin-A
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Fig. 1. Maternal serum inhibin-A concentration in 800 normal controls in relation to maternal age and maternal weight.
provided a 20% increase in the detection of tri¬
somy 21 for a given fixed false positive rate15.
The aim of this study was to examine the level of
maternal serum inhibin-A in first trimester trisomy 21
pregnancies and to explore whether this placental
product may also improve the sensitivity of free (3-
hCG in the detection of trisomy 21 at this gestation.
METHODS
Serum free (3-hCG and inhibin-A concentrations were
measured in blood samples obtained immediately
before ultrasound examination in women with single¬
ton pregnancies attending the Harris Birthright
Research Centre for Fetal Medicine. The patients
were self-referred for screening for fetal trisomy 21
by maternal age and fetal nuchal translucency
thickness at 10 to 14 weeks of gestation. The assays
were carried out in samples from 76 pregnancies with
trisomy 21 and 800 chromosomally normal controls,
over the same range of maternal age and gestation.
Written consent was obtained from all the patients
and the study was approved by the hospital ethics
committee.
Maternal serum inhibin-A was determined retro¬
spectively after samples had been stored at -20 °C for
up to 12 months. Maternal serum free (3-hCG was
determined prospectively after samples had been
stored overnight at 4°C, or when samples were
taken on Friday, at -20°C for two days. Biochemical
analysis for both analytes was performed without
knowledge of fetal karyotype.
Inhibin-A was measured using a specific two-site
enzyme linked immunosorbent assay (ELISA) as
previously described16 but with some minor modifi¬
cations. Briefly, serum samples and standards were
mixed with 1% (final w/v) hydrogen peroxide for 30
minutes prior to the assay. The assay used an
immobilised anti inhibin-A subunit monoclonal anti¬
body covalently bound to hydrazide microplates
(Avidplate-HZ) as the capture antibody. The second
antibody is the Fab fraction of a mouse anti (3-inhibin
subunit monoclonal antibody conjugated to alkaline
phosphatase. Detection was afforded by colour
change after adding alkaline phosphatase substrate
(P-NPP KPL, Maryland, USA). Recombinant 32 kD
human inhibin-A (Genentech) was used for standards
with the results expressed as pg/mL. The sensitivity
of the assay was 39 pg/mL and the intra and inter-
plate coefficients of variation were 4-3% and 5-6%,
respectively.
The concentration of maternal serum free (3-hCG
was determined using an immunoradiometric assay
(CIS, Paris, France). The sensitivity was 0-15 ng/mL
and intra- and inter-assay coefficients of variation
were 3T% and 5-7%, respectively.
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Table 1. Median maternal weight, maternal serum inhibin-Aand free
(3-hCG concentration (median and 90% CI) in normal controls in
relation to gestation. CI = confidence intervals
SD
Gestation Maternal Inhibin-A (3-hCG 3-
(weeks) n weight (kg) Median 90% CI Median 90% CI
10 52 61 204 67-481 44 16-120 2-
11 318 62 173 50-373 41 15-119
12 325 62 168 62-382 34 13-98
13 105 62 146 50-313 30 12-91 1-
o-
Table 2. Median maternal weight, maternal serum inhibin-A and free
(3-hCG concentration (median and 90% CI) in 76 pregnancies with -1 -
trisomy 21 in relation to gestation.
Gestation Maternal Inhibin-A (3-hCG -2-
(weeks) n weight (kg) Median 90% CI Median 90% CI
10 3 62 354 244^163 91 81-121 -3-
11 27 65 274 102—483 66 32-192
12 31 63 213 37-571 60 21-210











The distribution of maternal serum inhibin-A mea¬
surements was examined and found to be skewed. To
normalise the distribution, log transformation was
applied. Regression analysis was used to determine
the inter-relation of log transformed maternal serum
inhibin-A measurements with fetal crown-rump
length and maternal weight. The equation which
described the relation was then used to calculate for
each pregnancy the number of standard deviations by
which the concentration differed from the appropriate
normal mean for maternal weight and gestation (delta
value). Delta values for maternal serum free [5-hCG
were calculated using the findings from a previous
study17. Regression analysis was applied to examine
the relation between delta inhibin-A and delta free
(3-hCG and paired t-test was used to compare devia¬
tions.
RESULTS
The median maternal age was 34 years (range 15^47)
and the median gestation by crown-rump length was
12 weeks (range 10-14). In the control group mater¬
nal serum log10 inhibin-A was significantly associ¬
ated with both maternal weight and gestational age
(Fig. 1, log,0(inhibin-A) = 2-897 - 0 0423 x gestation
[weeks] - 0-002786 x maternal weight [kg],
SD 0-250, SE for gestation coefficient = 0-0119, SE
for maternal weight coefficient = 0 000876, R = 0-166,
F = 11-2, P < 0-0001). To allow comparison with
Fig. 2. Maternal serum inhibin-Aand free p-hCG concentration in 76
pregnancies with trisomy 21 expressed as the number of standard
deviations by which values differed from the appropriate normal
mean for gestation and maternal weight.
previous and future studies, basic information on
actual maternal serum inhibin-A measurements for
normal and affected pregnancies is summarised in
Tables 1 and 2.
In pregnancies with trisomy 21 the maternal serum
inhibin-Aand free (3-hCG concentrations were signif¬
icantly increased (Fig. 2, mean difference inhibin-A =
0-51 SD, F= 18, P < 0-0001 and mean difference free
(3-hCG = 1-13 SD, F = 80, P < 0-0001) and the
increase was constant throughout the gestational range
of the study population (Table 2, r = 0-003, P = 0-98
and r = 0-132, P = 0-26, respectively). Delta inhibin-A
was significantly associated with delta free (3-hCG
(Fig. 3, r = 0-386, P < 0-0001 and Fig. 4, r = 0-308,
P < 0-01), but the deviation from the normal mean
for free (3-hCG was significantly higher than the
deviation for inhibin-A (t = 4 0, P < 0 0001). Delta
inhibin-A was above the 95th centile in 10 (12-8%)
cases, while delta free (3-hCG was above the 95th
centile in 22 (28-9%) cases. For the same false posi¬
tive rate (5%), the combined information from delta
inhibin-Aand delta free (3-hCG identified 23 (30-3%)
of the pregnancies with trisomy 21 which is not sig¬
nificantly different from the detection of trisomy 21
by free p-hCG alone (28-9%, %2 = 0 023).
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delta free B-hCG (SD)
delta Inhibin-A (SD)
Fig. 3. Maternal serum inhibin-A concentration in 800 normal controls in relation to maternal serum free (3-hCG concentration. Individual val¬
ues for both biochemical markers were expressed as the number of standard deviations from the appropriate normal mean for gestation and
maternal weight
delta free B-hCG (SD)
delta Inhibin-A (SD)
Fig. 4. Maternal serum inhibin-A concentration in 76 pregnancies with trisomy 21 in relation to maternal serum free (3-hCG concentration.
Individual values for both biochemical markers were expressed as the number of standard deviations from the appropriate normal mean for ges¬
tation and maternal weight.
DISCUSSION
The findings of this study demonstrate that in the first
trimester of trisomy 21 pregnancies maternal serum
inhibin-A is increased; for a 5% false positive rate,
12-8% of pregnancies with trisomy 21 can be identi¬
fied. However, there is a significant association
between inhibin-A and free (3-hCG, and the latter is
more sensitive in detecting trisomy 21 (28-9% for a
5% false positive rate). Studies in the second
trimester have demonstrated that addition of inhibin-
A to maternal serum screening with alpha-fetoprotein
and free (3-hCG provides a 20% increase in the sensi¬
tivity of the test13. Our findings indicate that this is
not the case in the first trimester of pregnancy; the
addition of inhibin-A to screening with free (3-hCG
did not significantly increase the sensitivity.
The gestational age-related differences in the rela¬
tion between free (3-hCG and inhibin-A15 in maternal
blood suggest that with advancing gestation there is a
change in the regulation of these glycoproteins.
Trophoblast, in particular syncytiotrophoblast, is
thought to be the primary source of both inhibin-A
and hCG18,19. It is also apparent from in vitro studies
that the secretion of hCG and inhibin may be interde¬
pendent20-21. hCG stimulates inhibin secretion from
the trophoblast, and inhibin suppresses GnRH-stimu-
lated hCG secretion from term but not first trimester,
trophoblast cell cultures. While inhibin levels fall
from a peak at 10 to 12 weeks to a plateau at 15
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weeks8 22 the fall is not as profound as that for hCG22.
hCG levels remain low in later pregnancy when
inhibin levels rise to a maximum levels at term7.
Therefore, it would appear that the regulation of
inhibin is hCG-dependent in early pregnancy but
hCG-independent from the second trimester onwards.
The sensitivity of screening for trisomy 21 by
maternal age and fetal nuchal translucency thickness
at 10 to 14 weeks of gestation is about 80% for a 5%
false positive rate23. Addition of maternal serum free
(3-hCG increases the sensitivity to 85%17. Although
we have not specifically examined the combination
of inhibin-A and nuchal translucency thickness (with
or without free (3-hCG), the data presented here
suggest that inhibin-A would not expect to improve
the sensitivity of first trimester screening by maternal
age, fetal nuchal translucency thickness and maternal
serum free P-hCG and so would not be a valuable
marker at this stage ofpregnancy.
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